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Dipeptides and tripeptides serve as important sources of amino acids, nitrogen and 
carbon for the growth of all organisms.  To identify genes involved in the regulation of 
small peptide utilization, I performed a systematic, functional examination of this process 
in a haploid, non-essential, single-gene deletion mutant library of Saccharomyces 
cerevisiae. In addition, we used high-throughput phenotyping in which we grew yeast 
cells on 284 different dipeptides or 11 tripeptides as the sole nitrogen source to dissect 
different mechanisms of di/tri-peptide utilization in seven genetically diverse strains. I 
have identified 103 candidate genes involved in regulating peptide utilization: 57 genes 
whose deletion decreased dipeptide utilization and 46 genes whose deletion enhanced 
dipeptide utilization. Since in S. cerevisiae the membrane transport protein Ptr2p, 
encoded by PTR2, mediates the uptake of di/tri-peptides and is a key player in the di/tri-
peptide utilization process, I focused our studies on the regulation of PTR2 expression, 
Ptr2p-GFP localization, and dipeptide uptake assays. Forty-two genes were ascribed to 
the regulation of PTR2 expression, 37 genes were involved in Ptr2p localization, and 24 
genes apparently did not affect expression or localization. Together with the high-
throughput phenotyping study, we have identified gene components involved in 
regulation of dipeptide utilization in many cellular processes: 1) proteins involved in up- 
or down-regulation of PTR2 transcription including the chromatin remodeling INO80 
protein complex (Arp5p, Arp8p, Ies6p and Taf14p), transcription factors (Cup9p, Rpn4p, 
Stp2p, and Dal81p), polymerase mediators (Ssn3p/Srb10p, Ssn8p/Srb11p, Ssn2p/Srb9p, 
and Srb8p), and mRNA maturation (Kem1p and Pat1p); 2) proteins involved in the Ptr2p 
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trafficking system including ESCRT I, II, III protein complex; 3) proteins participating in 
metabolic processes including the pyruvate dehydrogenase complex (Pdx1p, Lpd1, 
Pdb1p, and Lat1p), the fatty acid synthase complex (Oar1p, Mct1p, and Etr1p), and the 
glycine decarboxylase multienzyme complex (Gcv2p, Gcv3p, and Lpd1p); 4) proteins 
involved in other cellular processes, such as Ybt1p, a protein located at the vacuole 
membrane likely related to the storage of dipeptides in the cytosol and Dal5p previously 
identified as an allantoate/ureidosuccinate permease, which facilitates di/tri-peptide 
transport. Specifically, Dal5p is involved in the uptake of non-N-end rule dipeptides. 
Moreover, even in the absence of Dal5p and Ptr2p, an additional activity - almost 
certainly the periplasmic asparaginase II Asp3p - facilitates the utilization of dipeptides 
with C-terminal asparagine residues by a different strategy.  Another, as yet unidentified 
activity, enables the utilization of dipeptides with C-terminal arginine residues.  The 
identified genes regulating dipeptide utilization were distributed among most of the Gene 
Ontology functional categories indicating a very wide regulatory network involved in 
transport and utilization of dipeptides in yeast. It is anticipated that further 
characterization of how these genes affect peptide utilization should add new insights into 
the global mechanisms of regulation of transport systems in general and peptide 
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A Review of the Di/tri-peptide Utilization Literature 
 
The utilization of di/tri-peptides is an important cellular activity and has been 
documented in all organisms from archaea to bacteria, plants, and animals. The 
introduction of this chapter is a literature survey of what was known about peptide 
utilization and transport before I undertook the research presented in this dissertation.  
 
Proteins and peptides as a major energy source:  
Organisms utilize amino acids and peptides from exogenous proteins for 
nitrogen/carbon sources and protein synthesis. In the natural environment, the source of 
proteins and peptides for microorganisms is mainly from decomposition of dead 
organisms and secreted proteins of living organisms. While microorganisms degrade 
proteins and peptides in the surrounding environment where they reside, in mammals the 
digestion of proteins and peptides begins in the stomach and intestine. Both dietary and 
luminally-secreted proteins and polypeptides undergo limited or complete proteolysis by 
aminopeptidases, carboxypeptidases, endopeptidases and other pancreatic and intestinal 
proteolytic enzymes. The brush border peptidases located at the luminal surface of the gut 
further degrade oligopeptides into di/tri-peptides and amino acids. 
 
Degradation of proteins and peptides: 
The degradation of proteins is an important process not only for providing a 
nutritional source for the growth of organisms, but also for the defense against  
proteinaceous toxins and modulation of the host immune system (DANIEL 2004; 
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PRITCHARD and COOLBEAR 1993). Degradation of proteins and peptides, mediated by a 
set of proteases, or peptidases, can take place extracellularly or intracellularly (Figure 1).  
Extracellular degradation: Extracellular degradation is mediated by many hydrolytic 
enzymes, and proteolytic systems can produce oligopeptides, di/tri-peptides and amino 
acids useful for microbial growth. Proteolytic digestion is particularly important for some 
pathogenic and parasitic organisms to acquire peptides. For example, the genome of the 
fungal pathogen Candida albicans harbors ten secreted acid proteinase (SAP) genes 
encoding extracellular aspartic proteinases that appear to allow adaption to variable tissue 
environments such that these SAP enzymes enable C. albicans to grow on medium 
containing serum albumin as a sole nitrogen source (HUBE and NAGLIK 2001) and can 
function in environments from pH 2 to 7.  SAPs have been shown to be involved during 
the infection process and are required for pathogenicity (NAGLIK et al. 2003).    The 
parasitic organism Plasmodium falciparum, the causative agent of intraerythrocytic 
malaria, can secret proteolytic enzymes plasmepsins I and II (two aspartic proteases), 
falcipain (a cysteine protease), and endoproteinase to generate a variety of peptides with 
average length of 8.4 amino acid residues from host hemoglobin.  This parasite may 
solely rely on peptides for growth (KOLAKOVICH et al. 1997).  
Hydrolytic enzymes can be secreted by the signal peptide-dependent general 
export pathway, and this secretion process is ubiquitous from bacteria to mammals. 
Signal peptidase, an endoprotease, removes the N-terminal signal sequence from 
secretory proteins, and leads to the release of mature polypeptides into the surrounding 
medium (DEV and RAY 1990). Hydrolytic enzymes can also be exported by ABC 
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Figure1 Protein degradation and di/tri-peptide transporters in a general model. Exogenous proteins are degraded into 
oligopeptides extracellularly by secreted proteases, and further degraded into di/tri-peptides and amino acids by peptidases. Proteins 
can also be degraded into oligopeptides intracellularly by the 26S proteasome via the ubiquitin pathway or by cytoplasmic proteases, 
and further degraded into di/tri-peptides by endopeptidases. Proteins can be also degraded into peptides and amino acids in the vacuole 
in eukaryotic organisms. Extracellular di/tri-peptides can be transported into the cell by the PTR system and by ABC transporters. The 
translocation of di/tri-peptides by the PTR system is coupled with protons, and the H+ concentration is regulated by several means 
including the Na+/H+ exchanger (NHE) and the H+-ATPase. Extracellular di/tri-peptides can also be translocated into the cell by an 
ABC transporter in prokaryotic organisms. This process is coupled with ATP hydrolysis. 
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transporters in both prokaryotic and eukaryotic organisms. In Gram negative bacteria, 
proteins lacking an N-terminal signal peptide can be transported by ABC protein-
mediated exporters (BINET et al. 1997; WANDERSMAN 1998). In addition, a variety of 
proteinases and peptidases are associated with the cell wall and are involved in 
extracellular polypeptide degradation (GONZALES and ROBERT-BAUDOUY 1996).  
Intracellular degradation: Peptides can also be generated intracellularly due to protein 
turnover. For example, about 1-2% of intracellular proteins in log phase bacteria cells and 
5-12% of proteins in stationary phase cells undergo a degradation process (GONZALES 
and ROBERT-BAUDOUY 1996). Proteins are hydrolyzed into oligopeptides by the 
ubiquitin/proteasome system and cytoplasmic proteases/peptidases in prokaryotic and 
eukaryotic organisms (Figure 1) and by other proteolytic enzymes in vacuoles in 
eukaryotes.  In the ubiquitin system, target proteins are covalently tagged with multi-Ub 
and processed by an ATP-dependent 26S proteasome containing a 20S core protease and 
two 19S particles. The 19S particles mediate the binding and unfolding of the target 
proteins and then transfer them to 20S core for degradation (XIE and VARSHAVSKY 2000). 
Peptides with three to twenty-four amino acid residues are generated by 26S proteasome 
with about two-thirds of the generated peptides having less than 8 amino acid residues 
(SARIC et al. 2004). The oligopeptides produced in this process are further degraded into 
di/tri-peptides or amino acids for nutrient recycling by aminopeptidases and other 
peptidases. For example, tripeptides can be released from a free N-terminus of larger 
peptides in eukaryotic cells by tripeptidyl-peptidase II (TPP II), an aminopeptidase 
associated with the plasma membrane (TOMKINSON and LINDAS 2005). Furthermore, 
di/tri-peptides derived from proteins or polypeptides can be further degraded into amino 
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acids by peptidases in both prokaryotic and eukaryotic organisms. For instance, at least 
four aminopeptidase activities and one single dipeptidase activity were found in yeast and 
were capable of di/tri-peptide degradation (ROSE et al. 1979); and at least five peptidases, 
pepN, pepC, pepO, pepX, and pepT are involved in di/tri-peptides degradation in 
Lactococcus lactis (KUNJI et al. 1996b). Some bacterial strains also possess beta-peptidyl 
aminopeptidase, which can use unnatural beta-di/tri-peptides for carbon and nitrogen 
sources (GEUEKE et al. 2005). The intracellular or extracellular degradation of proteins 
provides a variety of peptides and amino acids for the growth and reproduction.  
 
Biological significance of di/tri-peptides  
A large number of different size peptides including di/tri-peptides are produced 
by both microbial proteolytic systems and by gastrointestinal digestion of dietary proteins, 
such as milk, animal meat, maize, wheat, soybean, or egg (KORHONEN and PIHLANTO 
2003; MEISEL and BOCKELMANN 1999; PELLEGRINI 2003; YAMAMOTO et al. 2003). 
These peptides contribute to many cellular functions. For example, casein-derived 
peptides, produced by the activity of lactic acid bacteria in milk, contain regulatory 
compounds with hormone–like activity, and other physiologically functional peptides 
such as opioid peptides, immunostimulating peptides, and angiotension I converting 
enzyme inhibitors (MEISEL and BOCKELMANN 1999). Some oligopeptides (peptides 
containing more than three amino acids) are bioactive and are involved in Ca2+, iron, or 
steroid metabolism, have antiviral/antimicrobial/antifungal or antitumor activity,  are 
neuroactive, inhibit proteases, regulate growth, act as hormones, or are involved in 
electrolyte turnover, fertility, and coagulation (ADERMANN et al. 2004; PELLEGRINI 2003). 
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However, more and more research has documented that di/tri-peptides have a great 
physiological significance as well. There are 400 possible different dipeptides and 8000 
possible tripeptides composed of the 20 naturally-occurring L-α-amino acids. 
 
Di/tri-peptides serve as a nitrogen and/or carbon source and as a source of amino 
acids: Since di/tri-peptides can be further degraded by peptidases intracellularly to 
release amino acids, these peptides can satisfy amino acid auxotrophic requirements in 
prokaryotic and eukaryotic microorganisms (BECKER et al. 1973; MONETON et al. 1986) 
(Table 1).  
 
Di/tri-peptides possess physiological activities whose molecular mechanism has not 
been elucidated: Di/tri-peptides are not only important nutrient sources, but also some of 
them possess additional biological activities. A diverse group of biologically active 
peptides such as antiviral agents, neuroactive peptides, enzyme regulators and inhibitors, 
hormonal peptides, and immunoactive peptides have been isolated from bacteria, fungi, 
plants and animals (KUMAR and BHALLA 2005).  
Analysis of some naturally-occurring dipeptides reveals a variety of physiological 
functions (Table 1). Kyotorphin (Tyr-Arg), an analgesic neuropeptide, has morphine-like 
and naloxone-reversible effects, possibly due to depolarization of the enkephalinergic 
neurons, which leads to a release of Met-enkephalin from the striatum and spinal cord 
(SHIOMI et al. 1981). In addition, Tyr-Arg also inhibits the isoprenaline-induced increase 
in twitch tension of rat cardiac muscle, and this inhibition can be reversed by another 
dipeptide, Leu-Arg (LI et al. 2006). Lactokinin (Tyr-Leu) derived from milk proteins by  
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Table 1 The biological functions of di/tri-peptides and di/tri-peptide derived 
products 
 
Functions Di/tri-peptides and 
Components 
Activity References 
Nutrient source Some Met and Lys contained 
di/tri-peptides; 284 of 400 
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1973; MONETON 
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Lactokinin (Tyr-Leu) ACE-inhibitory effect (MEISEL and 
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Dopa derivative (Dopa-Phe) Increased absorption of Dopa; 
effective for Parkinson’s 
disease 
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YSL or  YSV(Tyrosyl-seryl-
leucine/valinine) 
Inhibit tumor growth  (JIA et al. 2005); 
(YAO et al. 2005) 
Thyrotropin releasing 
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(L-pyroglutamyl-L-histidyl-
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(FADEN et al. 
2005; PROKAI-
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the digestion has angiotensin-I-converting enzyme (ACE) inhibitory activity (Meisel and 
Bockelmann 1999). 
 Many modified dipeptides have also been chemically synthesized for commercial 
usage (Table 1). For example, aspartame (Carbobenzoxy-Asp-Phe-OMe) has been widely 
used as a non-nutritive sweetener (ERBELDINGER et al. 2001). The dipeptide derivative, 
L-Dopa-L-Phe is synthesized to target PepT1 and PepT2, the two major di/tri-peptide 
transporters in mammals. This compound, significantly increased the absorption of L-
dopa (L-3,4-dihydroxyphenylalanine), an effective drug for the treatment of Parkinson’s 
disease, in a tested Caco-2 cell line (TAMAI et al. 1998).   
 Some naturally-occurring tripeptides also showed physiological important 
activities including antihypertension, stimulation of immune system, inhibition of tumor 
growth, and neuroprotective activity (Table 1). For example, Val-Pro-Pro and Ile-Pro-Pro, 
generated from casein by extracellular proteinase followed by peptidase activity in sour 
milk, were found to act as antihypertensive peptides (YAMAMOTO 1997). In addition, 
Leu-Leu-Tyr and Tyr-Gly-Gly also derived from the degradation of milk proteins are 
immunopeptides, which increase the proliferation of human peripheral blood 
lymphocytes and stimulate activity of the immune system (MEISEL and BOCKELMANN 
1999). The tripeptides Tyr-Ser-Leu or Tyr-Ser-Val inhibit the growth of human 
hepatocarcinoma and increase the survival capability of mice carrying tumor cells (JIA et 
al. 2005; YAO et al. 2005). Thyrotropin-releasing hormone (TRH) (L-pyroglutamyl-L-
histidyl-L-prolinamide) is a brain hormone and a neuro-tripeptide modulator, which has 
considerable neuroprotective effects in spinal cord injuries (FADEN et al. 2005). The 
related TRH metabolic product, cyclo-His-Pro (CHP) and pyroGlu-Glu-Pro-NH2 have a 
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similar function as that of TRH and CHP and are more resistant to enzymatic degradation 
(FADEN et al. 2005). Tripeptide GPE (Gly-Pro-Glu) binds N-methyl-D-aspartate (NMDA) 
receptor and promotes the release of acetylcholine and dopamine and shows 
neuroprotective properties (ALONSO DE DIEGO et al. 2005). 
 
Di/tri-peptides regulate cellular processes by mechanisms elucidated at the 
molecular level: Some di/tri-peptides can regulate gene transcription, protein translation, 
and potentially modulate enzyme activity and function of regulatory proteins (Table 2) 
(TROITSKAYA and KODADEK 2004). First, N-end rule dipeptides [peptides with basic (Arg, 
His, or Lys) or bulky (Ile, Leu, Phe, Trp, or Tyr) residues at the N-terminus] act as 
ligands to modulate PTR2 transcription in yeast. Dipeptides with N-terminal residues can 
bind to the scaffold protein Ptr1p to promote Cup9p degradation via a ubiquitination 
pathway and up-regulate the transcription of the PTR2 (TURNER et al. 2000). Second, 
tripeptides such as PAT (Pro-Ala-Thr) and SPF (Ser-Pro-Phe) can recognize the stop 
codon and serve as functional elements to decipher stop codons in the translation process. 
These tripeptides can serve as translational release factors to terminate polypeptide 
synthesis (ITO et al. 2000; NAKAMURA and ITO 2002). Third, some di/tri-peptides can 
regulate enzyme activities. For instance, tripeptidomimetic compound Ac-Asp-
Tyr(SO3H)-Nle-NH2 inhibits the function of protein tyrosine phosphatase 1B. As a result, 
this tripeptide can negatively regulate the insulin signal by dephosphorylation of tyrosine 
residues on the insulin receptor and promote insulin resistance (LARSEN et al. 2002). 
Furthermore, di/tri-peptides can also serve as, or promote, agonists or antagonists to  
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Table 2 The mechanisms of biological functions of di/tri-peptides and di/tri-peptide 
derived products 
 





N-end rule dipeptides 
(dipeptides with bulky or 
basic N-terminal residues) 
 
Transcriptional 
regulation on PTR2  
(TURNER et al. 2000) 
Regulation of 
translation 




Functional elements to 







Inhibitor of protein 
tyrosine phosphatase 1 
B (PTP1B); improve 
insulin resistance 
 
(LARSEN et al. 2002) 
Melanocyte-stimulating 
hormone release-inhibiting 





binding to human 
dopamine (DA) 
receptor 

















 modulate the function of receptors. For example, hypothalamic tripeptide PLG and its 
analog 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) 
enhance agonist binding to the human dopamine receptor (VERMA et al. 2005). The 
formylpeptide family, derived from bacterial proteins and disrupted cells, as well as the 
synthetic tripeptide N-formyl-L-methionyl-L-Leucyl-L-phenylalanine can interact with 
specific receptors in neutrophil plasma membranes and activate a transduction pathway in 
response to bacterial infection and tissue damage (DALPIAZ et al. 2003).  
 
Di/tri-peptides serve as promoieties, soluble agents for covalent attachment of drugs: 
Di/tri-peptides are also used as the soluble agents for covalent attachment of drugs to 
increase drug delivery efficiency. The conjugation of di/tri-peptide to drugs usually alters 
the physical and chemical properties of drugs and di/tri-peptides can serve as a vehicle to 
deliver drugs via targeting hPepT1/2 transporters in humans (Table 3) (TEMSAMANI and 
VIDAL 2004). First, di/tri-peptidomimetic prodrugs are designed to increase the solubility 
and enhance the influx by increasing the affinity of the modified compound. For example, 
Val-Val-ACV (valyl-valyl-acyclovir), an antiviral nucleoside used to treat herpetic 
epithelial and stromal keratitis, shows high water-solubility in the physiological pH range 
in vivo and an increase of absorption of drugs due to high affinity toward the hPEPT1 
(ANAND et al. 2003a; ANAND et al. 2003b). The conjugation of polyoxins and 
nikkomycins, antifungal agents for inhibiting chitin synthetase, with di/tri-peptides 
increases the permeability of compounds via the transport system (KRAINER et al. 1991). 
Second, di/tri-peptidomimetic prodrugs are designed to decrease efflux. Val-Val-SQV 
and Gly-Val-SQV uptake into cells are significantly enhanced by the reduced secretion 
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Table 3 The significance of di/tri-peptides serving as vehicles to deliver drugs 
 
Significance Di/tri-peptides and 
Components 
Activity References 
Val-Val- acyclovir (ACV)/ 
Gly-Val-ACV 
 
Antiviral nucleoside acyclovir (ANAND et al. 





Di/tri-peptidyl polyoxin and 
Nikkomycin 
 




Val-Val-saquinavir (SQV)  Enhanced cellular 
permeability of saquinavir 
(SQV) and modulate p-gp 
mediate efflux 
 





propenoic acid -Ala-Pro 
Activated by intestinal ACE 
and used in the treatment of 
different forms of colon 
cancer 
 









 of SQV, an effective HIV protease inhibitor, due to fact that the membrane bound efflux 
protein P-gp can not recognize the tripeptide prodrug (JAIN et al. 2005). Third, di/tri-
peptidomimetic prodrugs are designed to stabilize drugs, or protect them from different 
pH or from enzymatic digestion such as pancreatic and intestine peptidases. Ala-Pro 
dipeptide is used to conjugate with the anticancer compound 3-(4’-geranyloxy-3’-
methoxyphenyl)-2-trans-propenoic acid. This dipeptidyl prodrug is highly stable but can 
be activated by intestinal angiotension converting enzyme (ACE, dipeptidyl 
carboxypeptidase) located on the external side of the intestinal brush border membrane of 
the small and large intestines to release the anticancer compound (CURINI et al. 2005). 
Dipeptides with unnatural amino acids, such as D-Asp-Ala and D-Glu-Ala have also been 
used to couple with drugs for the protection of the drug from enzyme digestion by 
enhancing the permeability across the intestine (FRIEDRICHSEN et al. 2001).  Furthermore, 
dipeptides also act as effective promoieties to deliver unnatural amino acids. (+)-2-
Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid is a potent agonist for metabotrophic 
glutamate receptors, and suppresses enhanced glutamatergic excitations in brain synapses 
blocking anxiety. A derivative of this compound containing a N-terminal dipeptide 
addition showed an 8-fold increase in drug absorption and a 300-fold increase in potency 
compared with its parent chemical (BUENO et al. 2005).  Other dipeptides, such as Val-
Asp, Phe-Gly, and Phe-Asp, were also demonstrated to be promising pro-moieties in drug 
delivery (VABENO et al. 2004a; VABENO et al. 2004b). In spite of the fact that many 
studies have been performed to elucidate the structural requirements for an optimal 
peptide transport substrate for hPEPT1/2 (DANIEL 2004; MEREDITH and BOYD 2000; 
NIELSEN and BRODIN 2003), it is not entirely clear how to design the peptide portion of 
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the prodrug to facilitate drug delivery via PepT1/2 peptide transporters, although the size 
of drug and modification of N-terminal amino acid side chain should be taken into 
consideration (FRIEDRICHSEN et al. 2001; ERIKSSON et al. 2005).   
 
Peptide transporter systems 
Di/tri-peptide transport has been documented in a wide variety of organisms 
including bacteria, fungi, plants, invertebrates, and vertebrates. Influx of di/tri-peptides is 
mediated by two types of transport systems, ATP-binding cassette (ABC) peptide 
transporters and proton-driven peptide transporters (Table 4) (STEINER et al. 1995). 
 
ABC transporter systems: Three ABC peptide transporters, oligopeptide permease 
(Opp), dipeptide permease (Dpp), and other single protein peptide permeases have been 
reported in prokaryotic organisms. The Opp transport system consists of five essential 
polypeptide proteins, OppA, OppB, OppC, OppD, and OppF (Figure 1). OppA is a 
substrate binding protein located in the periplasmic space between the cytoplasmic 
membrane and the outer membrane in gram-negative bacteria, and the binding of a 
substrate leads to the conformational change of this protein. Similar to eukaryotic cells, 
which typically have 12 transmembrane domains in their permeases, OppB and OppC are 
two transmembrane proteins each containing six TMs for a total of 12 membrane-
spanning domains. Together, these two proteins create a transmembrane pore for 
substrate translocation. OppD and OppF located at the cytoplasmic membrane are related 
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Table 4 ATP-binding cassette (ABC) transport systems involved in di/tri-peptide utilization in prokaryotes 
 
Identified systems Transmembrane 
domains 
Substrate Involved proteins Regulation Representative 
organisms 
Dpp 2 six-trans-membrane 
domains  
Dipeptides; 
Limited in tripeptides 
Multiple proteins 





down regulates DppA 
E. coli 
S. tryphimurium  
P. Aureuginosa 
S. pyogenes 
Opp 2 six-transmembrane 
domains  
High affinity for 








(oppA, oppB, oppC, 
oppD, oppF) 
Induced in anaerobic 
conditions and media 
containing Leu Ala; 
Repressed through Lrp 
protein in E.coli; 
 
Repressed by codY and 










Opt Not-reported larger than tetrapeptides Multiple proteins 
[optABCDF 
two oligopeptide 
binding proteins (OptS 
and OptA)] 
unknown L. lactis 
DtpP Not-reported di-/tripeptides 
(branched-chain 
Hydrophobic peptides) 
Single protein Induced in the presence 
of di- and tripeptides 
containing branched-








to ATP binding and hydrolysis, where energy is needed for substrate translocation 
(PAYNE and SMITH 1994). The Opp transport system has a high affinity for tripeptides 
and has limited activity for transporting dipeptides in E.coli and S.typhimium. However, 
Opp system can also transport 3-5 amino acid residues in B.subtilis (SOLOMON et al. 
2003), and peptides of 4 to 35 amino acids in L. lactis (DETMERS et al. 1998; DOEVEN et 
al. 2004). OppA is the major determinant of substrate specificity for the Opp transport 
system, and has been identified in other bacterial organisms with limited differences in 
OppA (LIN et al. 2001). To adapt to the changes in the environment, several versions of 
OppA substrate binding proteins OppA-1,-2,-3, -4, -5 have also been identified in B. 
burgdorferi. For example, OppA-5 is regulated by temperature stress; while the other 
functional homolog of OppAs might be responsible for other environmental conditions. 
Multiple versions of these substrate binding proteins possibly reflect the capabilities of 
peptide uptake for nutrient requirements and possess an evolutionary advantage in 
different environments (LIN et al. 2001). 
Similar to the Opp transport system, the dipeptide permease (Dpp) system also 
contains five polypeptides (DppA to DppE) and is involved in the uptake of essential 
amino acids, and dipeptide chemotaxis  (Table 4) (PODBIELSKI and LEONARD 1998). The 
Dpp transporter system transports primarily dipeptides and to a limited extent, tripeptides 
(PAYNE and SMITH 1994). DppA has structural homology to the substrate-binding OppA 
protein (ABOUHAMAD et al. 1991); DppB and DppC are transmembrane proteins involved 
in the translocation of substrates; DppD and DppE are membrane associated ATPases 
that provide energy for translocation of the substrates. 
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 Other ABC transporters such as oligopeptide transporter (Opt system) have also 
been identified (Table 4). Similarly, the Opt transport system contains multiple proteins 
OptA, OptB. OptC, OptD, OptF. In L. lactis, OptS and OptA, two binding proteins are 
identified, which might function at different environment conditions. Compared with Opp 
or Dpp system, Opt has a different genetic organization and mainly transports larger than 
tetrapeptides as its substrate (LAMARQUE et al. 2004). Single protein ABC dipeptide 
permeases such as DtpP have also been identified in L. lactis (KUNJI et al. 1996a). DtpP 
preferentially transports di/tri-peptides composed of hydrophobic residues (branched-
chain amino acids). DtpP is driven by ATP or a related energy-rich phophorylated 
intermediate since the activity is inhibited by o-vanadate, an inhibitor of ATP production 
in the glycolytic pathway. DtpP is induced by its own substrates such as in the presence 
of di/tri-peptides with branched-chain amino acids (FOUCAUD et al. 1995). However, how 
ATP is involved in the single protein peptide transport remains unknown. 
 
Regulation of ABC transporter systems: ABC transporter systems are regulated by the 
cell’s environment. Some small molecules in the media can even trigger the expression of 
the entire transporter activity. For example, the Dpp transporter system is constitutively 
expressed, but the transport ability is down-regulated when bacteria grow in phosphate-
limited medium due to decreased expression of DppA (ABOUHAMAD et al. 1991). The 
Opp transporter system is induced under anaerobic conditions, while the amino acids 
leucine and alanine up-regulate peptide transport by increasing transcriptional expression 
of OppA in E. coli and S. tryphimurium. In addition, some regulatory proteins have been 
identified that are involved in the expression of the transporter system at the 
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transcriptional level. For instance, the expression of the Opp operon is repressed by the 
leucine-responsive regulatory protein (Lrp) in E. coli. Mutation of this gene results in 
constitutive expression of the Opp system (CALVO and MATTHEWS 1994). However, how 
the Opp system is regulated by Leu and how the Lrp repressor is related to leucine 
upregulation remains unclear. It might be possible that a sensor system can detect leucine 
which results in the regulation of Opp transcription. In L. lactis, CodY, a transcriptional 
regulator, interacts with the upstream promoter of the Opp transport system, and 
branched amino acids directly impact the binding of repressor CodY on the promoter 
region of the Opp operon (DEN HENGST et al. 2005).  
 
Proton-driven di/tri-peptide transport: The proton oligopeptide transporter (POT) or 
PTR superfamily is another type of peptide transporter involved in the uptake of di/tri-
peptides. PTR transporters are symporters in that the influx of di/tri-peptides is coupled 
with the uptake of protons. As a result, this process leads to a decrease in the pH in the 
cytosol. The fluctuation of pH in the cytosol is regulated by an antiporter, Na+/H+ 
exchange transporter (NHE) in both prokaryotic and eukaryotic organisms (BOOTH 1985; 
MADSHUS 1988). NHE exports the proton by uptaking Na+ across the plasma membrane 
into the cytosol. Furthermore, Na+/K+ pump regulates Na+ intracellular concentration by 
the exchange of K+ (Figure 1). In addition, H+-ATPase is also involved in the proton 
homeostasis. H+-ATPase pumps protons out of the cell by hydrolysis of ATP.  
 PTR family members are present in all cells studied to date (HAUSER et al. 2001). 
At least 40 members are classified into the PTR family in both prokaryotic and 
eukaryotic organisms (SAIER et al. 2006). Among theses transporters, DtpT, Ptr2p, and 
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PepT1/2 are the most studied peptide transporters in bacteria, yeast, and mammals, 
respectively (Table 5).  
In prokaryotic organisms, the DtpT transporter is predicted to contain 12 
transmembrane domains and has high affinity for transporting hydrophilic and charged 
peptides in L. lactis (HAGTING et al. 1997). DtpT is also identified in Listeria 
monocytogenes, and is involved in salt stress protection and might also contribute to the 
virulence of L. monocytogenes (WOUTERS et al. 2005). In addition, several 
uncharacterized E.coli transporters including YhiP, f493 and Yjd also have the ability to 
transport di/tri-peptides (SAIER 1999). Another type of peptide transporter, tripeptide 
permease (Tpp) was identified in S. typhimurium, however, it does not carry the signature 
sequence of PTR transport family nor is it an ABC transporter. The Tpp system has a 
restricted range of tripeptide substrates containing hydrophobic residues and is not able to 
transport substrates larger than tetrapeptides (SMITH et al. 1999). Expression of Tpp is 
induced under anaerobic conditions and is positively regulated by the gene products of 
ompR and anvZ (ABOUHAMAD et al. 1991). 
In eukaryotic organisms, two distinct peptide transport systems have been 
reported in a variety of organisms (Hauser et al. 2001): the PTR (Peptide TRansport) 
system transports di/tri-peptides (STEINER et al. 1995) and the OPT (OligoPeptide 
Transport) system highly favors the transport of peptides of four to five amino acid 
residues and also glutathione (LUBKOWITZ et al. 1997; MIYAKE et al. 2002). Both the 
PTR and OPT transport systems are predicted to contain twelve transmembrane domains, 
and have specific signature sequences distinguishing them from one another as well as 
from all other proteins in the database (HAUSER et al. 2001). Ptr2p, encoded by the PTR2  
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Gene expression or mRNA stability 
 
Protein trafficking Organism 
DtpT Unknown 1) Induced in anaerobic condition; 
2) Up-regulated by Leu and Ala  
 
unknown Bacteria 
PTR2 Unknown  
 
1) Poor nitrogen medium 
2) N-end rule dipeptides enhance PTR2 expression 
3) Ssy1p-Ptr3p-Ssy5p protein complex induces 
PTR2 expression. 
4) Stp1/2p is PTR2 transcriptional activation. 
5) Cup9p represses PTR2 transcription 
6) Ptr1p, Ubc2p and Ubc4p are involved in the 
degradation of Cup9p. 
 
1) Protein components of 
ESCRT I, II, III complex 
 








1) High protein diet, fasting, or starvation increases 
expression. 
2) Presence of Phe,Arg, Lys and Gly-Sar, Gly-Phe, 
Lys-Phe,Asp-Lys increases PEPT1/2 expression via 
influence the level of transcriptional factor AP-1  
3) Tissue specific expression 
4) Epidermal growth hormone and thyroid  hormone 
5) Ligand of  σ receptor 
6) Organism development, injury and disease states 
 
1) Insulin and leptin increase 




gene, is the only member of the PTR system transporting di/tri-peptides in S. cerevisiae. 
Highly conserved regions of the PTR family are located in TM2, TM3, and TM5 and the 
intracellular loop between TM2 and TM3 (MEREDITH and BOYD 2000). Another di/tri-
peptide transporter Dal5p has been recently discovered in yeast but does not contain the 
PTR signature sequence. Dal5p has di/tri-peptide transport activity, and additionally 
transports allantoate/ureidosuccinate (HOMANN et al. 2005).  
In mammals, two major di/tri-peptides transporters, PepT1 and PepT2 of the PTR 
system have been utilized for drug delivery. PepT1 and PepT2 were first identified in the 
intestine and kidney, respectively (FEI et al. 1994; LIU et al. 1995). PepT1 has a low 
affinity but a high capacity for di/tri-peptide transport, while PepT2 has a low capacity 
but high affinity. Expression and activity of these peptide transporters were also shown in 
other organs such as lung, placenta, mammary gland, pancreas, pituitary gland, 
reproductive organs, and the central nervous system (LU and KLAASSEN 2005). Two 
other peptide transporters, PHT1 and PHT2, have also been identified to transport free 
histine and certain di/tri-peptides (DANIEL and KOTTRA 2004; MEREDITH and BOYD 2000; 
NIELSEN and BRODIN 2003). PepT1/2 transporters provide the means for absorption of 
nutritional peptides and peptidomimetic drugs. Peptidomimetic substances  such as beta-
lactam antibiotics (Cefadroxil, Cefadrine, cyclacillin, Cefixime, cephalosporins and 
Ceftibuten), the anticancer compound Bestatin, and angiotension-converting enzyme 
(ACE) inhibitors (Captopril, Enalapril, and Fosinopril) can also be transported by peptide 
transporters (RUBIO-ALIAGA and DANIEL 2002), and has been commercialized for 
treating many diseases. The substrate specificity of these transporters has provided an 
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mpetus to many pharmaceutical companies to develop peptide transporters as drug 
delivery systems (HERRERA-RUIZ and KNIPP 2003; LEE 2000).    
 
Regulation of PTR transport system: It is not clear whether the members of the PTR 
transport system are regulated in a similar pattern, however understanding the regulation 
of one peptide transporter might shed light on the study of another. In prokaryotic 
organisms, DtpT expression is induced under anaerobic conditions, and growth medium 
containing Leu or Ala up-regulates peptide transport (PAYNE and SMITH 1994). Further 
research is needed on the regulation of DtpT expression and function since little 
information is known for the mechanism of the regulation. 
Among the peptide transporters of the PTR system, PTR2 transcriptional 
regulation in yeast has been studied in a great detail at the molecular level due to the 
simplicity of genetic manipulation. This research might provide clues for understanding 
the genetic regulation of PEPT1/2 for drug delivery in mammalian organisms. 
 
Regulation of di/tri-peptide utilization via transcriptional regulation of PTR2 in yeast: 
Peptide transport is up-regulated by growth media containing poor nitrogen sources, such 
as allantoin, isoleucine, or proline (ISLAND et al. 1991). Under poor nitrogen conditions, 
PTR2 expression is highly upregulated and results in more efficient di/tri-peptide 
transport. In media containing the rich nitrogen source ammonium, PTR2 expression is 
down-regulated via nitrogen catabolite repression (MARZLUF 1997).  
At least three pathways have been shown to be related to the transcriptional 
regulation of PTR2 (Figure 2). First, specific amino acids regulate PTR2 expression via a  
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Figure 2 The regulation of SPS protein complex on amino acid permeases and PTR2.  
There are at least three types of sensors in the yeast plasmic membrane. Mep2p sensors 
NH4+ concentration; Snf3/Rgt2p and Gpr1p sensor glucose; and Gap1p and Ssy1p sensor 
amino acids in the extracellular environment. Ssy1p-Ptr3p-Ssy5p form a protein complex 
and deliver signal to up-regulate the expression level of PTR2 encoding di/tri-peptide 
tansporter, and other amino acid permeases such as AGP1, BAP2, and down-regulate the 
expression level of GAP1. The regulation of PTR2 is involved in the modification of 
Stp2p by trancating the N-terminal of Stp2p. The truncated Stp2p is translocated into 
nucleus to regulate PTR2 transcription. SCF GRR1 protein complex is involved in the SPS 
signal transduction pathway, but the role of this protein complex is not clear. In addition, 
PTR2 transcription is also repressed by Cup9p. Cup9p is destabilized by the protein 
complex of Ptr1p, Ubc2p, and Ubc4p via ubiquitination pathway. SPS protein complex 
also regulates the release of amino acid from vacuole. The process remains unclear. 
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signal transduction pathway. Peptide utilization was markedly enhanced by addition of 
micromolar amounts of certain amino acids, most notably leucine and tryptophan, to the 
growth medium (BAETZ et al. 2004; ISLAND et al. 1987). The addition of these amino 
acids has been shown to up-regulate the expression of PTR2 (PERRY et al. 1994). Amino 
acids regulate PTR2 expression by the SPS (Ssy1p-Ptr3p-Ssy5p) signal transduction 
pathway (BARNES et al. 1998; FORSBERG et al. 2001a; FORSBERG et al. 2001b; FORSBERG 
and LJUNGDAHL 2001b). In the SPS complex, Ssy1p is a transmembrane receptor that 
senses extracellular amino acids. Similar to the amino acid permeases, Ssy1p contains 12 
predicted transmembrane domains and requires Shr3p function for its localization to the 
cytoplasmic membrane (KLASSON et al. 1999). However Ssy1p is not able to transport 
amino acids, but instead acts as a sensor for the induction of several permease genes and 
a di/tri-peptide transporter gene PTR2. These permeases include branched-chain amino 
acid permease (BAP2 and BAP3), tyrosine and tryptophan permease (TAT1), dicarboxylic 
amino acid permease (DIP5), carnitine transporter (AGP2), methionine permease 
(MUP1), broad-specificity amino acid permease (AGP1), tyrosine permease (TAT2), 
glutamine permease (GNP1), gamma-aminobutyrate (GABA) and Delta-aminolevulinic 
permease (UGA4), arginase gene (CAR1), nitrogen catabolite repression (NCR)-sensitive 
genes (BERMUDEZ MORETTI et al. 2005; ECKERT-BOULET et al. 2004; FORSBERG et al. 
2001a; KODAMA et al. 2002), reduction of the arginine permease gene (CAN1), high-
affinity proline permease (PUT4), and the general amino acid permease gene (GAP1) 
(FORSBERG et al. 2001a; KLASSON et al. 1999; KODAMA et al. 2002). Compared to other 
amino acid permease, Ssy1p has a unique extended N-terminal region, which is essential 
for its function. Plasmid-borne over-expression of this N-terminal region interferes with 
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Ssy1p function in a dominant negative manner (BERNARD and ANDRE 2001b). The 
mutation of threonine 382 of Ssy1p to other amino acids results in constitutive amino 
acid signaling, which further supports that Ssy1p is a sensor responding to extracellular 
amino acids (BERNARD and ANDRE 2001b; POULSEN et al. 2005). In addition to the 
amino acid sensor Ssy1p, other sensor components, the glucose sensors Snf3/Rgt2p and 
the ammonium sensor Mep2p have also been studied. Recently, the general amino acid 
permease, Gap1p, has also been reported to act as an amino acid sensor for the activation 
of protein kinase A targets, such as the activation of trehalase and repression of HSP12, 
CTT1 and SSA3, which results in the fermentable growth (DONATON et al. 2003). 
Ptr3p and Ssy5p are hydrophilic proteins, but are associated with the cytoplamic 
side of the membrane. Yeast two hybrid experiments show protein-protein interactions of 
Ptr3p-Ssy5p and Ptr3p-Ptr3p (BERNARD and ANDRE 2001a). Ptr3p and Ssy5p interact 
with the cytoplasmically located N-terminus of Ssy1p, and are required for their function 
(FORSBERG and LJUNGDAHL 2001a; POULSEN et al. 2005). Single and double deletion 
mutations of these three components showed identical growth phenotypes (FORSBERG 
and LJUNGDAHL 2001a), and overexpression of Ssy5p suppresses the growth defect 
caused by the deletion of SSY5 and PTR3 (BERNARD and ANDRE 2001a). In addition, the 
deletion of SSY1 and PTR3 caused a change in cell morphology with invasive growth and 
accumulation of histidine and arginine in the vacuole (KLASSON et al. 1999). Two related 
transcription factors, Stp1p and Stp2p, are downstream of the SPS complex and regulate 
the expression of PTR2 and branched-chain amino acid permeases, BAP2, BAP3, and 
AGP1 (DE BOER et al. 2000). Stp1p and Stp2p are synthesized in an inactive form and 
were first identified as necessary for the maturation of pre-tRNAs. The activation of 
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Stp1p and Stp2p depends on the endoproteolytic-processing of their N-terminal domain 
mediated by Ptr3p and Ssy5p (ANDREASSON and LJUNGDAHL 2002; ANDREASSON and 
LJUNGDAHL 2004). In the study of the SPS complex on the regulation of AGP1 
expression, Ssy1p and Ptr3p are involved in signal sensing while Ssy5p is involved in the 
activation of Stp1p. Ssy5p acts as an endoprotease catalyzing the cleavage of Stp1p in 
response to extracellular amino acids. Likely Ptr3p self-association brings Ssy5p together, 
which leads to Ssy5p undergoing Ptr3p-dependent self-processing (ABDEL-SATER et al. 
2004a). Furthermore, casein kinase I is involved in the phosphorylation of the inactive 
form of the membrane bound transcription factor Stp1p before undergoing an 
endoproteolytic process (ABDEL-SATER et al. 2004a). The truncated forms of Stp1p and 
Stp2p are translocated into the nucleus to up-regulate expression of down-stream genes 
including PTR2 (ANDREASSON and LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 
2004). The processing of Stp1p/2p is also required for the F-box protein Grr1p, which is 
a component of the SCFGrr1 ubiquitin ligase complex (Skp1p, Hrt1p, Cdc34p, and 
Cdc53p) that labels proteins for degradation by the proteasome. However, the detailed 
process of the participants of this protein complex remains unclear in the SPS signal 
transduction pathway (ABDEL-SATER et al. 2004a; ANDREASSON and LJUNGDAHL 2004; 
BERNARD and ANDRE 2001b).  
PTR2 expression is negatively regulated by the repressor Cup9p, which binds the 
PTR2 promoter region between nucleotides -488 and -897 upstream of the PTR2 start 
codon. In a cup9 null mutant, PTR2 is over-expressed and results in a marked increase in 
dipeptide uptake (BYRD et al. 1998).  Cup9p is degraded by Ptr1p through the 
ubiquitinylation pathway. In this pathway, Ptr1p acts as a scaffolding protein or ubiquitin 
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ligase (E3) for two other proteins, Ubc2p and Ubc4p, which serve as ubiquitin-
conjugating (E2) enzymes in the Cup9p degradation process (XIE and VARSHAVSKY 
1999). Dipeptides containing N-terminal basic (Arg, Lys, His) or bulky hydrophobic (Phe, 
Leu, Tyr, Trp and Ile) residues directly bind to two distinct binding sites of Ptr1p, and 
accelerate the Ptr1p-dependent degradation of Cup9p (TURNER et al. 2000). Deletion of 
PTR1 results in the stabilization of Cup9p, lack of expression of PTR2, and a null 
peptide-uptake phenotype (DU et al. 2002; ISLAND et al. 1991; TURNER et al. 2000). 
Other transcription factors, such as Dal81p/Uga35p, have also been reported to be 
involved in PTR2 and AGP1 expression (ABDEL-SATER et al. 2004b; IRAQUI et al. 1999), 
however it is not clear how Dal81p responds to the external amino acid sensing pathway 
(IRAQUI et al. 1999). Obviously, the systems regulating PTR2 expression are complex, 
and there has not been a systematic study to uncover other proteins involved in the 
regulation of peptide utilization.  
Regulation of di/tri-peptide utilization in mammals: In the mammalian peptide 
transport system, the mechanisms of the regulation on di/tri-peptide transport are still not 
clear at the molecular level; however some studies have demonstrated several 
physiological conditions and possible cellular processes that could impact di/tri-peptide 
transport activity. These physiological conditions mainly impact di/tri-peptide transport 
in three aspects (Table 3) (NIELSEN and BRODIN 2003). First, some factors that affect 
NHE3 activity, defined as Na+/H+ exchanger, resulting from the alteration of pH will 
indirectly alter di/tri-peptide uptake. For example, the uptake of di/tri-peptides is 
regulated by the intracellular calcium concentration. The calcium concentration might 
trigger the activation of protein kinase A (PKA) and C (PKC), which lead to alteration of 
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NHE3 function. As a result, the calcium concentration will eventually influence dipeptide 
influx via NHE3 activity, and the increase of calcium leads to a decrease of peptide 
uptake through the PepT1 transporter (MEREDITH and BOYD 2000). 
Second, alteration of hPepT1/2 trafficking system will change di/tri-peptide 
transport. Several hormones such as insulin and leptin show significant alteration in the 
capability of di/tri-peptides uptake. An increased insulin level immediately elevates the 
rate of Gly-Gln influx in Caco-2 cells; increases Vmax two fold by increasing the amount 
of transporters in the plasma membrane without a change in the Km value of the 
transporter, suggesting peptide transporter activity remains the same (NIELSEN et al. 2003; 
THAMOTHARAN et al. 1999). 
Third, modification of transcriptional expression of the peptide transporter or its 
mRNA stability leads to a change in di/tri-peptide transport. A high protein diet, fasting 
or starvation increases the level of mRNAs of hPepT1 in the intestine (MEREDITH and 
BOYD 2000; NIELSEN and BRODIN 2003). It is not clear how this diet condition triggers 
the changes in expression level. In addition, the expression of hPepT1/2 is also up-
regulated in the presence of dietary amino acids (Phe, Arg, and Lys) and peptides (Gly-
Sar, Gly-Phe, Lys-Phe and Asp-Lys) possibly through the transcription factor AP-1 since 
the PepT1 gene promoter contains its binding sequence. It is possible that high 
concentrations of amino acids and peptides up-regulates the expression level of AP-1 
(SHIRAGA et al. 1999; THAMOTHARAN et al. 1998). Expression of the peptide transporter 
also varies in different tissues. hPEPT1 has higher expression in the small intestine and 
lower in kidney and liver, and no expression in colon. However, how the expression is 
changed in different tissues remains unsolved. Epidermal growth factor and thyroid 
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hormone show a significant alteration in the uptake of di/tri-peptides by increasing the 
PEPT1 expression (ADIBI 2003; ASHIDA et al. 2002). A ligand such as (+)pentazocine for 
sigma receptor, the plasma membrane receptor binding with nonopiate and 
nonphencyclidine, can also up-regulate the expression of PEPT1 (FUJITA et al. 1999). In 
addition, the expression of the di/tri-peptide transporter also changes in the development 
process, injury and disease states such as cancer, as well as diabetes and intestinal 
inflammation (ADIBI 2003); the mechanisms of these conditions affecting the expression 
level are largely unknown. Compared with the known gene products involved in the 
regulation of PTR2 in yeast, such as SPS sensor, it is not known whether the counterparts 
in mammals to regulate PEPT1/2 exist and play the similar role. 
Rationale for this study: 
This study was undertaken to identify possible genes involved in the regulation of 
peptide utilization in yeast. In my study, I performed a genome-wide screen on a yeast 
single gene deletion mutant library. In addition, we used high-throughput phenotyping in 
which we grew yeast cells on 284 different dipeptides or 11 tripeptides as the sole 
nitrogen source in several genetically diverse strains.  Several gene products and signal 
pathways involved in the regulation of di/tri-peptide utilization have been identified in 
this study. The identified genes regulating dipeptide utilization represented a very wide 
regulatory network involved in transport and utilization of dipeptides in yeast.  The 
identified components involved in dipeptide utilization may help understand the 
regulation of peptide transport in mammals. This is the first such study of a membrane 
transport system in any organism and initiates a systems biology approach to 
understanding membrane transport in cells. 
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ABSTRACT 
Small peptides of two to six residues serve as important sources of amino acids 
and nitrogen required for growth by a variety of organisms.  In the yeast Saccharomyces 
cerevisiae, the membrane transport protein Ptr2p, encoded by PTR2, mediates the uptake 
of di/tri-peptides. To identify genes involved in regulation of dipeptide utilization, we 
performed a systematic, functional examination of this process in a haploid, non-essential, 
single-gene deletion mutant library. We have identified 103 candidate genes: 57 genes 
whose deletion decreased dipeptide utilization and 46 genes whose deletion enhanced 
dipeptide utilization. Based on Ptr2p-GFP expression studies, together with PTR2 
expression analysis and dipeptide uptake assays, 42 genes were ascribed to the regulation 
of PTR2 expression, 37 genes were involved in Ptr2p localization, and 24 genes did not 
apparently affect Ptr2p-GFP expression or localization. The 103 genes regulating 
dipeptide utilization were distributed among most of the Gene Ontology functional 
categories indicating a very wide regulatory network involved in transport and utilization 
of dipeptides in yeast. It is anticipated that further characterization of how these genes 
affect peptide utilization should add new insights into the global mechanisms of 
regulation of transport systems in general and peptide utilization in particular. 
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INTRODUCTION 
Peptides can serve as a major nutritional source of amino acids and nitrogen for 
microbial cell growth and for human nutrition as well (DANIEL 2004; PRITCHARD and 
COOLBEAR 1993). Peptides are generated by the action of proteases and peptidases in 
environments where microbes reside (DANIEL 2004; GONZALES and ROBERT-BAUDOUY 
1996). All cellular organisms from bacteria to fungi, plants and mammals are capable of 
taking up small peptides (two to six amino acids) through a system mediated by 
cytoplasmic membrane transporters specific for peptides (HAUSER et al. 2001). In 
mammalian systems, two major peptide transporters, PepT1 and PepT2, have been found 
in the intestine and kidney, respectively (FEI et al. 1994; LIU et al. 1995). The PepT1 
transporter provides the means for absorption of nutritional peptides and peptidomimetic 
drugs, such as beta-lactam antibiotics, angiotensin converting enzyme inhibitors, renin 
inhibitors, and antivirals. The substrate specificity of these transporters has provided an 
impetus to many pharmaceutical companies to develop peptide transporters as drug 
delivery systems (HERRERA-RUIZ and KNIPP 2003; LEE 2000).  
 Two peptide transport systems have been characterized in the model eukaryote 
Saccharomyces cerevisiae: the PTR (Peptide TRansport) system transports di/tri-peptides 
(STEINER et al. 1995) and the OPT (OligoPeptide Transport) system highly favors 
transport of peptides of four to five amino acid residues and glutathione (LUBKOWITZ et 
al. 1997; MIYAKE et al. 2002). While PTR family members are present in all cells studied 
to date and are in the same family as the mammalian transporters PepT1 and PepT2, OPT 
family members have been found only in plants and fungi (HAUSER et al. 2001). Both 
The PTR and OPT transport systems are dependent on the proton-motive force, are 
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predicted to have twelve transmembrane domains, and have specific signature sequences 
distinguishing them from one another and from all other proteins in the database 
(HAUSER et al. 2001). Yet the amino acid sequence of the PTR and OPT members places 
them in different, unrelated families of transport proteins with presumably totally 
separate evolutionary origins. The only S. cerevisiae member of the PTR system is Ptr2p, 
encoded by the PTR2 gene. Di/tri-peptide utilization is regulated by a number of means 
including PTR2 transcriptional regulation. 
 In early studies pre-dating the cloning of PTR2, peptide utilization was shown to 
be up-regulated by growing cells on organic nitrogen sources such as allantoin, isoleucine, 
or proline defined as poor nitrogen sources in comparison to the rich nitrogen source 
ammonium sulfate (ISLAND et al. 1991). Peptide utilization was also stimulated markedly 
by addition of micromolar amounts of certain amino acids, most notably leucine and 
tryptophan, to the growth medium (BAETZ et al. 2004; ISLAND et al. 1987). These 
environmental conditions were later shown to up-regulate the expression of PTR2 (PERRY 
et al. 1994). Although nitrogen source apparently regulates PTR2 expression via nitrogen 
catabolite repression (MARZLUF 1997), amino acids regulate PTR2 expression via the 
SPS (Ssy1p-Ptr3p-Ssy5p) signal transduction pathway (BARNES et al. 1998; FORSBERG et 
al. 2001a; FORSBERG et al. 2001b; FORSBERG and LJUNGDAHL 2001b). 
  In the SPS complex, Ssy1p is a transmembrane receptor that senses extracellular 
amino acids. Ptr3p and Ssy5p interact with the cytoplasmically located N-terminus of 
Ssy1p (FORSBERG and LJUNGDAHL 2001a; POULSEN et al. 2005). Two related 
transcription factors, Stp1p and Stp2p, are down-stream of the SPS complex and regulate 
the expression of PTR2 and branched-chain amino acid permeases (DE BOER et al. 2000). 
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Stp1p and Stp2p are synthesized in an inactive form, and the activation of Stp1p and 
Stp2p depends on the endoproteolytic-processing of their N-terminus domain mediated 
by Ptr3p and Ssy5p. The truncated forms of Stp1p and Stp2p are translocated into the 
nucleus to up-regulate expression of down-stream genes including PTR2 (ANDREASSON 
and LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 2004).  
 In addition to the SPS complex regulation, PTR2 expression is positively 
regulated by the import of di/tri-peptides with basic (Arg, His, or Lys) and bulky (Ile, Leu, 
Phe, Trp, or Tyr) N-terminal residues that bind to Ubr1p to allosterically activate Ubr1p-
mediated degradation of the PTR2 repressor Cup9p (BYRD et al. 1998; DU et al. 2002; 
TURNER et al. 2000).  Relief of Cup9p repression of PTR2 results in enhanced PTR2 
expression.  In a cup9 null mutant strain, PTR2 is over-expressed, resulting in a marked 
increase in dipeptide uptake (BYRD et al. 1998).  Cup9p is degraded by Ptr1p through the 
ubiquitinylation pathway. In this pathway, Ptr1p acts as a scaffolding protein or ubiquitin 
ligase (E3) for two other proteins, Ubc2p and Ubc4p, which serve as ubiquitin-
conjugating (E2) enzymes in the Cup9p degradation process (XIE and VARSHAVSKY 
1999). Deletion of PTR1 results in the stabilization of Cup9p, lack of expression of PTR2, 
and a null peptide-uptake phenotype (DU et al. 2002; ISLAND et al. 1991; TURNER et al. 
2000). Other transcription factors, such as Dal81p/Uga35p, have also been reported to be 
involved in PTR2 expression, in ways apparently different from their involvement in the 
SPS or Cup9p pathways (IRAQUI et al. 1999). Obviously, the systems regulating PTR2 
expression are numerous and complex, and there has not been a systematic study to 
uncover other proteins involved in the regulation of peptide utilization.  
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 Systematic screening of yeast deletion mutant collections has been successfully 
applied in identifying genes related to drug resistance (AOUIDA et al. 2004; BAETZ et al. 
2004; PAGE et al. 2003), human disease (STEINMETZ et al. 2002), telomere function 
(ASKREE et al. 2004), centromeric cohesion (MARSTON et al. 2004), vacuolar protein 
sorting (BONANGELINO et al. 2002), and other biological processes (SCHERENS and 
GOFFEAU 2004). In order to identify other gene products involved in the regulation of 
peptide utilization in yeast, we conducted a genome-wide screen using the haploid, non-
essential, single-gene deletion strain library. We have identified a total of 103 Open 
Reading Frames (ORFs), accounting for about 2 percent of the non-essential deletion 
mutants as being involved in causing increased or decreased utilization of peptides for 
growth. We monitored Ptr2p-GFP expression in the identified 103 deletion mutant 
strains, and genes involved in multiple cellular functions including transcriptional 
regulation and membrane trafficking were revealed as being involved in dipeptide 
utilization. The data generated provide a global view of molecular components regulating 
dipeptide utilization by S. cerevisiae.  
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MATERIAL AND METHODS 
Strains, media, and mutant library growth assay screen:  A yeast haploid, non-
essential, single-gene deletion mutant strain library was purchased from Open 
Biosystems (Huntsville, AL) containing 4827 deletion strains, 4750 in the BY4742 
(MATα his3∆1 leu2∆0 lys2∆0 ura3∆0) background, and 77 strains in the BY4739 (MATα 
leu2∆0 lys2∆0 ura3∆0) strain background. The list of strains contained in the library is 
available at the company’s website (http://openbiosystems.com/yeast_knock_outs.php). 
The deletion mutants were arrayed in 96-well microtiter plates kept at -80˚C in YPD 
broth containing G418 and glycerol (1% yeast extract, 2% peptone, 2% dextrose, 200 
μg/mL G418, and 15% glycerol). After thawing, the deletion mutants were inoculated 
into minimal medium supplemented with amino acids to satisfy the auxotrophic 
requirements using a 96-well plate replicator. The minimal medium used in this study is 
referred to as MM+HLKU and contained (per liter) 20g dextrose, 1.7g Yeast Nitrogen 
Base (Difco) without (NH4)2SO4 and amino acids, 1g allantoin as nitrogen source, 
supplemented with 20μg/mL His (H), 30μg/mL Leu (L), 30μg/mL Lys (K), and 20μg/mL 
Ura (U). The plates were incubated at 30˚C for 2 days, then the liquid medium growth 
assay was performed as follows. Five microliters from each well were inoculated into 
200μL of three different liquid media: (1) MM+HLKU medium as described above, (2) 
MM+(H-L)HKU medium, or (3) MM+(H-L)HKU+Trp medium. The MM+(H-L)HKU 
and MM+(H-L)HKU+Trp media contained 80μM His-Leu dipeptide (H-L) in place of 
leucine with all other components identical to the MM+HLKU medium, except that 
tryptophan (30μg/mL) was added to the MM+(H-L)HKU+Trp medium. The purpose of 
the tryptophan addition was to induce PTR2 expression as shown in previous studies 
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(ISLAND et al. 1987). The efficiency of the utilization of His-Leu was reflected in cell 
growth. The mini-cultures in the microtiter plates were grown at 30˚C with shaking at 
200 rpm. The OD620 was measured at incubation times of 0, 12, 24, 48, and 72 hours with 
a 96-well plate reader (Labsystems Multiskan MCC/340, Finland). In some 
circumstances, growth at incubation times of 36, 60, 84, and 96 hours were also recorded. 
The ptr2 deletion mutant was not able to grow in the His-Leu supplemented medium, 
although its growth in the medium MM+HKLU was excellent.  Strains either defective in 
peptide utilization (ptr1 deletion) or over-expressing PTR2 (cup9 deletion) were 
inoculated into wells of each plate as controls showing defective or enhanced dipeptide 
utilization, respectively. In this manner, deletion strains were identified that grew more, 
or less, efficiently than wild-type in MM+(H-L)HKU or MM+(H-L)HKU+Trp medium. 
 
Solid medium growth assay:  Using the same principle as that employed in the liquid 
medium growth assay, a solid medium growth assay was used to determine whether the 
candidate gene deletion strains obtained from the liquid medium growth screen could 
utilize dipeptide on solid medium as their substrate to satisfy auxotrophic requirements. 
The deletion mutant candidates from the screen, wild type BY4742, cup9, and ptr1 
deletion mutants were grown overnight in MM+HLKU liquid medium at 30˚C while 
shaking at 200rpm. Cells were harvested by centrifugation and washed three times with 
sterile, distilled water. Cells were then counted by hemacytometer and adjusted to the cell 
number of 5x106/mL. Five microliters of a suspension containing 2.5x104 and 2.5x103 
yeast cells were spotted onto agar plates containing one of three different media: (1) 
MM+HLKU, (2) MM+(H-L)HKU, or (3) MM+(H-L)HKU+Trp. The plates were 
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incubated at 30˚C, and growth was recorded after 2 days. A score was given to the 
growth of each strain compared to the growth of wild-type, cup9, and ptr1 deletion 
mutant strains.  
 
Toxic halo assays and osmotic sensitivity assay:  For the toxic dipeptide halo assay, the 
sensitivity of deletion mutants to the toxic dipeptide Ala-Eth was measured as previously 
described (ISLAND et al. 1987). Ethionine (Eth) is an analog of methionine, and 
utilization of Eth causes cell death. This assay is more sensitive than the previously 
described dipeptide growth assays. Yeast cells having a functional dipeptide transport 
system will take up the toxic dipeptide and die (indicated by a clear halo of growth 
inhibition on plates spotted with ethioninyl-containing peptides). Cells with a defective 
dipeptide uptake system will not take up the dipeptide efficiently and will survive (as 
indicated by a small halo or no halo). Cells were grown overnight in MM+HLKU 
medium, then harvested and washed three times with sterile, distilled water. Yeast cells 
were counted and adjusted to the cell number of 5x106/mL. One milliliter of the cell 
suspension was added to 0.8% noble agar (3mL) and plated onto solid MM+HLKU 
medium. Two 6mm sterile paper disks containing either 0.2 or 0.1µmoles of Ala-Eth 
were placed on the lawn of cells. The halo size was measured after two days of 
incubation at 30˚C. The halo size formed by each deletion mutant was compared to the 
halo size of the wild-type strain by dividing the halo size of the mutant by the halo size of 
the wild-type strain and multiplied by 100 to get a percentage. A strain that gave a higher 
than 100% value was considered to be deleted for a gene that would was involved in 
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down-regulation of peptide utilization, whereas a strain deleted for a gene involved in up-
regulation would give a lower than 100% value in this test.  
 For the canavanine toxicity assay, the procedure was the same as the toxic 
dipeptide halo assay.  Two 6 mm sterile paper disks containing 1µg of canavanine were 
placed on the lawn of cells. The size of halo was measured and the image was taken after 
two days incubation at 30˚C.  
 For the osmotic sensitivity assay, the wild type and deletion mutant strains were 
grown overnight in MM+HLKU medium, then harvested and washed three times with 
sterile, distilled water. Yeast cells were counted and adjusted to the cell number of 
5x106/mL, then cells were further diluted to 5x105/mL, 5x104/mL, and 5x103/mL.Ten 
microliters of each cell suspension was spotted into MM+HLKU media containing 0M, 
0.4M, and 1.0M NaCl.  
 
Uptake assays:  The strains were grown overnight in MM+HLKU, then sub-cultured 
into a fresh medium. Cells were harvested in log phase, washed with 2% glucose and 
adjusted to a final concentration to 2x108 cells/mL. The uptake assay was initiated by 
combining equal volumes of pre-warmed (30˚C) cells and uptake assay mixture [2% 
glucose, 20mM sodium citrate/potassium phosphate, pH 5.5, 320µM Leu-Leu (Sigma), 
and 2µCi/ml [3H]Leu-Leu (ISLAND et al. 1987)]. After 10 minutes, portions (100µL) 
were removed onto a membrane filter and washed four times by vacuum filtration with 
1mL ice cold water. The radioactivity retained on the filter was determined by liquid 
scintillation spectrometry, and results were reported as nmol Leu-Leu uptake/1x109 
cells/10 min. The accumulation of [3H]Leu-Leu in ptr2 strain was subtracted from that of 
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the tested strains, and the percentage of the accumulation of [3H]Leu-Leu in each deletion 
mutant vs the wild-type was calculated. 
 
Reporter gene assay:  The centromeric plasmid pRD1, which contained a selectable 
URA3 marker and the lacZ gene under the control of the PTR2 promoter was transformed 
into the tested deletion mutant strains. The reporter gene assay was performed using a 
protocol adapted from Hoffman (HOFFMAN et al. 2002). The strains were grown 
overnight in MM+HLK, and sub-cultured into a fresh medium. Cells were harvested in 
log phase, washed with sterile water and adjusted to a final concentration to 1x108 
cells/mL. Cell suspension (100µL) was added to a well of a 96-well plate, then 20µl FDG 
(Fluorescein di-β-D-galactopyranoside) solution was added. The FDG solution was 
prepared by mixing solution 1 (0.1mM FDG diluted in 25mM PIPES, pH7.2) and 
solution 2 (5% Triton X-100 diluted in 250mM PIPES, pH7.2) in equal amounts just 
prior to use. The plate was incubated at 37˚C for 1.5 hours, then read with a fluorescence 
multi-well plate reader (Wallac Victor2, 1420 multilabel counter, PerkinElmer Life and 
Analytical Sciences, Inc., MA) using 485nm and 530nm as excitation and emission 
wavelengths, respectively.  
 
Classification of the obtained genes:  The classification of the 103 genes identified 
through this screen was based on the Gene Ontology (GO) annotation found in the 
Saccharomyces Genome Database (SGD) (http://db.yeastgenome.org/cgi-
bin/GO/goTermMapper) (CHRISTIE et al. 2004), where 34 functional categories of 
biological process were given. Among the 103 genes, some genes fell into several 
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categories due to their multiple known functions. The detailed gene function could also 
be referenced from Yeast Proteome Database (YPD) database 
(https://proteome.incyte.com/control /tools/ proteome) (HODGES et al. 1999). 
 
Northern analysis of PTR2 mRNA in deletion mutant strains:  Approximately 3x108 
cells of select candidate deletion mutant strains were harvested after overnight growth in 
MM+HLKU medium. Yeast total RNA was isolated using an extraction kit (RiboPureTM- 
yeast, Ambion, Austin, TX). Total RNA was quantified by monitoring absorbance at 
260nm, and 20µg was loaded per lane into a formaldehyde-reducing gel. Gels were run in 
buffer containing MOPS (pH 7.0) for 5 hours at 75V and then transferred by capillary 
action onto a nylon hybridization membrane in 20x SSC. Total RNA was UV cross-
linked to the membrane with a Stratalinker UV source. The blot was prehybridized at 
65ºC in Church buffer (7% SDS, 1% BSA, 1mM EDTA, and 250 mM Na2HPO4, pH 7.2) 
for 2 hours and hybridized overnight in the same buffer containing radioactive probes at 
65ºC. Radioactive probes were prepared as follows. A 1.7kb fragment of PTR2 was 
obtained by PCR amplification using the primers PTR2-F (Northern) and PTR2-R 
(Northern), and a 0.92 kb fragment of ACT1 was obtained by PCR amplification using 
the primers ACT1-F (Northern) and ACT1-R (Northern) (primer sequences are 
represented in Supplemental Table S1). DNA fragments were labeled with (α-32P)-dATP 
by random-primed probe synthesis. Blots were rinsed with post-hybridization buffer 
(0.1X SSC, 0.1% SDS) at 65ºC, and the RNA images were developed with a Storm 840 
phosphoimager (Molecular Dynamics, Sunnyvale, CA).  The expression of PTR2 in each 
mutant was analyzed at least twice in separate experiments, with similar expression found 
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in each experiment. The quantification of PTR2 and ACT1 mRNA was performed using 
the software ImageQuant5.0 (GE Healthcare, Technologies, Waukesha, Wisconsin). 
 
Real-Time RT PCR:  Approximately 3 x 108 cells of the tested deletion mutant strains 
were harvested after overnight growth in MM+HLKU medium. Yeast total RNA was 
isolated using RiboPureTM-Yeast extraction kit (Ambion, Austin, TX), and then treated 
with TURBO DNA-freeTM Kit to eliminate the genomic DNA contamination (Ambion, 
Austin, TX). The amount of total RNA was quantified by monitoring absorbance at 
260nm. To check that the genomic DNA had been eliminated, the obtained total RNA 
was used for the template to PCR amplify the target genes, and no PCR product was 
obtained. cDNA was synthesized using M-MLV RT (Invitrogen; 400 U reverse 
transcriptase) in a reaction mixture containing 1µg Oligo(dT), 1 mM deooxynucleoside 
triphosphates, 14 U anti-RNase and 1µg of total RNA at 42°C for 45min, and the reaction 
was stopped after 5 minutes by incubation at 72°C.  
 Real-Time PCR analysis was performed in the DNA Engine OpticonTM (MJ 
Research, Boston, MA). QuantiTectTM SYBR Green PCR Kit (Qiagen, Valencia, CA) 
and the primers (the sequences are presented in Supplemental Table S1) resulting in 
about 100bp amplicon were applied in the PCR reaction. The reaction contained 12.5 µl 
of 2x qPCR reaction mix, 15pmol of Primers, and run with a cycle of 50ºC for 2min, 
95ºC for 15 min, followed by 40 cycles of 95ºC for 15s, 54ºC for 30s, and 72ºC for 15s. 
A standard curve for each primer set was performed with 1, 1:10, 1:100, 1:1000, 1:10000, 
1:100000 dilutions of the wild type cDNA. The CT value, the cycle when sample 
fluorescence exceeds a chosen threshold above background fluorescence, was determined 
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using the software program. The copy number of PTR2, PMA1, and ACT1 genes in each 
deletion mutant strain was calculated based on the standard curve. The ratio of the fold 
change of target genes (PTR2 and PMA1) vs the fold change of the internal control gene 
(ACT1) in the tested mutant strains was calculated to show up-regulation or down-
regulation. The ratio of the fold change in the wild type was standardized as 1.0. 
 
Ptr2p localization in deletion mutant strains:    In order to trace the localization of 
Ptr2p, a Ptr2p-GFP construct was created as follows. The primers PTR2-FLAG-GFP-F 
and PTR2-Flag-GFP-R (see Supplemental Table S1 for the sequence) were used to PCR 
amplify two tandem copies of the GFP gene using pKW430 [a gift of Dr. Mary Miller, 
Rhodes College, Memphis, TN (STADE et al. 1997)] as the template. The amplified PCR 
product (1.5kb) had two copies of GFP sequence with 40bp of flanking sequence 
homologous to pMS2, which contained PTR2 with its endogenous promoter and 
terminator sequences and both FLAG and His tags located at the C terminus. The plasmid 
was linearized with AgeI at a unique restriction site located between the FLAG and His 
tags. The centromeric plasmid pMS4, containing Ptr2p-FLAG-GFP2-His6 and the 
selectable marker URA3, was created by homologous recombination.  
 To test the localization of Ptr2p-GFP in different yeast strains, the pMS4 
construct was transformed into each deletion mutant of interest and transformants 
selected by growth in the absence of uracil. Yeast strains carrying pMS4 were pre-grown 
in MM+HLK overnight, then inoculated into fresh MM+HLK at an initial cell 
concentration of 2x106 cells/mL. Cells were concentrated by centrifugation and observed 
at 10 hours after inoculation by fluorescence microscopy using a 470-490nm excitation 
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wavelength and 515nm emission filter fitted to an Olympus microscope. Images were 
taken with a MicroFireTM camera (Model S99809, Olympus). All mutants were in the log 
phase at the 10 hour time point as ascertained by the high proportion of cells with buds 
and the low density of cells under the experimental conditions used. To visualize the 
amount of GFP expression, each image was captured with the same exposure time. 
Significantly higher and lower GFP signal could be distinguished from the captured 
images. For those images with higher GFP signal, the images were taken with a 





Primary Screening of Deletion Mutants to Identify Strains Demonstrating Increased 
or Decreased Dipeptide Utilization 
 In order to identify genes involved in dipeptide utilization, we screened a library 
of 4826 haploid, single-gene deletion strains for mutants with an altered dipeptide 
utilization profile. The leucine auxotrophic marker in the BY4742 strain background 
(MATα his3∆1 leu2∆0 lys2∆0 ura3∆0) was used to monitor how well each strain was 
able to utilize the dipeptide His-Leu. Under the conditions of the screen, cells could grow 
only if they were able to take up the dipeptide His-Leu from the medium and release 
leucine from the peptide intracellularly. Numerous previous studies have shown that there 
is no extracellular peptidase or protease in S. cerevisiae able to catalyze the hydrolysis of 
dipeptides under the growth conditions used. In this screening, any mutant strain 
demonstrating either an enhanced or decreased growth was considered to have a deletion 
in a gene involved in dipeptide utilization. Since Ptr2p is the only dipeptide transporter 
expressed in this yeast under the conditions used for the screen, we expected that genes 
related to the regulation of PTR2 expression or Ptr2p function would comprise the list of 
candidates. The yeast deletion mutant library was generated by the Saccharomyces 
Genome Deletion Project, which involved several laboratories (WINZELER et al. 1999). 
Only non-essential genes are represented in this deletion mutant collection.  
In the primary screening, yeast deletion mutants were grown in a poor nitrogen 
medium with allantoin as the nitrogen source. These conditions are known to partially up-
regulate PTR2 expression (ISLAND et al. 1991). All deletion mutant strains not capable of 
growing in allantoin as the sole nitrogen source were necessarily excluded from this 
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study. One hundred and nine strains of the haploid collection were identified in this 
category. For a full list of the 109 strains see supplemental data Table S2. The rest of the 
deletion series, including strains known to be deficient (ptr1) and hyper-active (cup9) for 
dipeptide utilization, grew similarly in the MM+HLKU medium.  
  A screen was performed to the mutant collection in medium [MM+(H-
L)HKU+Trp] containing His-Leu as the only leucine source. Tryptophan up-regulates 
PTR2 expression via the SPS system over the enhancement induced by growth on MM 
alone thus providing the maximal dipeptide utilization phenotype (FORSBERG and 
LJUNGDAHL 2001b; ISLAND et al. 1987). The screen was also performed without 
tryptophan addition with identical results observed (data not shown). Two hundred 
seventy-eight deletion mutants were obtained from the primary screening that showed 
either enhanced dipeptide utilization (the deleted genes are “negative regulator genes”) or 
decreased dipeptide utilization (the deleted genes are “positive regulator genes”). As 
controls for comparison of strains that show increased or decreased dipeptide utilization, 
cup9 and ptr1 mutants were used. Cup9p is a repressor of PTR2 transcriptional 
expression; the cup9 deletion mutant strain has a higher expression level of PTR2 in 
comparison to that of the wild-type (BYRD et al. 1998), therefore the hyper-active strain 
(cup9) grew better than wild-type on dipeptide (Figure 1 A). Ptr1p is required for 
degradation of Cup9p; in the ptr1 deletion mutant strain Cup9p is stabilized (DU et al. 
2002; ISLAND et al. 1991), and there is an undetectable level of PTR2 expression 
preventing this strain from growing on dipeptide (Figure 1 A).  For clarity of presentation 
and to present data representative of the phenotypes among the mutants identified, we 
highlight in the Results section of this paper eighteen deletion mutant strains (bud32,  
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Figure 1 Growth patterns of various selected strains that demonstrate increased or 
decreased dipeptide utilization. A) The growth pattern of wild-type (BY4742), ptr1, 
cup9, and eight other deletion mutant strains in MM+H(H-L)KU+Trp medium. B) The 
growth pattern of wild-type (BY4742), ptr1, cup9, and nine other deletion mutant strains 






















































































cup9, dal81, gcv3, hal9, kem1, lpd1, npr1, ptr1, reg1, rpn4, ssn3, srn2, ubc2, ubp14, 
ubr2, vps8, and ybt1).   
 Growth patterns of deletion mutant strains hal9, kem1, npr1, srn2, ssn3, ubr2, 
vps8, and ybt1 were similar to that of the cup9 deletion mutant in that they had a shorter 
lag phase and a higher growth rate compared to the wild type (Figure 1A). Therefore, 
these deletion strains were considered to carry a deletion in a gene involved in decreasing 
dipeptide utilization. Growth patterns of deletion mutants bud32, dal81, gcv3, lpd1, reg1, 
rpn4, ubc2, and ubp14, had a similar growth pattern to the ptr1 deletion strain which did 
not grow in MM+(H-L)HKU+Trp medium (Figure 1 B). These deletion mutants were 
considered to carry a deletion in a gene involved in increasing dipeptide utilization.   
 
Verification of Candidate Genes: Solid Media Growth Assay and Toxic Dipeptide 
Halo Assay 
 
 The candidate mutants were further tested in a solid medium growth assay and a 
toxic dipeptide halo assay. The deletion mutant strains were grown on solid medium 
plates containing MM+HLKU, MM+(H-L)HKU, or MM+(H-L)HKU+Trp. Eighteen 
representative deletion mutant strains with enhanced or decreased dipeptide utilization 
are shown in Figure 2. All the tested deletion mutant strains grew to a similar extent as 
compared to that of the wild type in MM+HLKU. The deletion mutants hal9, kem1, npr1, 
srn2, ssn3, ubr2, vps8, and ybt1 had a similar growth pattern to the cup9 deletion mutant 
strain, which grew better than wild-type in both MM+(H-L)HKU+Trp (Figure 2) and 
MM+(H-L)HKU (data not shown). In contrast, the deletion mutants bud32, dal81, gcv3, 
lpd1, reg1, rpn4, ubc2, and ubp14 had a similar growth pattern to the ptr1 deletion 
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Figure 2 Growth of selected strains on solid medium. Two cell dilutions, 3x104 cells /mL, and 3x103 cells/mL were tested on 
MM+HLKU and MM+(H-L)HKU+Trp media.  
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mutant strain, which could not grow in MM+(H-L)HKU+Trp medium (Figure 2) or in 
MM+(H-L)HKU (data not shown). The growth phenotype found in the liquid growth 
screening of these chosen candidate mutants with respect to the regulation of dipeptide 
utilization was therefore confirmed in this solid medium test.  
 The mutants identified in the initial screen were also subjected to a toxic dipeptide 
assay for further verification of the peptide transport phenotype. In this assay, cells were 
grown on MM+HLKU and tested for their sensitivity to Ala-Eth. The halo size of each 
deletion mutant strain was measured and compared to that of wild-type. A larger halo 
indicated that the deletion mutant strain was more sensitive to Ala-Eth toxic dipeptide 
than the wild-type, while a smaller halo indicated less sensitivity. As expected, cup9 
developed a larger halo than that of wild-type and ptr1 was not sensitive to the toxic 
dipeptide. Similar to that of cup9, deletion strains hal9, kem1, npr1, srn2, ssn3, ubr2, 
vps8, and ybt1 developed a larger halo than that of wild-type (Table 1), indicating the 
deleted genes negatively regulated dipeptide utilization. Conversely, similar to that of 
ptr1, deletion strains bud32, dal81, gcv3, lpd1, reg1, rpn4, ubc2, and ubp14 were not 
sensitive to toxic dipeptide (Table 2), indicating that the deleted genes positively 
regulated dipeptide utilization.  
Of the 278 strains identified in the initial liquid growth screen, 103 strains showed 
increased or decreased peptide utilization in all three assays: liquid and solid media 
growth and the toxic dipeptide halo assay (Table S3 and S4 listed in order of biological 
process according to Gene Ontology annotation). These 103 genes were considered to be 
the set of genes involved as either negative or positive regulators of peptide utilization as 
determined by the three experimental tests. As expected, five genes (PTR1, CUP9,  
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Table 1 The response of deletion mutants with increased dipeptide utilization to Ala-Eth, NaCl, and canavanine.a 
Gene name Description of gene product Toxicity of  Ala-Eth 




    (% of the wild type)d
Wild-type   100     
CUP9  Specific RNA polymerase II transcription 
factor activity 
120 - - 
HAL9 Specific RNA polymerase II transcription 
factor activity 
131 - - 
KEM1  5'-3' exoribonuclease activity 135 More sensitive Less sensitive 
 
NPR1  Serine/threonine protein kinase 129 - Less sensitive 
 
SRN2 Class E vacuolar sorting protein 109 More sensitive More sensitive 
 
SSN3  Cyclin-dependent protein kinase activity 114 - - 
UBR2 Ubiquitin-protein ligase activity 129 - - 
VPS8  Vacuolar sorting 121 More sensitive More sensitive 
 
YBT1  Bile acid transporter activity 156 - - 
 
aThese data are also presented in supplementary Table S3, Figure S4, and Figure S5. 
b The halo size formed by each deletion mutant was compared to the halo size of the wild-type strain by dividing the halo size of the mutant by the halo size of 
the wild-type strain and multiplied by 100 to get a percentage.    
c “-” indicates that the deletion strain had no difference in its sensitivity to NaCl compared to that of the wild-type. A strain that was more sensitive exhibited 
greater growth inhibition to 1.0 M NaCl in comparison to that shown by the wild-type. 
d  “-” indicates that the deletion strain had no difference in sensitivity to canavanine compared to that of the wild-type.  
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Table 2 The response of deletion mutants with decreased dipeptide utilization to Ala-Eth, NaCl, and canavanine.a  
Gene name Description of gene product Toxicity of  Ala-Eth 




    (% of the wild type)d
Wild-type   100     
PTR1 Ubiquitin-protein ligase activity 0 - - 
BUD32 Protein serine/threonine kinase activity 0 (Fuzzy halo) More sensitive Less sensitive 
 
DAL81 Specific RNA polymerase II transcription 
factor activity 
0 - More sensitive  
 
GCV3  Glycine dehydrogenase (decarboxylating) 
activity 
0 - More sensitive  
 
LPD1 Dihydrolipoyl dehydrogenase activity 0 - More sensitive  
 




Transcriptional activator activity 0 - - 
UBC2 Ubiquitin conjugating enzyme activity 0 - - 
UBP14 Ubiquitin-specific protease activity 73 - - 
 
aThese data are also presented in supplementary Table S3, Figure S4, and Figure S5. 
b The halo size formed by each deletion mutant was compared to the halo size of the wild-type strain by dividing the halo size of the mutant by the halo size of 
the wild-type strain and multiplied by 100 to get a percentage.    
c “-” indicates that the deletion strain had no difference in its sensitivity to NaCl compared to that of the wild-type. A strain that was more sensitive exhibited 
greater growth inhibition to 1.0 M NaCl in comparison to that shown by the wild-type. 
d  “-” indicates that the deletion strain had no difference in sensitivity to canavanine compared to that of the wild-type. 
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UBC2, DAL81/UGA35, and STP2) previously known to be involved in dipeptide 
utilization were identified among the 103 genes, which validated the utility of the 
screening method. Three other genes (SSY1, PTR3, and SSY5), known to affect dipeptide 
utilization via the regulation of PTR2 mRNA expression, were not found in the screen 
since they are not included in the deletion mutant library. The number of deletion mutant 
strains found by our methods to modulate dipeptide utilization accounted for about 2% of 
the entire collection. Of the 46 genes whose deletion mutant strains enhanced dipeptide 
utilization (Table S3), 20 encoded proteins with more than a 30% protein sequence 
identity to a human protein (Table S3, footnote a). Additionally, of the 57 genes whose 
deletion mutant strain decreased dipeptide utilization (Table S4), 33 encoded proteins 
with more than a 30% sequence identity to a human protein (Table S4, footnote a). 
According to Gene Ontology (GO) annotation in SGD, the 103 genes covered 29 out of 
the 34 given categories in the Biological Processes GO categories. The categories of each 
gene are indicated in Table S3 and S4. 
Ptr2p-GFP Expression and Localization in the Identified Deletion Strains  
In order to further explore the impact of the identified 103 genes on dipeptide 
utilization, we measured Ptr2p expression and localization using a Ptr2p-GFP chimera. 
This construct (pMS4), which encoded Ptr2p-GFP under the control of its native 
promoter, was transformed into the 103 deletion strains, and Ptr2p-GFP in log phase cells 
was observed by fluorescence microscopy. The addition of the GFP tag did not affect the 
function of Ptr2p as demonstrated by halo and uptake assays (data not shown). Ptr2p-GFP 
was primarily localized to the plasma membrane in wild-type log-phase cells (Figure 3).  
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Figure 3 Ptr2p-GFP expression and localization in the wild-type (WT) and 9 
deletion strains that demonstrated increased dipeptide utilization. The right-hand 
panel of each strain shows phase microscopy of the same field as the left-hand panel 
which shows the fluorescently-labeled Ptr2p-GFP. Deletion strain ssn3 showed a very 
high amount of GFP signal under the same exposure time as that of the wild-type. 
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The amount of the Ptr2p-GFP expression signal and its localization in the 103 deletion 
mutant strains revealed seven phenotypic patterns (Table 3).  
 
Ptr2p-GFP expression and localization in deletion strains with increased dipeptide 
utilization: The Ptr2p-GFP expression signal and localization in 46 deletion strains with 
increased dipeptide utilization are shown in Figure S1 (9 deletion strains and wild type 
are shown in Figure 3 as representative of the full set).   
Strains with enhanced Ptr2p-GFP expression signal: A higher level of Ptr2p-GFP 
expression signal in the plasma membrane was observed in the cup9 deletion strain as 
compared to the wild-type (Figure 3 and Table 3). The enhanced Ptr2p-GFP expression 
level corresponded with the phenotype of increased dipeptide utilization as reflected in 
growth on dipeptide in liquid and solid medium and toxicity to Ala-Eth (Figure 1, Figure 
2, and Table 1). In addition, Ptr2p-GFP was also observed in the vacuole, possibly due to 
the over-expressed PTR2 in the cup9 strain. Similar to the cup9 strain, the deletion of 
HAL9, KEM1, SSN3, and UBR2 showed an increased Ptr2p-GFP expression signal in 
both the plasma membrane and the vacuole. Enhanced Ptr2p-GFP expression signal was 
also observed in 18 other deletion strains including four unknown gene deletion mutants, 
yfr044c, ylr114c, ynl123w, and yor322c (Table 3 and Figure S1). Consistently, the 
increased Ptr2p-GFP expression agreed with increased sensitivity to toxic dipeptide and 
better growth on dipeptide substrate (Table S3).  
Strains with altered Ptr2p-GFP localization: Fourteen deletion strains with increased 
dipeptide utilization showed altered localization of Ptr2p-GFP (Table 3 and Figure S1). 
An example of three deletion mutants, npr1, srn2, and vps8 is shown in Figure 3. These  
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Table 3 Ptr2p-GFP expression and localization in 103 identified strains with decreased or increased dipeptide utilization.a  
 
Phenotypic Category Increased dipeptide utilization 
(46 strains) 
Decreased dipeptide utilization 
(57 strains) 
Strains with enhanced Ptr2p-GFP 
expression 
 
arp5, arp8, cup9, csm1, dbr1, eaf3, hal9, 
ies6, kem1, mrps9, pat1, sfp1, srb8, ssd1, 
ssn2, ssn3, ssn8, tom72, ubr2, yor322c, 
ynl123w, yfr044c, ylr114c  
asm4, ydr015c, ydr290w  
Strains with altered Ptr2p-GFP 
localization  
 
bni1, def1, eaf7, lst4, npr1, sac6, snf7, srn2, 
tpm1, vam10, vps8, vps36, ypl073c, ynl295w  
 
bem4, bud32 , csf1, etr1, gcv2, gcv3, hfm1, 
ilm1, isa1, isa2, mck1, mre11,  npl3, shp1, 
reg1, rmd12, rps9b, tsa1, vbm1, ydr433w, 
yjl046w, ydr157w, yjl175w 
Strains with no apparent effect on 
Ptr2p-GFP localization or  
expression  
cik1, kti12, mlh1, mrp17, pho2, rim101, tif3,  
ybt1, ydr417c 
bud28, bye1, elf1, hfa1, ira2, lat1, lpd1, 
mct1, oar1, pdb1,  pdx1, prd1, rad23, spo21, 
ypl098c 
Strains with  decreased Ptr2p-GFP 
expression 
No mutant strains were found in this 
category. 
dal81, hof1, ipk1, nfu1, pho85, ptr1, rpl21a, 
rpn4, shm2, stp2, taf14, thp1, uba3, ubp14, 
ubc2, ypr174c  
aPtr2p-GFP expression and localization in the underlined strains are shown in Figures 3 and 4. The underlined strains were the representatives chosen to highlight 
in the Results section of this paper.  Ptr2p-GFP expression and localization of all the listed strains are shown in supplemental data (Figures S1 and S3). The 
strains in bold (cup9, dal81, ptr1, stp2, and ubc2) contain the deleted genes previously identified as being involved in regulation of PTR2 transcription. 
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gene products had GO annotations of transport, vesicle-mediated transport, cytokinesis, 
or related to protein modification. Ptr2p-GFP signal in the srn2 and vps8 deletion mutants 
was mainly localized to the plasma membrane and the endosome. In addition, Ptr2p-GFP 
remained in the endosome in stationary phase cells and targeting of Ptr2p-GFP to the 
vacuole was defective (data not shown). Similar to srn2 and vps8 strains, the deletion 
strains eaf7, sac6, snf7, vps36, and ypl073c exhibited Ptr2p-GFP localization to the 
plasma membrane and to the endosome (Figure S1), suggesting that these gene products 
are involved in a similar cellular process regulating dipeptide utilization. Snf7p, Srn2p, 
and Vps36p are three key proteins involved in ESCRT protein complexes required for 
endocytotic degradation of membrane proteins (BOWERS et al. 2004).  
To further characterize the ESCRT protein complexes involved in Ptr2p 
endocytotic degradation, deletion mutant strains of other components of the ESCRT 
protein complexes (vps2, vps20, vps22, vps23, vps24, vps25, and vps28) were also 
transformed with the pMS4 construct. The localization of Ptr2p-GFP in these strains was 
similar to that in snf7, srn2, and vps36 strains (Figure S2). Additionally, vps2, vps20, 
vps22, vps23, vps24, vps25, and vps28 strains were more sensitive to toxic dipeptide as 
compared to the wild type (Table S5), confirming the role of the ESCRT protein complex 
in dipeptide utilization.  
The deletion strain npr1 showed an accumulation of Ptr2p-GFP signal in both 
endosomal vesicles and the vacuole in addition to the plasma membrane localization 
(Figure 3). The Ptr2p sorting process is likely regulated by Npr1p, a protein kinase 
involved in the regulation of vesicle transport systems (Table S3). Similar to Ptr2p-GFP 
localization in the npr1 strain, deletion strains bni1, def1, lst4, and tpm1 showed Ptr2p-
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GFP localization to the plasma membrane and the vacuole (Figure S1), implicating them 
as well as being involved in the protein trafficking of Ptr2p.  
Strains with no apparent effect on Ptr2p-GFP expression or localization: The deletion 
strain ybt1 showed no apparent difference in the expression level of Ptr2p-GFP signal in 
the cytoplasmic membrane (Figure 3), although there was an increase in the Ptr2p-GFP 
signal in the vacuole.  In this strain dipeptide utilization was increased (Figure 1, Figure 
2, and Table 1). In addition, seven other deletion strains, cik1, kti12, mlh1, mrp17, pho2, 
rim101, tif3, and ydr417c demonstrated increased dipeptide utilization with no apparent 
effect on Ptr2p-GFP expression in the cytoplasmic membrane (Table 3 and Figure S1). 
These gene products might impact dipeptide utilization independently of Ptr2p function. 
For example, Ybt1p, known as an ABC transporter and localized on the vacuolar 
membrane, may be involved in the uptake of dipeptides into the vacuole. The deletion of 
this gene resulted in increased growth response and dipeptide toxicity. 
 
Ptr2p-GFP expression and localization in deletion strains with decreased dipeptide 
utilization: The expression level of Ptr2p-GFP signal and localization of nine 
representative strains are shown in Figure 4, and all 57 deletion strains listed in Table 3 
with decreased dipeptide utilization are shown in Figure S3. 
Gene deletion enhanced the expression level of Ptr2p-GFP signal: The deletion strains 
asm4, ydr015c and ydr290w showed an enhanced expression level of Ptr2p-GFP at the 
cytoplasmic membrane and the vacuole (Figure S4). These strains showed a decreased 
sensitivity to toxic dipeptide, however, with no growth change on dipeptide (Table S4). 
In the asm4 strain, a fuzzy halo was observed in the toxic dipeptide halo assay indicating  
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Figure 4 Ptr2p-GFP expression and localization in 9 selected deletion strains that 
demonstrated decreased dipeptide utilization. The right-hand panel of each strain 
shows phase microscopy of the same field as the left-hand panel which shows the 
fluorescently-labeled Ptr2p-GFP. 
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a transient growth inhibition. ASM4 encodes a component of the karyopherin docking 
complex of the nuclear pore (MARELLI et al. 1998) indicating that some cellular protein 
involved in ethionine toxicity requires Asm4p for its full expression.  
Strains with altered Ptr2p-GFP localization: Compared to the wild-type, deletion strains 
bud32 and reg1 showed higher expression level of Ptr2p-GFP signal at the vacuole and 
less expression in the plasma membrane (reg1) or no visible plasma membrane 
expression (bud32) (Figure 4). In addition, deletion strain gcv3 showed Ptr2p-GFP 
localization both at the vacuole and plasma membrane (Figure 4). Similar to the Ptr2p-
GFP localization at the vacuole in bud32, reg1, or gcv3 strains, the deletion strains bem4, 
csf1, etr1, gcv2, hfm1, ilm1, isa1, isa2, mck1,  mre11, npl3, rps9b, rmd12, shp1, tsa1, 
vbm1, and four unknown gene deletion strains (ydr157w, ydr433w, yjl046w, and yjl175w) 
resulted in Ptr2p-GFP localization both at the vacuole and plasma membrane (Table S4 
and Figure S3).  
Strains with no apparent effect on the expression or localization of Ptr2p-GFP: No 
apparent change in the expression or localization of Ptr2p-GFP was observed in the lpd1 
deletion strain (Figure 4). Similarly, Ptr2p-GFP localization and expression level was not 
different in the deletion strains bye1, bud28, elf1, hfa1,  ira2, lat1, mct1, oar1, pdb1, pdx1, 
rad23, and ypl098c as compared to the wild-type (Table S4 and Figure S3).  
Strains with decreased expression of Ptr2p-GFP: The expression level of Ptr2p-GFP 
signal was lower in the ptr1, dal81, rpn4, ubc2, and ubp14 deletion strain as compared to 
the wild-type (Figure 4). A decreased Ptr2p-GFP expression signal was also observed in 
the deletion strains hof1, ipk1, nfu1, pho85, rpl21a, shm2, stp2, taf14, thp1, uba3, and 
ypr174c (Table S4 and Figure S3). The decreased Ptr2p-GFP expression signal in these 
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strains was consistent with a decrease of dipeptide utilization which was previously 
documented (Table S4) and is consistent with the observation that Ptr1p, Stp2p, Ubc2p, 
and Dal81p positively regulate PTR2 transcription (ANDREASSON and LJUNGDAHL 2002; 
BERNARD and ANDRE 2001; DU et al. 2002). 
 
Transcriptional Regulation of PTR2  
In order to explore whether strains with enhanced or reduced expression level of 
Ptr2p-GFP showed a change in the transcriptional regulation of PTR2, the fold change of 
PTR2 mRNA compared to that of the wild type was measured by Real-Time reverse 
transcription PCR in the eighteen representative deletion strains.  In control experiments, 
PTR2 mRNA expression level in the cup9 strain was up-regulated more than nine times 
that of the wild-type (Table 4). This result also agreed with the increased PTR2 mRNA 
level in Northern analysis and lacZ activity as compared to the wild-type (data not 
shown). The increase in PTR2 mRNA expression in the cup9 strain is consistent with the 
increased expression level of Ptr2p-GFP signal (Figure 3). Similar to that of the cup9 
strain, PTR2 mRNA expression level was highly up-regulated in ssn3 and kem1. PTR2 
mRNA expression was up-regulated in ubr2, hal9, ybt1, vpc8, and gcv3 less than two-
fold. In contrast to the cup9, hal9, kem1, ssn3, ubr2, vps8, and ybt1 strains, which showed 
increased dipeptide utilization, the gcv3 strain exhibited a decrease in peptide utilization 
(Table S4). The apparent discrepancy between decrease in utilization and robust 
expression in gcv3 strain could result from a post-translational alteration of Ptr2p 
function or the alteration of the metabolic pathway(s) of dipeptide utilization.  
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Expressiona   
ubc2 0.06 (0.02) 0.94 (0.50) 
ptr1 0.07 (0.03) 1.08 (0.40) 
ubp14 0.08 (0.04) 1.09 (0.48) 
rpn4 0.21 (0.02) 1.23 (0.25) 
npr1 0.48 (0.1) 1.33 (0.08) 
dal81 0.79 (0.07) 1.70 (0.31) 
reg1 0.88 (0.06) 1.03 (0.31) 
lpd1 0.82 (0.19) 2.30 (0.03) 
srn2 0.92 (0.05) 0.87 (0.08) 
bud32 0.94 (0.10) 1.44 (0.44) 
ubr2 1.23 (0.62) 2.95 (0.35) 
hal9 1.37 (0.21) 1.93 (0.35) 
ybt1 1.51 (0.14) 2.37 (0.25) 
vps8 1.66 (0.22) 2.09 (0.44) 
gcv3 1.93 (0.56) 1.22 (0.33) 
ssn3 5.00 (1.17) 2.41 (0.47) 
cup9 9.36 (2.60) 0.98 (0.21) 
kem1 12.12 (1.47) 3.06 (0.24) 
 
aExpression level measured by Real-Time RT-PCR analysis is shown as a ratio calculated by the fold 
change of the target gene (PTR2 or PMA1) in the mutant compared to that of the wild-type divided by the 
fold change of ACT1 in the mutant compared to that of the wild-type. The datum in the bracket is the 
standard deviation. 
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PTR2 mRNA expression level in the ptr1 strain was only 7% that of the wild type 
(Table 4) in accordance with the known requirement of Ptr1p for PTR2 transcription 
(BYRD et al. 1998; TURNER et al. 2000). This result also agreed with the decreased PTR2 
mRNA level in Northern analysis and lacZ activity as compared to the wild-type (data 
not shown). The decrease in PTR2 mRNA expression in the ptr1 strain is consistent with 
the decreased expression level of Ptr2p-GFP signal (Figure 4). Similar to the ptr1 strain, 
PTR2 mRNA expression was highly down-regulated in ubc2, ubp14, and rpn4 strains. 
The expression of PTR2 mRNA in npr1, dal81, reg1, lpd1, srn2, and bud32 strains was 
not more than two-fold less than that of the wild-type.  
Dipeptide Uptake Capability  
In order to explore whether altered dipeptide utilization was correlated directly to 
flux of dipeptide, the accumulation of [3H]Leu-Leu dipeptide was measured in the 
eighteen representative strains (Figure 5). In a control experiment, the accumulation of 
[3H]Leu-Leu increased remarkably in the cup9 strain as compared to the wild-type 
(Figure 5). Similar to the cup9 strain, the accumulation of [3H]Leu-Leu was higher in the 
hal9, kem1, npr1, srn2, ssn3, ubr2, vps8, and ybt1 strains as compared to that of the wild-
type. The increased uptake in these strains was reflected in their increased ability to 
utilize dipeptide. In contrast to the increased accumulation of dipeptide in hal9, kem1, 
npr1, srn2, ssn3, ubr2, vps8, and ybt1 strains, the accumulation of [3H]Leu-Leu in gcv3 
was not significantly different as compared to the wild-type, suggesting that deletion of 


























































Figure 5 The uptake of [3H]Leu-Leu dipeptide in log phase cells of the wild-type, 
cup9, ptr1, and  the 16 deletion strains bud32, dal81, gcv3, hal9, kem1, lpd1, npr1, 
reg1, rpn4, srn2, ssn3, ubc2, ubr2, ubp14, vps8, and ybt1. The percentage of the 
accumulation of [3H]Leu-Leu for each deletion mutant was calculated as [(the 
accumulation of [3H]Leu-Leu in each mutant strain)/(the accumulation of [3H]Leu-Leu in 





The accumulation of [3H]Leu-Leu in the ptr1 strain was lower than that of the 
wild-type. The reduced accumulation of dipeptide was consistent with the decreased 
expression level of PTR2 mRNA and Ptr2p-GFP in the ptr1 strain. Similar to the ptr1 
strain, the accumulation of [3H]Leu-Leu was lower in the bud32, dal81, lpd1, reg1, rpn4, 
ubc2, and ubp14 strains as compared to that of the wild-type (Figure 5). The decreased 
uptake in these strains was reflected in their decreased expression of PTR2 in dal81, 
rpn4, ubc2, and ubp14 strains (Table 4), decreased amount of Ptr2p-GFP in the 
cytoplasmic membrane (Figure 4) and the alteration localization of Ptr2p in bud32 and 
reg1 strains (Figure 4). In contrast, although the transport of dipeptide was reduced in the 
lpd1 strain, the expression level of Ptr2p-GFP remained similar to that in the wild-type 
(Figure 4).  
  
Effects of Gene Deletions on Osmotic and Canavanine Sensitivity and PMA1 
Expression 
In order to determine whether gene deletions also affected general membrane 
properties, additional assays were performed. Osmotic sensitivity, toxicity of canavanine, 
and the expression level of PMA1 encoding a proton transporter localized in the 
cytoplasmic membrane were examined.  NaCl at 1.0 M inhibits the growth of wild type S. 
cerevisiae by causing osmotic de-stabilization of the cell membrane (HOHMANN 2002). 
NaCl at 1.0 M significantly inhibited the growth of all strains on MM+HLKU plates. 
Fourteen deletion mutant strains, cup9, dal81, gcv3, hal9, lpd1, npr1, ptr1, reg1, rpn4, 
ssn3, ubc2, ubp14, ubr2, and ybt1, showed similar effects to NaCl as that of the wild type 
(Table 1 and 2, and Figure S4) suggesting that the deletion of those genes did not change 
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the osmotic sensitivity of the deletion mutant strains. In contrast, four deletion mutant 
strains, bud32, kem1, srn2, and vps8, showed greater sensitivity to 1.0 M NaCl than that 
of the wild-type (Tables 1 and 2 and Figure S4).  
 Canavanine is transported by the arginine permease, and changes in canavanine 
toxicity have been correlated directly to arginine permease function (HAMPSEY 1997). In 
the canavanine toxicity assay, nine deletion mutant strains, cup9, hal9, ptr1, rpn4, ssn3, 
ubc2, ubp14, ubr2, and ybt1, did not show significant alteration in the canavanine 
sensitivity as compared with that of the wild-type. In contrast, six deletion mutants, dal81, 
gcv3, lpd1, reg1, srn2, and vps8 were more sensitive to canavanine, and three deletion 
mutant strains, bud32, kem1, and npr1 were less sensitive than the wild type (Table 1 and 
2 and Figure S5).  
 To examine whether the gene representative deletion mutants were also affected 
in the expression of other transport proteins, the expression level of PMA1 encoding a 
proton transporter was measured. PMA1 mRNA expression level in cup9 and ptr1 strains 
was similar to that of the wild type (Table 4). In contrast, PMA1 mRNA level was up-
regulated more than two-fold in kem1, lpd1, ssn3, ubr2, vps8, and ybt1 strains, and less 
than two-fold in bud32, dal81, gcv3, hal9, npr1, reg1, rpn4, srn2, ubc2, and ubp14 
strains (Table 4). Overall these changes in expression levels of PMA1 in the various 
mutant strains did not correlate with the changes in expression in PTR2 except for up-




 We have systematically screened a haploid, single-gene, deletion mutant library 
and identified 103 genes involved in dipeptide utilization. To our knowledge, this is the 
first such screen for a membrane transport system. PTR2 expression is known to be 
regulated by amino acids via the Ssy1p-Ptr3p-Ssy5p (SPS) protein complex and by 
dipeptides themselves (Figure 6). Import of di/tri-peptides containing basic or bulky 
hydrophobic N-terminal residues (N-end Rule peptides) induces PTR2 by reducing 
cellular levels of the PTR2 repressor Cup9p (BYRD et al. 1998; DU et al. 2002; TURNER 
et al. 2000).  In the SPS complex regulatory pathway a few down-stream proteins, such 
as STP2 and components of SCFGrr1 ubiquitin ligase complex (Skp1p, Hrt1p, Cdc34p, 
and Cdc53p), are involved in the Ssy1p-induced signal transduction pathway via 
proteolytic processing of Stp2p (ANDREASSON and LJUNGDAHL 2002; BERNARD and 
ANDRE 2001).  Due to the complex nature of signal transduction pathways, such as the 
well-studied pheromone-mediated mitogen-activated protein (MAP) kinase pathway in 
yeast (GUSTIN et al. 1998), we expected that other regulatory proteins would be identified 
in this screen.   
 The 103 genes identified in the screen cover a number of different Biological 
Processes based on the Gene Ontology annotation. It is clear from the broad range of 
mutants identified that genes involved in both direct and indirect regulation of peptide 
utilization were discovered.  Such a global array of genes supports the inter-connectivity 
of networks involved in regulating biological processes (CHEN et al. 2003; LEE et al. 
2002), but such a heterogeneous collection of interacting genes has not previously 
identified as specifically regulating membrane transport systems.    
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Figure 6 A hypothetical model for the regulation of dipeptide utilization in S. cerevisiae. The proteins with clear background 
represent those that have been reported previously to be involved in PTR2 regulation. Grey background represents those proteins that 
have been determined in this study. The SPS protein complex (Ssy1p-Ptr3p-Ssy5p) is an amino acid sensor, which leads to a cleavage 
of the N-terminal of Stp2p. The activated form of Stp2p is localized to the nucleus and regulates PTR2 expression. In addition, Dal81p 
synergistically regulates PTR2 expression together with Stp2p. Other proteins, Rpn4p, a positive regulator, and Cup9p, a negative 
regulator, bind at the PTR2 promoter region and are also involved in PTR2 transcription. The stability of Rpn4p is modulated by 
Ubr2p and Ubc2p, and the stability of Cup9p by Ptr1p, Ubc2p, and Ubc4p via the ubiquitination pathway. Binding of N-end Rule 
dipeptides to Ptr1p/Ubr1p results in ubiquitin-mediated degradation of Cup9p. Ubr2p competes with Ptr1p for the degradation of 
Cup9p. Arp5p, Arp8p, Ies6p, and Taf14p (components of the INO80 complex) together with Eaf3p possibly negatively regulates 
PTR2 transcription via repressing the acetylation of histones in the PTR2 coding region. The transcription of PTR2 is negatively 
regulated by a RNA polymerase mediator protein complex, which includes Ssn2p, Ssn3p, Ssn8p, and Srb8p. Thp1p might be involved 
in the translocation of PTR2 mRNA from the nucleus to the cytosol. The interaction between Kem1p and Pat1p is potentially involved 
in the degradation of PTR2 mRNA. Dipeptide utilization is also modulated by the Ptr2p trafficking system;  ESCRT-I, -II, III, together 
with Vps8p and Eaf7p, appear to regulate Ptr2p internalization from the endosome to the vacuole. In addition, Npr1 and Lst4p are also 
involved in Ptr2p trafficking and affect the retention of Ptr2p in the plasma membrane.  
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Genes that regulate PTR2 transcription:  In this study we have considerably expanded 
the identification of genes involved in PTR2 transcriptional regulation. The deletion of 
these genes results in the alteration of dipeptide utilization.  
First, we have shown that dipeptide utilization can be affected by gene products 
involved in the modification of the nucleosome, namely Arp5p, Arp8p, Ies6p and Taf14p. 
These proteins belong to the components of the chromatin remodeling INO80 protein 
complex that carries ATPase activity, DNA binding, and nucleosome mobilization 
(SANDERS et al. 2002), and that preferentially interacts with histones H3 and H4 (SHEN et 
al. 2003). Another histone- modification-related gene product, Eaf3p, was also identified 
in our screen. Eaf3p is a component of the NuA4 histone acetyltransferase complex 
which maintains the acetylation of histone H3 and H4 (REID et al. 2004). It is possible 
that these chromatin remodeling proteins negatively regulate PTR2 transcription via the 
modification of histones. A model representing the potential involvement of these 
proteins and others is shown (Figure 6).  
Second, four gene products with transcription factor activity, Cup9p, Dal81p, 
Stp2p, and Rpn4p were shown to regulate PTR2 expression and affected dipeptide 
utilization. Cup9p binds the region between -488 and -897 upstream of the PTR2 start 
codon (BYRD et al. 1998), while Rpn4p may bind between -610 and -603 due to the 
existence of the Rpn4p binding consensus sequence (5’-GGTGGAAA-3’) present at this 
location (MANNHAUPT et al. 1999). Cup9p is a repressor of PTR2, whereas Rpn4p is a 
“positive-regulator” as reflected in the observation that the cup9 deletion strain showed 
an increase in peptide utilization and the rpn4 strain has decreased peptide utilization. 
Subsequent to amino acid induction via the SPS system and its conversion into the active 
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form after proteolytically processing and translocation into the nucleus (ANDREASSON 
and LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 2004), the active form of Stp2p 
(truncated at the N-terminus) binds to the upstream activation sequence (UAS) of the 
promoter region of BAP2 and BAP3 (DE BOER et al. 2000; NIELSEN et al. 2001). Because 
BAP2, BAP3 and PTR2 are simultaneously regulated in response to amino acid induction 
via the SPS-Stp2p system, the active form of Stp2p likely also binds to the PTR2 
promoter region and regulates its transcription. Dal81p is a transcriptional activator 
essential for PTR2 expression under the induction by the SPS signal pathway as well 
(BERNARD and ANDRE 2001). Dal81p acts synergistically with Stp1p to regulate the 
transcription of AGP1 in response to the amino acid induction, and the sequence 5’-
CGGC-3’ of a UAS element is important for AGP1 transcriptional regulation (ABDEL-
SATER et al. 2004). Since the PTR2 promoter region has this consensus sequence and 
because Dal81p was identified as important for PTR2 transcription and dipeptide 
utilization in our screening, we speculate that Dal81p and Stp2p act synergistically in 
PTR2 transcription in a similar manner.  
Third, other gene products identified in this screen such as Ubr2p, Ptr1p, and 
Ubc2p regulate PTR2 expression by modulating the stability of Rpn4p and Cup9p (Figure 
6). Cup9p stability is regulated by Ptr1p, Ubc2p, and Ubc4p (DU et al. 2002). Ubr2p is 
associated with Rpn4p to regulate proteasome gene expression through the ubiquitination 
pathway (WANG et al. 2004). In addition, Ubr2p has high amino acid sequence similarity 
to Ptr1p presumably allowing a competition with Ptr1p for the stabilization of Cup9p 
(BARTEL et al. 1990). Therefore, Ubr2p probably regulates PTR2 transcription by 
impacting the stability of both Rpn4p and Cup9p (Figure 6).  
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Fourth, we identified one other gene product (SSN3) involved in PTR2 
transcription that is known to be general transcription factor, which also affected PMA1 
expression.   Ssn3p/Srb10p, Ssn8p/Srb11p, Ssn2p/Srb9p, and Srb8p have been identified 
as a cyclin-dependent serine/threonine protein kinase complex that functions as a 
mediator of RNA polymerase (KORNBERG 2005). This complex is also involved in 
glucose signaling pathway (BALCIUNAS and RONNE 1995; KUCHIN et al. 1995). Deletion 
of these genes leads to de-repression of a wide variety of down-stream genes, including 
GAL and SUC, which are important for galactose and raffinose metabolism, respectively 
(KUCHIN et al. 2000; MYER and YOUNG 1998). The deletion of SSN3 resulted in a change 
of PMA1 and PTR2 expression level. 
 Finally, we identified gene products involved in PTR2 transcription by means that 
are not clear. For example, UBP14 was important for PTR2 expression since deletion of 
these genes significantly decreased PTR2 mRNA level (Table 4), and the strain carrying 
deletion of this gene exhibited decreased peptide utilization. Ubp14p has ubiquitin-
specific protease activity (Table S4). It is probably modulating PTR2 transcription via the 
ubiquitination pathway. In addition, the deletion of UBP14 had no effect on the 
expression of PMA1 or on sensitivity to NaCl and canavanine. Further experiments are 
needed to provide some insight into whether the gene product acts directly or indirectly to 
control PTR2 expression.   
 
Genes involved in PTR2 mRNA maturation:  Gene products (Kem1p, Pat1p, and 
Thp1p) involved in post-transcriptional regulation impacting the stability and transport of 
PTR2 mRNA also affected dipeptide utilization (Figure 6). Both Kem1p and Pat1p 
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belong to an mRNA decay protein complex (BONNEROT et al. 2000; BOUVERET et al. 
2000).  PTR2 mRNA was highly up-regulated in the kem1 strain (Table 4). It is likely 
that PTR2 mRNA was more stable in kem1 and pat1 strains, which resulted in more Ptr2p 
being synthesized leading to enhanced Ptr2p-GFP expression (Figure 3) and increased 
dipeptide utilization (Table 1 and Figure 1 and 2). The deletion of KEM1 resulted as also 
an increased expression level of PMA1 and changes sensitivity to NaCl and canavanine 
(Table 1). It is not surprising that the deletion of this gene affected several phenotypes 
related to membrane function, since a deletion in this gene would impact gene expression 
of many different genes. Another gene shown to impacting dipeptide utilization was 
Thp1p, which is involved in mRNA export from the nucleus to the cytoplasm (FISCHER et 
al. 2002). The thp1 strain probably has a defect in transporting PTR2 mRNA into the 
cytoplasm for protein synthesis. Therefore this mutant demonstrated a decrease in peptide 
utilization.  
 
Genes that regulate Ptr2p trafficking: This screen revealed that dipeptide utilization is 
regulated by the trafficking system. Deletion of components of ESCRT-I, ESCRT-II, and 
ESCRT-III protein complexes showed a defect in Ptr2p-GFP trafficking from the 
endosome to the vacuole (Figure 6 and Figure S2).  These protein complexes are essential 
for sorting ubiquitinylated membrane proteins from the plasma membrane to the 
multivesicular body and to the vacuole for further degradation (RAIBORG et al. 2003). 
Ptr2p has been shown to be ubiquitinylated (HITCHCOCK et al. 2003). Strains srn2, vps36 
and snf7 demonstrated increased dipeptide utilization perhaps due to an increased 
residence time of Ptr2p at the cytoplasmic membrane.  In addition, the eaf7 and vps8 
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strains showed Ptr2p localization similar to that of the ESCRT protein mutants. 
Surprisingly, Eaf7p is annotated as a component of the NuA4 HAT complex, which is an 
essential histone acetyltransferase complex that acetylates the N-terminal tails of histones 
H4 and H2A (KROGAN et al. 2004). It is possible that Eaf7p has dual functions or 
indirectly affects Ptr2p localization through other proteins. Both srn2 and vps8 strains 
showed an altered sensitivity to NaCl and canavanine. It has been reported that the 
osmotic sensitivity changes if vacuolar development is affected (HAMPSEY 1997). Thus a 
disruption of the protein sorting process that affects the vacuole could lead to alteration of 
osmotic sensitivity.   
  
 Deletion mutants (npr1, lst4) with increased dipeptide utilization and mutants 
(bud32, reg1) with decreased utilization showed an accumulation of Ptr2p-GFP in 
vesicles. NPR1 encodes a Ser/Thr protein kinase, involved in post-translational control of 
Gap1p. Npr1p is required for Gap1p to be targeted to the plasma membrane, and an npr1 
deletion mutant loses Gap1p function by sorting Gap1p from the Golgi into the vacuole 
by-passing the plasma membrane (DE CRAENE et al. 2001). Similarly, mutations in LST4 
reduced the function of Galp1p and other amino acid permeases by the interruption of 
sorting of these transporters to the cell surface (ROBERG et al. 1997). Our observations 
indicated that NPR1 and LST4 regulate Ptr2p differently from the way they regulate 
Gap1p.  It is not clear how Lst4p and Npr1p regulate Ptr2p in a manner opposite to that 
of their regulation of Gap1p.  Bud32p is a Ser/Thr protein kinase involving in polar bud 
site selection and changing the vacuolar morphology (BONANGELINO et al. 2002).  Reg1p 
is a regulatory subunit for protein phosphatase Glc7p involved in the repression of many 
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glucose-regulated genes and vesicular trafficking (CUI et al. 2004).  The involvement of 
Bud32p and Reg1p in dipeptide utilization reflects their roles in Ptr2p trafficking. 
 
Genes that regulate dipeptide utilization independent of Ptr2p:  The alteration of 
dipeptide utilization also results from Ptr2p-independent metabolic processes as indicated 
by the observation of no apparent phenotypic change in expression or localization of 
Ptr2p-GFP in a number of mutants (Table 3). Mutation in genes encoding a variety of 
cellular metabolic processes (Figure S6) (NAGARAJAN and STORMS 1997; SCHNEIDER et 
al. 1997; STOOPS et al. 1997), such as the conversion of pyruvate into acetyl-CoA by 
pyruvate dehydrogenase complex (Pdx1p, Lpd1, Pdb1p, and Lat1p), the conversion of 
acetyl-CoA to malonyl-CoA by Hfa1p, fatty acid synthesis by fatty acid synthase 
complex (Oar1p, Mct1p, and Etr1p), glycine degradation (Gcv2p, Gcv3p, and Lpd1p), 
and a peptidase activity (Prd1p) resulted in a decrease of dipeptide utilization (Table 3). 
In these mutants the impairment of the dipeptide utilization appeared to be independent 
of Ptr2p transport activity since Ptr2p-GFP could be observed at the plasma membrane 
(Figure S3). The assay of [3H]Leu-Leu uptake in gcv3 strains suggested that the import of 
dipeptide was still maintained at wild-type level which showed that Ptr2p was functional 
(Figure 5), indicating that the decrease of dipeptide utilization resulted from the inability 
of the mutant to release amino acid from accumulated dipeptide or from a metabolic 
block in using the released amino acid for protein biosynthesis. Prd1p is a 
metalloendoproteinase (BUCHLER et al. 1994). The deletion mutant might be impaired in 
the degradation of intracellularly transported dipeptide which would result in a decrease 
of dipeptide utilization. 
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Deletion strains cik1, kti12, mlh1, mrp17, pho2, rim101, tif3, ybt1 and ydr417c 
showed no apparent effect on Ptr2p-GFP localization or expression but demonstrated 
increased dipeptide utilization. The utilization of dipeptide in these strains appears to 
involve Ptr2p-independent cellular processes as well. For example, Ybt1p belongs to the 
ABC transporter family exhibiting ATP-dependent bile acid transport (ORTIZ et al. 1997; 
PAULSEN et al. 1998). As expected for an ABC transporter, the ybt1 mutant was not only 
more sensitive to the toxic dipeptide Ala-Eth, but also this strain was more sensitive to 
ethionine and Lys-Ala-Eth (data not shown). We speculate that this protein might be 
involved in the transport of dipeptide into the vacuole. In the deletion mutant the defect in 
the uptake of dipeptide into the vacuole would lead to an increase of dipeptide 
availability in the cytoplasm. It is also possible that the deletion of a gene might result in 
a de-repression or change in function of other transport systems that may mediate 
dipeptide utilization in the mutant without alteration of PTR2 expression or Ptr2p 
function. We are currently working on unraveling the involvement of these metabolic 
genes in dipeptide utilization.  
Unknown genes that regulate dipeptide utilization:  Fifteen unknown gene deletion 
mutant strains were identified in this screen, including seven strains exhibiting increased 
and eight strains showing decreased dipeptide utilization (Table 3). Deletion mutants 
yor322c, ynl123w, yfr044c, and ylr114c showed enhanced expression level of Ptr2p-GFP 
signal compared to wild-type, and ypr174c had reduced expression of Ptr2p-GFP; these 
results were consistent with dipeptide utilization in these strains, suggesting these 
unknown genes products are involved in the regulation of PTR2 expression. Deletion 
mutants ynl295w, ypl073c, yjl175w, ydr157w, and ydr433w showed accumulation of 
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Ptr2p-GFP signal in the vesicles or the vacuole, suggestion these unknown gene products 
are involved in Ptr2p trafficking and localization. Similar to the expression level of Ptr2p-
GFP in the asm4 strain, enhanced Ptr2p-GFP expression was observed in the deletion 
mutant strains of unknown function ydr015c and ydr290w. These two mutants, however, 
showed a decreased sensitivity to toxic dipeptide and no growth change on dipeptide; it is 
not clear how these genes regulate dipeptide utilization. 
 
  Overall, this investigation has provided a list of genes involved directly and 
indirectly in the utilization of dipeptides in yeast. In our screen, 53 genes encoding 
proteins with more than 30% identity to human genes have been identified (See Tables 
S3 and S4, footnote a). To date no genes have been reported in the regulation of the 
human PTR2 homologs PEPT1 and PEPT2 (DANIEL 2004). Further investigation of these 
human genes may promote understanding of the regulation of dipeptide utilization in 
mammalian systems.  This study represents the first such global analysis of a membrane 
transport process and as such provides a rich starting ground for future investigations. 
 
Acknowledgements 
We thank Dr. Melinda Hauser, Dr. Amy Wiles and Dr. Tom Masi for helpful discussions 
and critical review of the manuscript.  
 94
REFERENCES 
ABDEL-SATER, F., I. IRAQUI, A. URRESTARAZU and B. ANDRE, 2004 The external amino 
acid signaling pathway promotes activation of Stp1 and Uga35/Dal81 
transcription factors for induction of the AGP1 gene in Saccharomyces cerevisiae. 
Genetics 166: 1727-1739. 
 
ANDREASSON, C., and P. O. LJUNGDAHL, 2002 Receptor-mediated endoproteolytic 
activation of two transcription factors in yeast. Genes Dev 16: 3158-3172. 
 
ANDREASSON, C., and P. O. LJUNGDAHL, 2004 The N-terminal regulatory domain of 
Stp1p is modular and, fused to an artificial transcription factor, confers full 
Ssy1p-Ptr3p-Ssy5p sensor control. Mol Cell Biol 24: 7503-7513. 
 
AOUIDA, M., N. PAGE, A. LEDUC, M. PETER and D. RAMOTAR, 2004 A genome-wide 
screen in Saccharomyces cerevisiae reveals altered transport as a mechanism of 
resistance to the anticancer drug bleomycin. Cancer Res 64: 1102-1109. 
 
ASKREE, S. H., T. YEHUDA, S. SMOLIKOV, R. GUREVICH, J. HAWK et al., 2004 A genome-
wide screen for Saccharomyces cerevisiae deletion mutants that affect telomere 
length. Proc Natl Acad Sci U S A 101: 8658-8663. 
 
BAETZ, K., L. MCHARDY, K. GABLE, T. TARLING, D. REBERIOUX et al., 2004 Yeast 
genome-wide drug-induced haploinsufficiency screen to determine drug mode of 
action. Proc Natl Acad Sci U S A 101: 4525-4530. 
 
BALCIUNAS, D., and H. RONNE, 1995 Three subunits of the RNA polymerase II mediator 
complex are involved in glucose repression. Nucleic Acids Res 23: 4421-4425. 
 
BARNES, D., W. LAI, M. BRESLAV, F. NAIDER and J. M. BECKER, 1998 PTR3, a novel 
gene mediating amino acid-inducible regulation of peptide transport in 
Saccharomyces cerevisiae. Mol Microbiol 29: 297-310. 
 
BARTEL, B., I. WUNNING and A. VARSHAVSKY, 1990 The recognition component of the 
N-end rule pathway. Embo J 9: 3179-3189. 
 
BERNARD, F., and B. ANDRE, 2001 Ubiquitin and the SCF(Grr1) ubiquitin ligase complex 
are involved in the signalling pathway activated by external amino acids in 
Saccharomyces cerevisiae. FEBS Lett 496: 81-85. 
 
BONANGELINO, C. J., E. M. CHAVEZ and J. S. BONIFACINO, 2002 Genomic screen for 
vacuolar protein sorting genes in Saccharomyces cerevisiae. Mol Biol Cell 13: 
2486-2501. 
 95
BONNEROT, C., R. BOECK and B. LAPEYRE, 2000 The two proteins Pat1p (Mrt1p) and 
Spb8p interact in vivo, are required for mRNA decay, and are functionally linked 
to Pab1p. Mol Cell Biol 20: 5939-5946. 
 
BOUVERET, E., G. RIGAUT, A. SHEVCHENKO, M. WILM and B. SERAPHIN, 2000 A Sm-like 
protein complex that participates in mRNA degradation. Embo J 19: 1661-1671. 
 
BOWERS, K., J. LOTTRIDGE, S. B. HELLIWELL, L. M. GOLDTHWAITE, J. P. LUZIO et al., 
2004 Protein-protein interactions of ESCRT complexes in the yeast 
Saccharomyces cerevisiae. Traffic 5: 194-210. 
 
BUCHLER, M., U. TISLJAR and D. H. WOLF, 1994 Proteinase yscD (oligopeptidase yscD). 
Structure, function and relationship of the yeast enzyme with mammalian thimet 
oligopeptidase (metalloendopeptidase, EP 24.15). Eur J Biochem 219: 627-639. 
 
BYRD, C., G. C. TURNER and A. VARSHAVSKY, 1998 The N-end rule pathway controls the 
import of peptides through degradation of a transcriptional repressor. Embo J 17: 
269-277. 
 
CHEN, Y., Y. LIU, G. K. M., J. M. BECKER, Y. XU et al., 2003 A computational study on 
the signal transduction pathway for amino acid and peptide transport in yeast: 
bridging the gap between high-throughput data and traditional biology. Applied 
Genomics and Proteomics 2: 43-50. 
 
CHRISTIE, K. R., S. WENG, R. BALAKRISHNAN, M. C. COSTANZO, K. DOLINSKI et al., 2004 
Saccharomyces Genome Database (SGD) provides tools to identify and analyze 
sequences from Saccharomyces cerevisiae and related sequences from other 
organisms. Nucleic Acids Res 32 Database issue: D311-314. 
 
CUI, D. Y., C. R. BROWN and H. L. CHIANG, 2004 The type 1 phosphatase Reg1p-Glc7p 
is required for the glucose-induced degradation of fructose-1,6-bisphosphatase in 
the vacuole. J Biol Chem 279: 9713-9724. 
 
DANIEL, H., 2004 Molecular and integrative physiology of intestinal peptide transport. 
Annu Rev Physiol 66: 361-384. 
 
DE BOER, M., P. S. NIELSEN, J. P. BEBELMAN, H. HEERIKHUIZEN, H. A. ANDERSEN et al., 
2000 Stp1p, Stp2p and Abf1p are involved in regulation of expression of the 
amino acid transporter gene BAP3 of Saccharomyces cerevisiae. Nucleic Acids 
Res 28: 974-981. 
 
DE CRAENE, J. O., O. SOETENS and B. ANDRE, 2001 The Npr1 kinase controls 
biosynthetic and endocytic sorting of the yeast Gap1 permease. J Biol Chem 276: 
43939-43948. 
 96
DU, F., F. NAVARRO-GARCIA, Z. XIA, T. TASAKI and A. VARSHAVSKY, 2002 Pairs of 
dipeptides synergistically activate the binding of substrate by ubiquitin ligase 
through dissociation of its autoinhibitory domain. Proc Natl Acad Sci U S A 99: 
14110-14115. 
 
FEI, Y. J., Y. KANAI, S. NUSSBERGER, V. GANAPATHY, F. H. LEIBACH et al., 1994 
Expression cloning of a mammalian proton-coupled oligopeptide transporter. 
Nature 368: 563-566. 
 
FISCHER, T., K. STRASSER, A. RACZ, S. RODRIGUEZ-NAVARRO, M. OPPIZZI et al., 2002 
The mRNA export machinery requires the novel Sac3p-Thp1p complex to dock at 
the nucleoplasmic entrance of the nuclear pores. Embo J 21: 5843-5852. 
 
FORSBERG, H., C. F. GILSTRING, A. ZARGARI, P. MARTINEZ and P. O. LJUNGDAHL, 2001a 
The role of the yeast plasma membrane SPS nutrient sensor in the metabolic 
response to extracellular amino acids. Mol Microbiol 42: 215-228. 
 
FORSBERG, H., M. HAMMAR, C. ANDREASSON, A. MOLINER and P. O. LJUNGDAHL, 2001b 
Suppressors of ssy1 and ptr3 null mutations define novel amino acid sensor-
independent genes in Saccharomyces cerevisiae. Genetics 158: 973-988. 
 
FORSBERG, H., and P. O. LJUNGDAHL, 2001a Genetic and biochemical analysis of the 
yeast plasma membrane Ssy1p-Ptr3p-Ssy5p sensor of extracellular amino acids. 
Mol Cell Biol 21: 814-826. 
 
FORSBERG, H., and P. O. LJUNGDAHL, 2001b Sensors of extracellular nutrients in 
Saccharomyces cerevisiae. Curr Genet 40: 91-109. 
 
GONZALES, T., and J. ROBERT-BAUDOUY, 1996 Bacterial aminopeptidases: properties and 
functions. FEMS Microbiol Rev 18: 319-344. 
 
GUSTIN, M. C., J. ALBERTYN, M. ALEXANDER and K. DAVENPORT, 1998 MAP kinase 
pathways in the yeast Saccharomyces cerevisiae. Microbiol Mol Biol Rev 62: 
1264-1300. 
 
HAMPSEY, M., 1997 A review of phenotypes in Saccharomyces cerevisiae. Yeast 13: 
1099-1133. 
 
HAUSER, M., V. NARITA, A. M. DONHARDT, F. NAIDER and J. M. BECKER, 2001 
Multiplicity and regulation of genes encoding peptide transporters in 
Saccharomyces cerevisiae. Mol Membr Biol 18: 105-112. 
 
HERRERA-RUIZ, D., and G. T. KNIPP, 2003 Current perspectives on established and 
putative mammalian oligopeptide transporters. J Pharm Sci 92: 691-714. 
 97
HITCHCOCK, A. L., K. AULD, S. P. GYGI and P. A. SILVER, 2003 A subset of membrane-
associated proteins is ubiquitinated in response to mutations in the endoplasmic 
reticulum degradation machinery. Proc Natl Acad Sci U S A 100: 12735-12740. 
 
HODGES, P. E., A. H. MCKEE, B. P. DAVIS, W. E. PAYNE and J. I. GARRELS, 1999 The 
Yeast Proteome Database (YPD): a model for the organization and presentation of 
genome-wide functional data. Nucleic Acids Res 27: 69-73. 
 
HOFFMAN, G. A., T. R. GARRISON and H. G. DOHLMAN, 2002 Analysis of RGS proteins in 
Saccharomyces cerevisiae. Methods Enzymol 344: 617-631. 
 
HOHMANN, S., 2002 Osmotic stress signaling and osmoadaptation in yeasts. Microbiol 
Mol Biol Rev 66: 300-372. 
 
IRAQUI, I., S. VISSERS, F. BERNARD, J. O. DE CRAENE, E. BOLES et al., 1999 Amino acid 
signaling in Saccharomyces cerevisiae: a permease-like sensor of external amino 
acids and F-Box protein Grr1p are required for transcriptional induction of the 
AGP1 gene, which encodes a broad-specificity amino acid permease. Mol Cell 
Biol 19: 989-1001. 
 
ISLAND, M. D., F. NAIDER and J. M. BECKER, 1987 Regulation of dipeptide transport in 
Saccharomyces cerevisiae by micromolar amino acid concentrations. J Bacteriol 
169: 2132-2136. 
 
ISLAND, M. D., J. R. PERRY, F. NAIDER and J. M. BECKER, 1991 Isolation and 
characterization of S. cerevisiae mutants deficient in amino acid-inducible peptide 
transport. Curr Genet 20: 457-463. 
 
KORNBERG, R. D., 2005 Mediator and the mechanism of transcriptional activation. 
Trends Biochem Sci 30: 235-239. 
 
KROGAN, N. J., K. BAETZ, M. C. KEOGH, N. DATTA, C. SAWA et al., 2004 Regulation of 
chromosome stability by the histone H2A variant Htz1, the Swr1 chromatin 
remodeling complex, and the histone acetyltransferase NuA4. Proc Natl Acad Sci 
U S A 101: 13513-13518. 
 
KUCHIN, S., I. TREICH and M. CARLSON, 2000 A regulatory shortcut between the Snf1 
protein kinase and RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 97: 
7916-7920. 
 
KUCHIN, S., P. YEGHIAYAN and M. CARLSON, 1995 Cyclin-dependent protein kinase and 
cyclin homologs SSN3 and SSN8 contribute to transcriptional control in yeast. 
Proc Natl Acad Sci U S A 92: 4006-4010. 
 98
LEE, T. I., N. J. RINALDI, F. ROBERT, D. T. ODOM, Z. BAR-JOSEPH et al., 2002 
Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298: 
799-804. 
 
LEE, V. H., 2000 Membrane transporters. Eur J Pharm Sci 11 Suppl 2: S41-50. 
 
LIU, W., R. LIANG, S. RAMAMOORTHY, Y. J. FEI, M. E. GANAPATHY et al., 1995 
Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter 
family, from human kidney. Biochim Biophys Acta 1235: 461-466. 
 
LUBKOWITZ, M. A., L. HAUSER, M. BRESLAV, F. NAIDER and J. M. BECKER, 1997 An 
oligopeptide transport gene from Candida albicans. Microbiology 143 ( Pt 2): 
387-396. 
 
MANNHAUPT, G., R. SCHNALL, V. KARPOV, I. VETTER and H. FELDMANN, 1999 Rpn4p 
acts as a transcription factor by binding to PACE, a nonamer box found upstream 
of 26S proteasomal and other genes in yeast. FEBS Lett 450: 27-34. 
 
MARELLI, M., J. D. AITCHISON and R. W. WOZNIAK, 1998 Specific binding of the 
karyopherin Kap121p to a subunit of the nuclear pore complex containing 
Nup53p, Nup59p, and Nup170p. J Cell Biol 143: 1813-1830. 
 
MARSTON, A. L., W. H. THAM, H. SHAH and A. AMON, 2004 A genome-wide screen 
identifies genes required for centromeric cohesion. Science 303: 1367-1370. 
 
MARZLUF, G. A., 1997 Genetic regulation of nitrogen metabolism in the fungi. Microbiol 
Mol Biol Rev 61: 17-32. 
 
MIYAKE, T., M. KANAYAMA, H. SAMMOTO and B. ONO, 2002 A novel cis-acting 
cysteine-responsive regulatory element of the gene for the high-affinity 
glutathione transporter of Saccharomyces cerevisiae. Mol Genet Genomics 266: 
1004-1011. 
 
MYER, V. E., and R. A. YOUNG, 1998 RNA polymerase II holoenzymes and 
subcomplexes. J Biol Chem 273: 27757-27760. 
 
NAGARAJAN, L., and R. K. STORMS, 1997 Molecular characterization of GCV3, the 
Saccharomyces cerevisiae gene coding for the glycine cleavage system hydrogen 
carrier protein. J Biol Chem 272: 4444-4450. 
 
NIELSEN, P. S., B. VAN DEN HAZEL, T. DIDION, M. DE BOER, M. JORGENSEN et al., 2001 
Transcriptional regulation of the Saccharomyces cerevisiae amino acid permease 
gene BAP2. Mol Gen Genet 264: 613-622. 
 99
ORTIZ, D. F., M. V. ST PIERRE, A. ABDULMESSIH and I. M. ARIAS, 1997 A yeast ATP-
binding cassette-type protein mediating ATP-dependent bile acid transport. J Biol 
Chem 272: 15358-15365. 
 
PAGE, N., M. GERARD-VINCENT, P. MENARD, M. BEAULIEU, M. AZUMA et al., 2003 A 
Saccharomyces cerevisiae genome-wide mutant screen for altered sensitivity to 
K1 killer toxin. Genetics 163: 875-894. 
 
PAULSEN, I. T., M. K. SLIWINSKI, B. NELISSEN, A. GOFFEAU and M. H. SAIER, JR., 1998 
Unified inventory of established and putative transporters encoded within the 
complete genome of Saccharomyces cerevisiae. FEBS Lett 430: 116-125. 
 
PERRY, J. R., M. A. BASRAI, H. Y. STEINER, F. NAIDER and J. M. BECKER, 1994 Isolation 
and characterization of a Saccharomyces cerevisiae peptide transport gene. Mol 
Cell Biol 14: 104-115. 
 
POULSEN, P., B. WU, R. F. GABER, K. OTTOW, H. A. ANDERSEN et al., 2005 Amino acid 
sensing by Ssy1. Biochem Soc Trans 33: 261-264. 
 
PRITCHARD, G. G., and T. COOLBEAR, 1993 The physiology and biochemistry of the 
proteolytic system in lactic acid bacteria. FEMS Microbiol Rev 12: 179-206. 
 
RAIBORG, C., T. E. RUSTEN and H. STENMARK, 2003 Protein sorting into multivesicular 
endosomes. Curr Opin Cell Biol 15: 446-455. 
 
REID, J. L., Z. MOQTADERI and K. STRUHL, 2004 Eaf3 regulates the global pattern of 
histone acetylation in Saccharomyces cerevisiae. Mol Cell Biol 24: 757-764. 
 
ROBERG, K. J., S. BICKEL, N. ROWLEY and C. A. KAISER, 1997 Control of amino acid 
permease sorting in the late secretory pathway of Saccharomyces cerevisiae by 
SEC13, LST4, LST7 and LST8. Genetics 147: 1569-1584. 
 
SANDERS, S. L., J. JENNINGS, A. CANUTESCU, A. J. LINK and P. A. WEIL, 2002 Proteomics 
of the eukaryotic transcription machinery: identification of proteins associated 
with components of yeast TFIID by multidimensional mass spectrometry. Mol 
Cell Biol 22: 4723-4738. 
 
SCHERENS, B., and A. GOFFEAU, 2004 The uses of genome-wide yeast mutant collections. 
Genome Biol 5: 229. 
 
SCHNEIDER, R., B. BRORS, F. BURGER, S. CAMRATH and H. WEISS, 1997 Two genes of 
the putative mitochondrial fatty acid synthase in the genome of Saccharomyces 
cerevisiae. Curr Genet 32: 384-388. 
 
 100
SHEN, X., R. RANALLO, E. CHOI and C. WU, 2003 Involvement of actin-related proteins in 
ATP-dependent chromatin remodeling. Mol Cell 12: 147-155. 
 
STADE, K., C. S. FORD, C. GUTHRIE and K. WEIS, 1997 Exportin 1 (Crm1p) is an essential 
nuclear export factor. Cell 90: 1041-1050. 
 
STEINER, H. Y., F. NAIDER and J. M. BECKER, 1995 The PTR family: a new group of 
peptide transporters. Mol Microbiol 16: 825-834. 
 
STEINMETZ, L. M., C. SCHARFE, A. M. DEUTSCHBAUER, D. MOKRANJAC, Z. S. HERMAN et 
al., 2002 Systematic screen for human disease genes in yeast. Nat Genet 31: 400-
404. 
 
STOOPS, J. K., R. H. CHENG, M. A. YAZDI, C. Y. MAENG, J. P. SCHROETER et al., 1997 On 
the unique structural organization of the Saccharomyces cerevisiae pyruvate 
dehydrogenase complex. J Biol Chem 272: 5757-5764. 
 
TURNER, G. C., F. DU and A. VARSHAVSKY, 2000 Peptides accelerate their uptake by 
activating a ubiquitin-dependent proteolytic pathway. Nature 405: 579-583. 
 
WANG, L., X. MAO, D. JU and Y. XIE, 2004 Rpn4 is a physiological substrate of the Ubr2 
ubiquitin ligase. J Biol Chem 279: 55218-55223. 
 
WINZELER, E. A., D. D. SHOEMAKER, A. ASTROMOFF, H. LIANG, K. ANDERSON et al., 
1999 Functional characterization of the S. cerevisiae genome by gene deletion and 
parallel analysis. Science 285: 901-906. 
 
XIE, Y., and A. VARSHAVSKY, 1999 The E2-E3 interaction in the N-end rule pathway: the 
RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain. Embo 










PTR2-FLAG-GFP-F  (5’- gatccaccaccaaatatGACTACAAGGACGACGATGACAAGcttgatatcaacaagacaggg-3’) 
PTR2-Flag-GFP-R (5’-GATGATGATGACTGCTGCCGCTGCCGCGCGGCACACCGGTcctcgagccgcttttcttgtac-3’) 
PTR2-F (Northern) (5’-TTCCGCACCATTCCAAAACTACAT-3’) 
PTR2-R (Northern) (5’-GCAGCACAGAAAACTCCCGTAAAC-3’) 
ACT1-F (Northern) (5’-GCCGGTTTTGCCGGTGACGAC-3’) 
ACT1-R (Northern) (5’-GGAAGATGGAGCCAAAGCGTG-3’). 
PTR2 (F) (5’-cagtgaccgttgatcctaaat-3’) 
PTR2 (R) (5’-ctgaagcacaaccagaacaaa-3’) 
ACT1 (F) (5’-ccaccatgttcccaggtatt-3’) 
ACT1 (R) (5’-ccaatccagacggagtactt-3’) 
PMA1 (F) (5’-ctggtccattctggtcttcta-3’) 
PMA1 (R) (5’-ccaccaaccgaataaggtaaa-3’) 
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Supplement Table S2 One hundred and nine strains of the haploid, deletion mutant collection were not capable of growing in 
MM+HLKU with allantoin as the sole nitrogen source. These deletion mutant strains were excluded from this study. The strains 
are listed alphabetically by gene name. 
ORF name Gene 
Name 
Gene description in SGD 
YLR304C ACO1 Mitochondrial aconitase, required for the tricarboxylic acid (TCA) cycle; mutation leads to glutamate auxotrophy 
YAR015W ADE1 N-succinyl-5-aminoimidazole-4-carboxamide ribotide (SAICAR) synthetase, required for 'de novo' purine nucleotide 
biosynthesis; red pigment accumulates in mutant cells deprived of adenine 
YOR128C ADE2 Phosphoribosylaminoimidazole carboxylase, catalyzes a step in the 'de novo' purine nucleotide biosynthetic pathway; red 
pigment accumulates in mutant cells deprived of adenine 
YGR204W ADE3 Cytoplasmic trifunctional enzyme C1-tetrahydrofolate synthase, involved in single carbon metabolism and required for 
biosynthesis of purines, thymidylate, methionine, and histidine 
YMR300C ADE4 Phosphoribosylpyrophosphate amidotransferase (PRPPAT; amidophosphoribosyltransferase), catalyzes first step of the 'de 
novo' purine nucleotide biosynthetic pathway 
YGL234W ADE5,7 Bifunctional enzyme of the 'de novo' purine nucleotide biosynthetic pathway, contains aminoimidazole ribotide synthetase 
and glycinamide ribotide synthetase activities 
YGR061C ADE6 Formylglycinamidine-ribonucleotide (FGAM)-synthetase, catalyzes a step in the 'de novo' purine nucleotide biosynthetic 
pathway 
YDR408C ADE8 Phosphoribosyl-glycinamide transformylase, catalyzes a step in the 'de novo' purine nucleotide biosynthetic pathway 
YNL220W ADE12 Adenylosuccinate synthase, catalyzes the first committed step in the 'de novo' biosynthesis of adenosine 
YOL058W ARG1 Arginosuccinate synthetase, catalyzes the formation of L-argininosuccinate from citrulline and L-aspartate in the arginine 
biosynthesis pathway; potential Cdc28p substrate  
YJL071W ARG2 Acetylglutamate synthase (glutamate N-acetyltransferase), mitochondrial enzyme that catalyzes the first step in the 
biosynthesis of the arginine precursor ornithine; forms a complex with Arg5,6p 
YJL088W ARG3 Ornithine carbamoyltransferase (carbamoylphosphate:L-ornithine carbamoyltransferase), catalyzes the sixth step in the 
biosynthesis of the arginine precursor ornithine  
YHR018C ARG4 Argininosuccinate lyase, catalyzes the final step in the arginine biosynthesis pathway  
YER069W ARG5,6 Bifunctional enzyme with N-acetyl-gamma-glutamyl-phosphate reductase and acetylglutamate kinase activities, catalyzes 
the second and third steps in the biosynthesis of the arginine precursor ornithine; forms a complex with Arg2p  
YDR127W ARO1 Pentafunctional arom protein, catalyzes steps 2 through 6 in the biosynthesis of chorismate, which is a precursor to aromatic 
amino acids 
YGL148W ARO2 Bifunctional chorismate synthase and flavin reductase, catalyzes the conversion of 5-enolpyruvylshikimate 3-phosphate 
(EPSP) to form chorismate, which is a precursor to aromatic amino acids 
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Supplement Table S2 Continued 
ORF name Gene 
Name 
Gene description in SGD 
YEL029C BUD16 Protein involved in bud-site selection; diploid mutants display a random budding pattern instead of the wild-type bipolar 
pattern; has similarity to pyridoxal kinases 
YER014C-A BUD25 Protein involved in bud-site selection; diploid mutants display a random budding pattern instead of the wild-type bipolar 
pattern 
YLR226W BUR2 Bypass UAS Requirement; involved in transcriptional regulation 
YJR122W CAF17 Mitochondrial protein that interacts with Ccr4p in the two-hybrid system; 3'-untranslated region contains a putative mRNA 
localization element common to genes encoding mitochondrial proteins 
YJR060W CBF1 Helix-loop-helix protein that binds the motif CACRTG (R=A or G), which is present at several sites including MET gene 
promoters and centromere DNA element I (CDEI); required for nucleosome positioning at this motif; targets Isw1p to DNA 
YDR364C CDC40 Pre-mRNA splicing factor, important for catalytic step II of pre-mRNA splicing and plays a role in cell cycle progression; 
required for DNA synthesis during mitosis and meiosis; has WD repeats 
YGL029W CGR1 Coiled-coil protein that may contribute to compartmentalization of nucleolar constituents; expression is growth-regulated 
YGL206C CHC1 Vesicle coat protein; presumed vesicle coat protein 
YOR303W CPA1 Small subunit of carbamoyl phosphate synthetase, which catalyzes a step in the synthesis of citrulline, an arginine precursor; 
translationally regulated by an attenuator peptide encoded by YOR302W within the CPA1 mRNA 5'-leader  
YJR109C CPA2 Large subunit of carbamoyl phosphate synthetase, which catalyzes a step in the synthesis of citrulline, an arginine precursor  
YML112W CTK3 Gamma subunit of C-terminal domain kinase I (CTDK-I), which phosphorylates the C-terminal repeated domain of the RNA 
polymerase II large subunit (Rpo21p) to affect both transcription and pre-mRNA 3' end processing  
YGR155W CYS4 Cystathionine beta-synthase, catalyzes the first committed step of transsulfuration in cysteine biosynthesis 
YDR294C DPL1 Dihydrosphingosine phosphate lyase, regulates intracellular levels of sphingolipid long-chain base phosphates (LCBPs), 
degrades phosphorylated long chain bases, prefers C16 dihydrosphingosine-l-phosphate as a substrate 
YJR137C ECM17 Sulfite reductase beta subunit, involved in amino acid biosynthesis, transcription repressed by methionine 
YJL201W ECM25 Non-essential protein of unknown function; promoter contains a consensus binding sequence for factor Abf1p 
YHL030W ECM29 Major component of the proteasome; tethers the proteasome core particle to the regulatory particle, and enhances the 
stability of the proteasome 
YFR019W FAB1 1-phosphatidylinositol-3-phosphate 5-kinase; vacuolar membrane kinase that generates phosphatidylinositol (3,5)P2, which 
is involved in vacuolar sorting and homeostasis 
YPR062W FCY1 Cytosine deaminase, involved in salvage pathways of pyrimidine metabolism 
YER060W-A FCY22 Putative purine-cytosine permease, very similar to Fcy2p but cannot substitute for its function 
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Supplement Table S2 Continued 
ORF name Gene 
Name 
Gene description in SGD 
YOR382W FIT2 Mannoprotein that is incorporated into the cell wall via a glycosylphosphatidylinositol (GPI) anchor, involved in the 
retention of siderophore-iron in the cell wall 
YOR381W FRE3 Ferric reductase, reduces siderophore-bound iron prior to uptake by transporters; expression induced by low iron levels 
YDL198C GGC1 Mitochondrial GTP/GDP transporter, essential for mitochondrial genome maintenance; has a role in mitochondrial iron 
transport; member of the mitochondrial carrier family; (putative) mitochondrial carrier protein 
YHR183W GND1 6-phosphogluconate dehydrogenase, decarboxylating; converts 6-phosphogluconate + NADP to ribulose-5-phosphate + 
NADPH + CO2; Phosphogluconate Dehydrogenase (Decarboxylating) 
YJL184W GON7 Protein of unknown function, proposed to be involved in the transfer of mannosylphosphate groups onto N-linked 
oligosaccharides; also proposed to be involved in responding to osmotic stress 
YER057C HMF1 Member of the p14.5 protein family with similarity to Mmf1p, functionally complements Mmf1p function when targeted to 
mitochondria; heat shock inducible; high-dosage growth inhibitor; forms a homotrimer in vitro 
YDR158W HOM2 Aspartic beta semi-aldehyde dehydrogenase, catalyzes the second step in the common pathway for methionine and threonine 
biosynthesis; expression regulated by Gcn4p and the general control of amino acid synthesis 
YJR139C HOM6 Homoserine dehydrogenase (L-homoserine:NADP oxidoreductase), dimeric enzyme that catalyzes the third step in the 
common pathway for methionine and threonine biosynthesis; enzyme has nucleotide-binding, dimerization and catalytic 
regions 
YER086W ILV1 Threonine deaminase, catalyzes the first step in isoleucine biosynthesis; expression is under general amino acid control; 
ILV1 locus exhibits highly positioned nucleosomes whose organization is independent of known ILV1 regulation 
YJR050W ISY1 Component of the spliceosome complex involved in pre-mRNA splicing, auxiliary splicing factor that may modulate Syf1p 
activity and help optimize splicing; isy1 syf2 double mutation activates the spindle checkpoint, causing cell cycle arrest 
YDR017C KCS1 Inositol hexaphosphate kinase, phosphorylates inositol hexakisphosphate (InsP6) to diphosphoinositol polyphosphates, 
required for proper vacuole morphology and involved in salt stress response, contains two leucine heptad repeats 
YFR001W LOC1 Nuclear protein involved in asymmetric localization of ASH1 mRNA; binds double-stranded RNA in vitro 
YKR069W MET1 S-adenosyl-L-methionine uroporphyrinogen III transmethylase, involved in sulfate assimilation, methionine metabolism, and 
siroheme biosynthesis 
YJR010W MET3 ATP sulfurylase, catalyzes the primary step of intracellular sulfate activation, essential for assimilatory reduction of sulfate 
to sulfide, involved in methionine metabolism 
YER091C MET6 Cobalamin-independent methionine synthase, involved in amino acid biosynthesis; also called N5-methyltetrahydrofolate 
homocysteine methyltransferase or 5-methyltetrahydropteroyltriglutamate homocysteine methyltransferase 
YOR241W MET7  Folylpolyglutamate synthetase, catalyzes extension of the glutamate chains of the folate coenzymes, required for methionine 
synthesis and for maintenance of mitochondrial DNA, present in both the cytoplasm and mitochondria 
   
 105
Supplement Table S2 Continued 
ORF name Gene 
Name 
Gene description in SGD 
YBR213W MET8 Bifunctional dehydrogenase and ferrochelatase, involved in the biosynthesis of siroheme; also involved in the expression of 
PAPS reductase and sulfite reductase 
YFR030W MET10 Subunit alpha of assimilatory sulfite reductase, which is responsible for the conversion of sulfite into sulfide 
YKL001C MET14 Adenylylsulfate kinase, required for sulfate assimilation and involved in methionine metabolism 
YPR167C MET16 3'-phosphoadenylsulfate reductase, reduces 3'-phosphoadenylyl sulfate to adenosine-3',5'-bisphosphate and free sulfite using 
reduced thioredoxin as cosubstrate, involved in sulfate assimilation and methionine metabolism  
YLR303W MET17 O-acetyl homoserine-O-acetyl serine sulfhydrylase, required for sulfur amino acid synthesis 
YIL128W MET18 DNA repair and TFIIH regulator, required for both nucleotide excision repair (NER) and RNA polymerase II (RNAP II) 
transcription; possible role in assembly of a multiprotein complex(es) required for NER and RNAP II transcription 
YIR017C MET28 Transcriptional activator in the Cbf1p-Met4p-Met28p complex, participates in the regulation of sulfur metabolism  
YML128C MSC1 Protein of unknown function, green fluorescent protein (GFP)-fusion protein localizes to the endoplasmic reticulum; msc1 
mutants are defective in directing meiotic recombination events to homologous chromatids 
YMR091C NPL6 Nuclear protein that may have a role in nuclear protein import 
YJR073C OPI3 Phospholipid methyltransferase (methylene-fatty-acyl-phospholipid synthase), catalyzes the last two steps in 
phosphatidylcholine biosynthesis 
YOR130C ORT1 Ornithine transporter of the mitochondrial inner membrane, exports ornithine from mitochondria as part of arginine 
biosynthesis; human ortholog is associated with hyperammonaemia-hyperornithinaemia-homocitrullinuria (HHH) syndrome 
YDR323C PEP7 Multivalent adaptor protein that facilitates vesicle-mediated vacuolar protein sorting by ensuring high-fidelity vesicle 
docking and fusion, which are essential for targeting of vesicles to the endosome; required for vacuole inheritance 
YNL316C PHA2 Prephenate dehydratase 
YPL188W POS5 Mitochondrial NADH kinase, phosphorylates NADH; also phosphorylates NAD(+) with lower specificity; required for the 
response to oxidative stress 
YGR006W PRP18 Splicing factor involved in the positioning of the 3' splice site during the second catalytic step of splicing, recruited to the 
spliceosome by Slu7p 
YHR001W-A QCR10 8.5 kDa subunit of the ubiqunol-cytochrome c oxidoreductase complex 
YOL143C RIB4 Lumazine synthase (6,7-dimethyl-8-ribityllumazine synthase, also known as DMRL synthase); catalyzes synthesis of 
immediate precursor to riboflavin 
YER070W RNR1 Ribonucleotide-diphosphate reductase (RNR), large subunit; the RNR complex catalyzes the rate-limiting step in dNTP 
synthesis and is regulated by DNA replication and DNA damage checkpoint pathways via localization of the small subunits 
YBL093C ROX3 RNA polymerase II holoenzyme component 
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Supplement Table S2 Continued 
ORF name Gene 
Name 
Gene description in SGD 
YIL069C RPS24B Protein component of the small (40S) ribosomal subunit; identical to Rps24Ap and has similarity to rat S24 ribosomal 
protein 
YOR184W SER1 Phosphoserine transaminase 
YGR208W SER2 Phosphoserine phosphatase 
YJR104C SOD1 Cu, Zn superoxide dismutase 
YHR178W STB5 Binds Sin3p in two-hybrid assay; Zinc finger  
YDL185W TFP1 Vacuolar ATPase V1 domain subunit A; protein precursor is spliced to yield the extein Tfp1p and the intein Vde (PI-SceI), 
which is a site-specific endonuclease  
YHR025W THR1 Homoserine kinase 
YCR053W THR4 Threonine synthase 
YJL138C TIF2 Translation initiation factor eIF4A 
YPR074C TKL1 Transketolase 1 
YGR260W TNA1 High affinity nicotinic acid plasma membrane permease 
YJL129C TRK1 180 kDa high affinity potassium transporter 
YDR120C TRM1 tRNA methyltransferase, localizes to both the nucleus and mitochondrion to produce the modified base N2,N2-
dimethylguanosine in tRNAs in both compartments 
YER090W TRP2 Anthranilate synthase Component I 
YKL211C TRP3 Anthranilate synthase Component II and indole-3-phosphate (multifunctional enzyme) 
YDR354W TRP4 Anthranilate phosphoribosyl transferase 
YGL026C TRP5 Tryptophan synthetase 
YBR166C TYR1 Step of tyrosine biosynthesis pathway; Prephenate dehydrogenase (NADP+) 
YDL077C VAM6 Protein involved in vacuolar morphogenesis 
YPR036W VMA13 Vacuolar ATPase V1 domain subunit H (54 kDa) 
YBR127C VMA2 Vacuolar H+ ATPase regulatory subunit (subunit B) of the catalytic (V1) sector 
YPL065W VPS28 Soluble, hydrophilic protein involved in transport of precursors for soluble vauolar hydrolases from the late endosome to the 
vacuole; involved in vacuolar protein targeting 
YDR495C VPS3 Vacuolar sorting protein 
YLR240W VPS34 Phosphatidylinositol 3-kinase 
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Supplement Table S2 Continued 
ORF name Gene 
Name 
Gene description in SGD 
YGL095C VPS45 Protein of the Sec1p family, essential for vacuolar protein sorting; required for the function of both Pep12p and the early 
endosome/late Golgi SNARE Tlg2p 
YLR322W VPS65 Dubious open reading frame, unlikely to encode a protein; not conserved in closely related Saccharomyces species; 75% of 
ORF overlaps the verified gene SFH1; deletion causes a vacuolar protein sorting defect 
YML097C VPS9 Protein required for Golgi to vacuole trafficking, has similarity with mammalian ras inhibitors 
YEL004W YEA4 Shows sequence similarity to GOG5, a gene involved in vanadate resistance; similar to Gog5, which is involved in vanadate 
resistance 
YNL241C ZWF1 Glucose-6-phosphate dehydrogenase 
YOR302W  CPA1 uORF , Arginine attenuator peptide, regulates translation of the CPA1 mRNA 
YOR302W  CPA1 uORF , Arginine attenuator peptide, regulates translation of the CPA1 mRNA 
YHR039C-B  Slow growth 
YER068C-A  Questionable ORF from MIPS 
YER091C-A  Hypothetical ORF 
YIL039W  Hypothetical ORF 
YDR008C  Hypothetical ORF 
YOL125W  Hypothetical ORF 
YDR442W  Hypothetical ORF 
YER137C  Hypothetical ORF 
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Supplement Table S3 List of 46 genes whose deletion mutant strain enhanced dipeptide utilization. In the solid medium plate, 
deletion strains were grown in MM+(H-L)HKU with or without Trp. In the toxicity halo assay, deletion strains were grown in 
MM+HLKU medium supplied with 0.1µmol Ala-Eth in the disk. According to the Gene Ontology (GO) in SGD 
(http://db.yeastgenome.org/cgi-bin/GO/goTermMapper), these genes cover 23 out of 34 categories of “Biological Processes”. A given 
gene is only listed once, although based on its functions some genes are classified into multiple categories. The gene in bold (CUP9) 
was previously identified as being involved in the regulation of PTR2 transcription. 
 
Growth in solid medium plate with 
His-Leu 





Toxicity of  Ala-





of Biological  
Processesb 
Wild-type  - + 100  
RIM101 a Specific transcriptional repressor activity ++ ++ 109 1 2 8 20 
SSN3 a Cyclin-dependent protein kinase activity ++ ++ 114 1 2 6 8 
SSN8 a Cyclin-dependent protein kinase regulator activity ++ ++ 106 1 2 8 
BNI1 Cytoskeletal regulatory protein binding ++ ++ 109 1 4 5 9 10 17 21 
CIK1 Microtubule motor activity ++ ++ 124 1 4 8 9 
CSM1 Required for monopolar attachment of homologous 
chromosomes to the spindle 
+ ++ 109 1 7 8 
MLH1 a DNA binding; ATPase activity + ++ 106 1 7 8  
PAT1 Required for faithful chromosome transmission and 
normal translation initiation 
+ ++ 121 1 13 
SRB8 RNA polymerase II transcription mediator activity ++ ++ 109 2 
SSN2 General RNA polymerase II transcription factor activity ++ ++ 123 2 
VPS36 Regulator of G-protein signaling activity + ++ 116 2 3 14 
HAL9 Specific RNA polymerase II transcription factor activity + ++ 131 2 5 
PHO2 a Transcription factor activity ++ ++ 121 2 5 26 
EAF3 a Histone acetyltransferase activity ++ ++ 133 2 6 7 19 
CUP9 a Specific RNA polymerase II transcription factor activity ++ ++ 120 2 23 
ARP5 a Actin-related protein ++ ++ 139 3 
ARP8 Actin-related protein ++ ++ 126 3  
LST4 Protein transporter activity - +++ 116 3 
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Supplement Table S3 Continued 
Growth in solid medium plate with 
His-Leu 





Toxicity of  Ala-





of Biological  
Processesb 
YBT1 a Bile acid transporter activity + ++ 156 3 
SRN2 Class E vacuolar sorting protein + + 109 3  
SAC6 a Actin filament binding + ++ 118 3 4 5 9 14 21 
TPM1 Actin lateral binding ++ ++ 119 3 4 9 10 14 21 
SNF7 a Protein sorting in the pre-vacuolar endosome +++ +++ 114 3 4 14 
VPS8 a Vacuolar sorting + ++ 121 3 4 14 
VAM10 Involved in early stages of vacuolar fusion + ++ 107 4 
DEF1 Involved in vacuolar import and degradation ++ +++ 113 5 12 
UBR2 Ubiquitin-protein ligase activity +++ +++ 129 6  
DBR1 a RNA lariat debranching enzyme activity + +++ 109 7 27 
SFP1 a Transcription factor activity ++ ++ 168 10 
KEM1 a 5'-3' exoribonuclease activity ++ ++ 135 10 27 28 
MRP17 a Structural constituent of ribosome ++ ++ 146 13 
MRPS9 a Structural constituent of ribosome ++ ++ 170 13 
TIF3 Translation initiation factor activity + ++ 124 13 
IES6 Involved in secretion and vacuolar trafficking and 
maintenance 
++ ++ 132 14 
NPR1 a Serine/threonine protein kinase + + 129 14  
KTI12 Enzyme regulator activity ++ +++ 109 19 
SSD1 Maintenance of cellular integrity + ++ 107 25 
TOM72 a Minor import receptor of the mitochondrial outer 
membrane 
++ ++ 108 29 
YDR417C Unknown ++ ++ 139 29 
YFR044C a Unknown ++ ++ 112 29 
YLR114C Unknown + ++ 143 29 
YNL123W Putative serine protease + ++ 106 29 
YNL136W Unknown ++ ++ 123 29 
YNL295W Unknown + ++ 106 29 
YOR322C Unknown - + 122 29 
YPL073C Unknown + ++ 114 29 
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a These genes encode proteins with more than 30% sequence identity to a human protein.  
b The functional categories found for each gene according to the gene annotation in SGD Gene Ontology (GO) (http://db.yeastgenome.org/cgi-
bin/GO/goTermMapper) are listed.  Many genes have multiple listings in GO. The GO functional categories are listed as follows, with the number of genes 
identified in this screen belonging to each category shown in parentheses taking into account the multiple functional categories found for many genes:  1) Cell 
cycle (8 genes); 2) Transcription (10 genes); 3) Transport (10 genes); 4) Organelle organization and biogenesis (8 genes); 5) Response to stress (6 genes); 6) 
Protein modification (3 genes); 7) DNA metabolism (4 genes); 8) Meiosis (6 genes); 9) Cytoskeleton organization and biogenesis (5 genes); 10) Morphogenesis 
(4 genes); 11) Energy pathways (0 gene); 12) Protein catabolism (1 genes); 13) Protein biosynthesis (4 genes); 14) Vesicle-mediated transport (8 genes); 15) 
Carbohydrate metabolism (0 gene); 16) Lipid metabolism (0 gene); 17) Signal transduction (2 genes); 18) Cytokinesis (0 gene); 19) Nuclear organization and 
biogenesis (2 genes); 20) Sporulation (1 gene); 21) Budding (3 genes); 22) Cellular respiration (0 gene); 23) Cell homeostasis (1 gene); 24) Coenzyme and 
prosthetic group metabolism (0 gene); 25) Cell wall organization and biogenesis (2 genes); 26) Amino acid and derivative metabolism (1 gene); 27) RNA 
metabolism (2 genes); 28) Ribosome biogenesis and assembly (1 gene); 29) Biological process unknown (9 genes); 30) Membrane organization and biogenesis 
(0 gene); 31) Electron transport (0 gene); 32) Pseudohyphal growth (0 gene); 33) Vitamin metabolism (0 gene); 34) Conjugation (0 gene).  
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Supplement Table S4 List of 57 genes whose deletion mutant strain decreased dipeptide utilization. In the solid medium plate, 
deletion strains were grown in MM+(H-L)HKU with or without Trp. In the toxicity halo assay, deletion strains were grown in 
MM+HLKU medium supplied with 0.1µmol Ala-Eth in the disk. According to the Gene Ontology (GO) in SGD 
(http://db.yeastgenome.org/cgi-bin/GO/goTermMapper), these genes cover 25 out of 34 categories of “Biological Processes”. A given 
gene is only listed once, although based on its functions some genes are classified into multiple categories. The genes in bold (DAL81, 
STP2, UBC2, and PTR1) were previously identified as being involved in the regulation of PTR2 transcription. 
 
Growth in solid medium plate 
with His-Leu 









Wild-type  - + 100  
TAF14 a General RNA polymerase II transcription factor activity - - 0 (Fuzzy halo) 1 2 7 19  
MCK1a Protein kinases, positive regulator of meiosis and spore 
formation 
- + 83 1 5 6 7 8 20 
MRE11a  3'-5' exonuclease activity - + 82 1 5 7 8 
PHO85 a Cyclin-dependent protein kinase activity - - 0 1 6 11 15  
HFM1 a  DNA helicase activity - - 0 (Fuzzy halo) 1 7 8 
SPO21 Structural molecule activity - - 0 (Fuzzy halo) 1 8 20 
RPN4 a Transcriptional activator activity - - 0 1 12 
BYE1 a Transcriptional elongation regulator activity - - 85 2  
DAL81 Specific RNA polymerase II transcription factor activity - - 0 2  
STP2 a Specific RNA polymerase II transcription factor activity - - 61 2  
THP1 Protein binding - - 88 2 3 4 7 9 10 18 
REG1 Protein phosphatase type 1 activity - - 0 (Fuzzy halo) 2 11 15 
ISA1 a Mitochondrial protein required for normal iron 
metabolism 
- - 0 3 
ISA2 Mitochondrial protein required for iron metabolism - - 0 3  
NPL3 a mRNA binding - - 90 3  
VBM1 Fatty acid elongase activity - - 93 3 14 16  
ASM4 Structural molecule activity - + 0 (Fuzzy halo) 3 19 
BUD32 a Protein serine/threonine kinase activity - - 0 (Fuzzy halo) 4 6 9 10 18 
BEM4 Rho-type GTPases - - 90 4 9 10 17 
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Supplement Table S4 Continued 
 
Growth in solid medium plate 
with His-Leu 









BUD28 Bud site selection - - 75 4 9 10 18 
UBC2 a Ubiquitin conjugating enzyme activity - - 0 5 6 7 12 19  
RAD23 a Damaged DNA binding - - 84 5 7 12 
TSA1 a Thioredoxin peroxidase activity - - 88 5 23 
PTR1 Ubiquitin-protein ligase activity - - 0 6 
UBA3 a NEDD8 activating enzyme activity - - 0 6 
UBP14 Ubiquitin-specific protease activity - - 73 6 11 15  
ELF1 a  Molecular function unknown - - 94 10 
CSF1 Required for normal growth rate - - 90 11 
SHP1 a Ubiquitin binding; Enzyme regulator activity - - 74 11 12 15 20 
ETR1 a Enoyl-[acyl-carrier protein] reductase activity - - 0 11 16 22 
MCT1 [acyl-carrier protein] S-malonyltransferase activity - + 0 11 16 22 
OAR1 3-oxoacyl-[acyl-carrier protein] reductase activity - - 0 11 16 22 
PRD1 a   Metalloendopeptidase activity - + 84 12  
RPL21A a  Structural constituent of ribosome - - 0 13 
RPS9B a Structural constituent of ribosome - - 65 13 
IPK1 Inositol or phosphatidylinositol kinase activity - - 67 15 
LAT1 a Dihydrolipoyllysine-residue acetyltransferase activity - - 0 15 
PDB1 a Pyruvate dehydrogenase (acetyl-transferring) activity - - 0 15 
HFA1 a Acetyl-CoA carboxylase activity - - 0 16 
IRA2 Ras GTPase activator activity - - 86 17 
HOF1 a Cytoskeletal protein binding - - 0 18 
RMD12 3-hydroxyacyl-[acyl-carrier protein] dehydratase activity - - 0 20 
NFU1 a Involved in maturation of mitochondrial iron-sulfur 
proteins 
- - 0 23 
PDX1 a Protein binding - - 0 24 
LPD1 a Dihydrolipoyl dehydrogenase activity - - 0 24 26 
GCV2 a Glycine dehydrogenase (decarboxylating) activity - + 0 26 
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Supplement Table S4 Continued 
 
Growth in solid medium plate 
with His-Leu 









GCV3 a Glycine dehydrogenase (decarboxylating) activity - - 0 26 
SHM2 a Glycine hydroxymethyltransferase activity - - 89 26 
ILM1 Mitochondrial DNA maintenance - - 85 29 
YDR015C  Unknown - + 82 29 
YDR157W Unknown - - 0 29 
YDR290W Unknown - + 85 29 
YDR433W Unknown - - 79 29 
YJL046W a Unknown - - 0 29 
YJL175W Unknown - - 0 29 
YPL098C a Unknown - - 82 29 
YPR174C Unknown - + 79 29 
 
a These genes encode proteins with more than 30% sequence identity to a human protein. 
b The functional categories found for each gene according to the gene annotation in SGD Gene Ontology (GO) (http://db.yeastgenome.org/cgi-
bin/GO/goTermMapper) are listed.  Many genes have multiple listings in GO. The GO functional categories are listed as follows with the number of genes 
identified in this screen belonging to each category shown in parentheses taking into account the multiple functional categories found for many genes:  1) Cell 
cycle (8 genes); 2) Transcription (6 genes); 3) Transport (7 genes); 4) Organelle organization and biogenesis (5 genes); 5) Response to stress (5 genes); 6) Protein 
modification (8 genes); 7) DNA metabolism (7 genes); 8) Meiosis (4 genes); 9) Cytoskeleton organization and biogenesis (5 genes); 10) Morphogenesis (5 
genes); 11) Energy pathways (8 genes); 12) Protein catabolism (5 genes); 13) Protein biosynthesis (2 genes); 14) Vesicle-mediated transport (1 gene); 15) 
Carbohydrate metabolism (7 genes); 16) Lipid metabolism (5 genes); 17) Signal transduction (2 genes); 18) Cytokinesis (4 genes); 19) Nuclear organization and 
biogenesis (3 genes); 20) Sporulation (4 genes); 21) Budding (0 gene); 22) Cellular respiration (3 genes); 23) Cell homeostasis (2 genes); 24) Coenzyme and 
prosthetic group metabolism (2 genes); 25) Cell wall organization and biogenesis (0 gene); 26) Amino acid and derivative metabolism (4 genes); 27) RNA 
metabolism (0 gene); 28) Ribosome biogenesis and assembly (0 gene); 29) Biological process unknown (10 genes); 30) Membrane organization and biogenesis 
(0 gene); 31) Electron transport (0 gene); 32) Pseudohyphal growth (0 gene); 33) Vitamin metabolism (0 gene); 34) Conjugation (0 gene).  
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Halo size (Ala-Eth) Protein complex Strains 
0.2µmol 0.1µmol 
 WT (BY4742) 28 23 
 ptr2 0 0 
 
ESCRT I  vps23  33 28 
 vps28 32 27.5 
 srn2  31 23 
ESCRT II  vps22 33 28.5 
 vps25 36 31 
 vps36 33 31 
ESCRT III vps2 (Sub-complexes 1) 34 30 
 vps24 (Sub-complexes 1) 33 29 
 vps20 (Sub-complexes 2) 38 34 
 snf7 (Sub-complexes 2) 32 34 
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Supplement Figure S1: Ptr2p-GFP expression signal and localization in deletion 
strains with increased dipeptide utilization. Some strains (underlined) are also shown 





                
 
 
            
 
 




      
 
 


















































Supplement Figure S1 Continued 
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Supplement Figure S2 Ptr2p-GFP localization in mutants of the ESCRT complex. 
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Supplement Figure S3: Ptr2p-GFP expression signal and localization in deletion 
strains with decreased dipeptide utilization. Some strains (underlined) are also shown 
in Figure 4 as examples of the expression level and localization of Ptr2p-GFP.   
 121
1) 
   












       
 
 






















    
 
 
       
 
 





         
 
 
     
 
 
          
 
 











spo21 prd1 bye1 










     
 
 
   
 
 
    
 
 
   
 
 














rpl21a ubp14 uba3 
taf14 
ypr174c 
ypl098c mct1 hfa1 
thp1 
 124
Supplement Figure S4 The osmotic sensitivity of selected deletion mutants. The 
selected strains were grown in either 0 or 1.0 M of NaCl.  In panel A, deletion strains 
showed a similar sensitivity to 1.0 M NaCl in comparison to that of the wild-type strain; 
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Supplement Figure S5 The canavanine sensitivity to the selected deletion mutants. The selected strains were grown in medium 
MM+HLKU and canavanine (1.0 μg) was added to each disk. In panel A, nine deletion strains showed a similar sensitivity to 
canavanine sensitivity in comparison to that of the wild-type. In panel B, the six deletion strains demonstrated a greater sensitivity to 




























































PDH (Pyruvate dehydrogenase complex): Pdx1p, Lpd1p, Pdb1p, and Lat1p 
GDC (Glycine decarboxylase multienzyme complex): Gcv2p, Gcv3p, and Lpd1p 
FAS (Fatty acid synthase): Oar1p and Mct1p 





Supplement Figure S6 Proteins involved in cellular metabolic processes impacted in 
dipeptide utilization. These proteins include the components of pyruvate dehydrogenase 
complex (Pdx1p, Lpd1p, Pdb1p, and Lat1p), the components of GDC [Glycine 
decarboxylase multienzyme complex (GCV2, GCV3, LPD1)], the components of FAS 
[Fatty acid synthase (Oar1p, Mct1p)], SHMT [Serine hydroxymethyltransferase 




































PROBING METABOLIC PATHWAYS OF DI/TRI-PEPTIDE UTILIZATION 















Part III was published in its entirety as Oliver R. Homann, Houjian Cai, Jeffrey M. 
Becker, and Susan L. Lindquist 2005.  Harnessing Natural Diversity to Probe Metabolic 
Pathways. PLoS Genetics 1(6):715-729. Houjian Cai was responsible for Ptr2p-GFP 
expression analysis and toxic dipeptide halo assay, and proposed a research on a second 





Analyses of cellular processes in the yeast Saccharomyces cerevisiae primarily 
rely upon a small number of highly domesticated laboratory strains, leaving the extensive 
natural genetic diversity of the model organism largely unexplored and unexploited.  We 
asked if this diversity could be used to enrich our understanding of basic biological 
processes.  As a test case, we examined a simple trait: the utilization of di/tri-peptides as 
nitrogen sources.  The capacity to import small peptides is likely to be under opposing 
selective pressures (nutrient utilization versus toxin vulnerability) and may therefore be 
sculpted by diverse pathways and strategies.  Hitherto, dipeptide utilization in S. 
cerevisiae was solely ascribed to the activity of a single protein, the Ptr2p transporter.  
Using high-throughput phenotyping and several genetically diverse strains, we identified 
previously unknown cellular activities that contribute to this trait.  We find that the Dal5p 
allantoate/ureidosuccinate permease is also capable of facilitating di/tri-peptide transport.  
Moreover, even in the absence of Dal5p and Ptr2p, an additional activity - almost 
certainly the periplasmic asparaginase II Asp3p - facilitates the utilization of dipeptides 
with C-terminal asparagine residues by a different strategy.  Another, as yet unidentified 
activity, enables the utilization of dipeptides with C-terminal arginine residues.  The 
relative contributions of these activities to the utilization of di/tri-peptides vary among the 
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strains analyzed, as does the vulnerability of these strains to a toxic dipeptide.  Only by 
sampling the genetic diversity of multiple strains were we able to uncover several 




Our understanding of the inner workings of eukaryotic cells owes much to the 
yeast Saccharomyces cerevisiae.  The application of powerful genetic and molecular 
tools to this model organism has yielded an extensively annotated proteome.  These 
analyses have benefited greatly from the engineering of experimentally tractable strains 
of S. cerevisiae, but an unintended consequence of this focus has been a tendency to 
ignore the vast wealth of natural genetic variation found in diverse strains of this 
organism.  Following the “gold rush” ushered in by the sequencing of the S. cerevisiae 
genome, efforts are being made to revisit this natural diversity.  Phenotypic analyses of 
diverse yeast strains (MORTIMER et al. 1994; TRUE and LINDQUIST 2000) and the 
application of microarray technology to the analysis of allelic variation (BREM and 
KRUGLYAK 2005; BREM et al. 2002; STEINMETZ et al. 2002; WINZELER et al. 1999; 
WINZELER et al. 1998; YVERT et al. 2003) and population genetic variation in gene 
expression (CAVALIERI et al. 2000; FAY et al. 2004; TOWNSEND et al. 2003) are 
providing new insights into the ecology and diversity of the species.  Such analyses 
should also be applicable to the elucidation of pathways that face strong diversifying 
selection, such as those governing uptake and metabolism of nutrients.  As a test case, we 
employed high-throughput phenotyping of diverse S. cerevisiae strains to dissect the 
multiple activities contributing to the utilization of di/tri-peptides as a nitrogen source. 
The capacity to import small peptides is a ubiquitous cellular function, found in 
bacteria, fungi, plants, and animals (HAUSER et al. 2001; HERRERA-RUIZ and KNIPP 2003; 
PAYNE and SMITH 1994; STACEY et al. 2002; STEINER et al. 1995).  While small peptides 
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have clear nutritional value as a source of amino acids, carbon, and nitrogen, they can 
have additional beneficial functions.  For example, studies in bacteria have demonstrated 
a link between peptide transport and chemotaxis (MANSON et al. 1986), sporulation 
(MATHIOPOULOS et al. 1991; PEREGO et al. 1991), and the recycling of cell wall peptides 
(GOODELL and HIGGINS 1987).  
Peptide transport systems, however, can also be a source of biological 
vulnerability.  A variety of antimicrobial and antifungal agents utilize the di/tri-peptide 
transport machinery to gain entry into the cell (RINGROSE 1980; ST GEORGIEV 2000).  
Thus, the benefits and risks associated with peptide import represent conflicting 
evolutionary pressures that may help shape the regulation and substrate specificity of 
peptide transporters.  In a similar vein, transporters of small peptides are also of great 
interest for their medical applications, as routes for delivery of peptidomimetic drugs 
(BECKER and NAIDER 1995; NIELSEN and BRODIN 2003). 
Members of the PTR family of peptide transporters transport a variety of 
substrates, including nitrates, amino acids, and di/tri-peptides (GRAUL and SADEE 1997; 
STEINER et al. 1995).  All PTR members contain 12 predicted transmembrane helices, 
and transport a variety of substrates by means of proton-motive force (CHIANG et al. 2004; 
MACKENZIE et al. 1996).  While many organisms, such as humans and plants, contain 
multiple PTR2 family members, the yeast S. cerevisiae contains only one, the di/tri-
peptide transporter Ptr2p (Swiss-Prot: P32901).   
The regulation of PTR2 expression in S. cerevisiae is strongly influenced by the 
composition of the extra-cellular environment.  PTR2 expression is induced in the 
absence of preferred nitrogen sources (ALAGRAMAM et al. 1995) - even more so when the 
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medium contains particular amino acids (ISLAND et al. 1987).  Import of di/tri-peptides 
containing basic or bulky hydrophobic N-terminal residues also induces PTR2 by 
reducing cellular levels of the PTR2 repressor Cup9p (Swiss-Prot: P41817).  Specifically, 
these di/tri-peptides serve both as ligands and as regulators of the E3 ubiquitin ligase 
Ubr1p (Swiss-Prot:P19812), which mediates a protein degradation system that is 
governed by the identity of N-terminal amino acids (VARSHAVSKY 1996; VARSHAVSKY 
1997) (Figure 1).  These peptides are too small to serve as targets for degradation by the 
proteasome and they are assimilated as nutrients via other peptidases in the cells.  
However, di/tri-peptides with basic (Type 1: Arg, His, or Lys) and bulky (Type 2: Ile, 
Leu, Phe, Trp, or Tyr) N-terminal residues can compete with larger protein substrates for 
binding at the type 1 and type 2 Ubr1p substrate binding sites.  Upon binding, these 
peptides allosterically activate Ubr1p-mediated degradation of Cup9p (Swiss-Prot: 
P41817) by release of the Ubr1p autoinhibitory domain, thus exposing a substrate 
binding domain that binds an internal degron in Cup9p (DU et al. 2002).  Relief of Cup9p 
repression of PTR2 results in enhanced PTR2 expression.  This initiates a positive 
regulatory feedback loop in which di/tri-peptide uptake perpetuates Ubr1p-mediated 
degradation of Cup9p, upregulation of PTR2, and additional di/tri-peptide uptake (BYRD 
et al. 1998; DU et al. 2002; TURNER et al. 2000). 
Investigations of di/tri-peptide import in S. cerevisiae have typically been limited 
to the analysis of a small number of substrates through complementation of auxotrophies 
or the use of radiolabeled dipeptides.  The recent development of the Biolog system of 
“Phenotype MicroArrays™” (PM; (BOCHNER 2003; BOCHNER et al. 2001)) provides the 
opportunity to dramatically expand the scope of these analyses.  The PM system  
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Figure 1 Di/tri-peptide uptake is enhanced by a positive feedback loop governed by 
the N-end rule pathway.  The E3 ubiquitin ligase Ubr1p contains binding sites for 
proteins containing Type 1 (Arg, His, Lys) and Type 2 (Ile, Leu, Phe, Trp, Tyr) N-
terminal amino acids.  In the absence of di/tri-peptides, the PTR2 repressor Cup9p is 
abundant and PTR2 expression is minimal.  Upon binding of Type 1 and/or Type 2 di/tri-
peptides to Ubr1p, an autoinhibitory domain blocking the recognition of an internal 
Cup9p degron dissociates from the Cup9p binding site, and Cup9p turnover is accelerated.  
Consequently, PTR2 repression is relieved and elevated levels of Ptr2p enhance di/tri-
peptide uptake, initiating a positive feedback loop.  This figure was adapted from the 
diagram of Turner et al. (TURNER et al. 2000), with the authors’ permission. 
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facilitates the classification of bacterial and fungal species by generating a characteristic 
phenotypic profile, which reflects the metabolic capabilities and chemical sensitivities of 
different species.  The strong representation of peptides in the PM assay plates – 284 of 
the 400 possible dipeptide permutations and 11 tripeptides – provides a unique 
opportunity to assay the capacity of different S. cerevisiae strains to import and utilize 
dipeptides as nitrogen sources. 
Using a combination of high-throughput data from the PM assays, we uncovered 
extensive variation in dipeptide utilization in different strains of S. cerevisiae.  We 
exploited this variation to uncover a diversity of strategies that may serve to balance the 
opposing selection pressures of nutrient utilization and toxin vulnerability.  We find that 
Ptr2p provides only one of at least four distinct molecular activities that facilitate the 
utilization of dipeptides in S. cerevisiae.  The varying strengths of these activities in 
different strains were key to their identification.  No single strain would have revealed the 
full complexity of dipeptide utilization, underscoring the importance of natural genetic 
variation for developing a comprehensive understanding of cellular processes.   
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                             MATERIALS AND METHODS 
 
Media and reagents:  Synthetic defined (SD), YPD, and 5-FOA (BioVectra) 
media were made using standard formulations (AUSUBEL et al. 1988).  When needed, 
G418 (Gibco) was added to the YPD media at 200 µg/ml to select for Kanr.  To select for 
HygBr, Hygromycin B (American Bioanalytical) was added to YPD at 250 µg/ml.  All 
dipeptides used outside of the PM assays were obtained from Bachem.  A minimal media 
(MM), supplemented with the indicated nitrogen sources, was utilized for the Bioscreen 
C growth curve assays.  MM media contained 2% glucose, 0.17% yeast nitrogen base 
without (NH4)2SO4 and amino acids (Bio101), 18 mg/L uracil (omitted for URA3 
plasmid-bearing strains), and 2% agar (for solid media).  The MMA medium used in the 
halo and GFP assays was identical to the MM media, except that it contained 1 g/L 
allantoin as a nitrogen source and a slightly different concentration of uracil (20 mg/L).  
The Biolog PM media contained 50 mM glucose, 1 mM disodium pyrophosphate, 2 mM 
sodium sulfate, and a proprietary tetrazolium dye mix and “IFY-0” media.  IFY-0 is a 
basal media, lacking nitrogen, carbon, phosphate, and sulfur sources, which are 
supplemented as needed. 
Plasmid construction:  Construction of the pMS2 plasmid is described in 
(HAUSER et al. 2005).  The plasmid pPTR2-2xGFP-SFH-KanR was constructed by 
addition of tandem copies of GFP (2xGFP) and a kanr selectable marker into plasmid 
pMS2.  First, primers PTR2-FLAG-GFP-F and PTR2-FLAG-GFP-R (all primer 
sequences are supplied in supplemental Table S1) were used to amplify a 1.5kb fragment 
containing 2xGFP from plasmid pKW430 (a gift of Dr. Mary Miller, Rhodes University 
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(STADE et al. 1997)) and an additional 40 bp of flanking sequence homologous to pMS2.  
The plasmid pMS2 was then linearized at the unique restriction site AgeI, located 
between the FLAG and His tags.  2xGFP was then inserted between these two tags by 
homologous recombination, creating pMS4.  A HincII fragment containing kanMX4 from 
pFA6a-kanMX4 (WACH et al. 1997) was then inserted into the NaeI site of pMS4, which 
lies beyond the stop codon following the 6xHis tag, creating the final pPTR2-2xGFP-
SFH-KanR plasmid. 
The plasmid pRS426-DAL5 was created by cloning an EcoRV genomic fragment 
from a plasmid recovered in the genomic screen (see below) into the 2µ vector pRS426 
(ATCC#77107; (CHRISTIANSON et al. 1992)).  This fragment spans a region from -1334 
to +2908, relative to the start codon of the DAL5 gene. 
pUG6-HygB was created by replacement of the kanMX marker in pUG6 
(GULDENER et al. 1996) with a hphMX cassette from pAG32 (GOLDSTEIN and 
MCCUSKER 1999).  First, a PCR fragment containing the hphMX cassette was amplified 
from pAG32 using primers O-199 and O-200 and digested with MluI and BsmI.  The 
resulting fragment was then inserted into the similarly digested pUG6. 
Strain construction:  The source and origins of the strains used in this study are 
indicated in Table 1.  To make all strains MATa ura3, some modifications were made to 
eliminate amino acid auxotrophies, mutate URA3, and change mating types (described in 
detail in Protocol S1).  All transformations were conducted using the standard lithium 
acetate technique (ITO et al. 1983). 
PTR2 was deleted with a short-flanking homology (SFH) cassette amplified from  
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Table 1  Strains used in this study 
Straina Genotype Type Source(s) 
W303-x MATa ura3 can1-100 ho laboratory G. Fink/ 
  R. Rothstein 
YAT7-x MATa ura3 ho::MX3 clinical  
  (peritoneal fluid) 
J. McCusker 
RM8-x MATa ura3Δ0 ho::loxP vineyard 
  (California) 
B. Garvik/ 
  R. Mortimer 
RM3-x MATa ura3Δ0 ho::loxP vineyard  
  (California) 
B. Garvik/ 
  R. Mortimer 
S288c-x MATa ura3 ho laboratory B. Garvik 
Y55-x MATa ura3 ho::KAN-MX3  vineyard (France) J. McCusker 
YAT17-x MATa ura3 ho::KAN-MX3  clinical 
  (broncheolar) 
J. McCusker 
YAT21-x MATa ura3 ho::KAN-MX3  clinical  
  (vaginal) 
J. McCusker 
 
aWhen additional deletions were introduced into the strains, these modifications were appended to the 




plasmid pFA6a-GFP(S65T)-kanMX6 (WACH et al. 1997) (pAG32 (GOLDSTEIN and 
MCCUSKER 1999) in the case of Y55; the GFP portion of the plasmid was not amplified).  
This deletion cassette replaced the PTR2 region spanning +77 to +1781, relative to the 
start codon, with a kanMX marker (hphMX in the case of Y55).  CUP9 was deleted with a 
SFH cassette amplified from plasmid pFA6a-GFP(S65T)-kanMX6, removing the CUP9 
region spanning +41 to +878, relative to the start codon.  DAL5 was deleted with a 
hphMX marker from a SFH cassette amplified from pAG32.  This deletion cassette 
eliminated the DAL5 region spanning -70 to +1594, relative to the start codon. 
Addition of a FLAG-2xGFP-6xHis tag to the C-terminus of endogenous PTR2 
was accomplished with a SFH cassette amplified from plasmid pPTR2-2xGFP-SFH-
KanR.  Proper integration was ensured by selection on G418 media and verification by 
colony PCR.  Final confirmation of proper integration was obtained by observation of 
membrane-localized GFP fluorescence in MMA+Leu media. 
PM assays of nitrogen source utilization (BOCHNER et al. 2001; TANZER et al. 
2003): A full list of the nitrogen sources tested in the PM assay plates is provided in 
Dataset S1.  Each well of the PM plates contains a very low micromolar amount of amino 
acids, at a level insufficient to complement auxotrophies or serve as an adequate nitrogen 
source.  All dipeptides are present at the same concentration (between 1-4 mM, the 
precise concentration is proprietary information), with the exception of the small set of 
dipeptides present in PM03, which are present at double the concentration of the others 
(these are notated as “(2x)” when presented in the figures).   
Strains were prepared for inoculation into the PM assay plates as follows.  
Glycerol stocks were streaked to YPD plates and incubated at 30 °C for ~48 h.  Next, 2-3 
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colonies from each strain were restreaked to one section of a fresh YPD plate and 
incubated overnight at 30 °C.  In the morning, cells on each YPD plate were spread over 
the plate to form a thin layer and incubated an additional 4-6 h to ensure that most cells 
were actively growing.  This technique also served to avoid the late-growth clumping 
encountered with some wild strains.  In the case of strains containing plasmids, standard 
SD –ura dropout plates were used in place of YPD. 
Cells were then inoculated into sterile water in 20x100 mm test tubes and adjusted 
to a transmittance of 63% (~5x106 cells/ml).  This 48x concentration cell suspension also 
contained 14.4 mM uracil, except when plasmids were used.  The cell suspension was 
then reduced to 1x concentration by dilution into the Biolog PM media.  100 µl of this 
mix were then inoculated into each well of the PM assay plates PM03, PM06, PM07, and 
PM08.  The plates were then sealed with sterile Axygen SealPlate film, placed in the 
OmniLog reader, and incubated for 48 h at 30 °C.  The OmniLog reader photographs the 
plates at 15-min intervals, converting the pixel-density in each well to a signal value 
reflecting cell growth and dye-conversion. 
After completion of the run, the signal data were compiled and analyzed.  Signal 
data were exported from the Biolog software, compiled using Microsoft Excel, and then 
visually represented using Java TreeView v1.0.8 (SALDANHA 2004) and Adobe Illustrator.  
We chose to export the average and maximum signal value for each well and then 
average the two values.  In doing so, we were able to represent the full time course by a 
single number and weight the value towards latter time points.  Shadows cast over 
perimeter wells in the OmniLog machine sometimes raised the basal signal level of these 
wells.  This was accounted for by determining a “baseline” signal level for each well by 
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calculating the average signal level for the first two hours of the run.  This value was then 
subtracted from the previously calculated signal value, yielding a final signal value.  
These calculations can be summarized as follows: 
 
Signal value = [((average signal over 48 h) + (maximum signal over 48 h)) / 2) 
- (average signal over first 2 h)] 
 
In all cases, a minimum of two replicate PM assay runs were conducted, and the average 
of the signal values was used.  Additionally, when non-wild-type strains were assayed, 
two independently constructed deletion strains were always tested.  The PM assay data 
used to calculate the signal values presented in this study are provided in Dataset S1.  
Images of all signal curves are provided in Datasets S2-S4. 
To ensure that dye reduction was not occurring in the absence of growth, all PM 
plates were carefully examined following each run.  The plates were inverted upon a 
light-box such that cells were visible in wells that supported growth.  This approach 
revealed that dipeptides containing lysine, histidine, and cysteine residues, and also the 
amino acid histidine, sometimes supported reduction of the dye in the absence of growth 
(dipeptides containing these residues were omitted from the analysis; see Results).  Two 
additional control measures were taken to ensure that the correlation between dye 
reduction and cell density was robust.  First, the PM assay was conducted once with each 
wild-type strain in the absence of the tetrazolium dye.  Second, several PM runs were 
plated as dilution series to YPD media at the conclusion of the 48h run.  These additional 
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measures confirmed that, with the exceptions noted above, the PM assay signal is a 
reliable indicator of growth in the presence of the nitrogen sources discussed in this study. 
Bioscreen growth curve analysis:  A selection of PM assay dipeptide-utilization 
phenotypes were verified using a Bioscreen C (Growth Curves, USA) plate reader.  
Strains were cultured as described for the PM assay, but were inoculated at an optical 
density at 595 nm (OD595) of 0.02 into MM media supplemented with the indicated 
nitrogen source.  The mixture was inoculated into a 100-well plate and incubated in the 
Bioscreen C at 30 °C with heavy shaking.  Measurements of OD600 were made at 45-min 
intervals.  Each growth curve was conducted in duplicate wells and was repeated at least 
once.   
Screen for Ptr2p-independent dipeptide utilization:  The screen was conducted 
using a pRS202-based genomic library (2µ; URA3) containing Sau3AI-digested genomic 
DNA with an average insert size of 6-8 kb (gift of Dr. Gerald Fink; originally constructed 
by Connelly and Hieter from a strain congenic with S288c (CONNELLY and HIETER 
1996)).  A full description of the screen can be found in the supplemental information 
(Protocol S2). 
Halo assay of Ala-Eth toxicity:  The sensitivity of deletion mutants to the toxic 
dipeptide Ala-Eth was measured as previously described (ISLAND et al. 1987).  Ethionine 
(Eth) is an analog of methionine, and utilization of Eth causes cell death.  The tested 
strains were grown overnight in MMA medium.  Yeast cells were harvested and washed 
three times with sterile, distilled water, then counted and adjusted to 5x106 cells/ml. One 
ml of the cell suspension was added to 0.8% noble agar (3 ml) and plated onto MMA 
medium with or without leucine (30 µg/ml), an inducer of PTR2 expression.  Four 6-mm 
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sterile paper disks containing either 0.2, 0.1, 0.05, or 0.025 µmoles of Ala-Eth were 
placed on the lawn of cells.  The size of the halo was measured after two days of 
incubation at 30 °C.  Between two and four replicates were conducted for each assay.  
Although strains Y55 and RM3 were unable to utilize allantoin in the PM assay (Figure 
2E) and in additional Bioscreen C assays using liquid media (0.5 mM allantoin; data not 
shown), both strains were capable of utilizing allantoin in the solid halo assay media. 
Sequencing upstream of PTR2:  While the region comprising the PTR2 
promoter has yet to be clearly defined, the sequenced span, an 889 bp region immediately 
upstream of the PTR2 start codon, should contain the key regulatory elements.  The 
region bound by the Cup9p repressor has been narrowed to the region spanning -897 to -
448 (BYRD et al. 1998), relative to the PTR2 start codon.  In addition, a predicted amino 
acid-dependent upstream activator sequence (UASAA) is located between -777 and -760 
(DE BOER et al. 1998).  Genomic DNA was prepared using the “smash and grab” 
technique (ROSE et al. 1990).  A 927 bp fragment containing the desired sequence was 
amplified with primers O-321 and O-324, using an equal amount of Taq and Vent 
polymerases.  Each reaction mix was split into eight aliquots and repooled following 
amplification.  This approach was taken to help control for the possibility that a single 
replication error could propagate through the entire sample.  PCR products were then 
purified with a Qiagen PCR purification kit and sequenced in both directions by 
Northwoods DNA Inc. using oligos O-321, O-322, O-323, and O-324.  Sequencing data 
were analyzed using Sequencher DNA sequencing software.  
GFP microscopy:  To test the localization of GFP-tagged Ptr2p, yeast strains 
carrying PTR2 with a C-terminal FLAG-2xGFP-6xHis tag were grown at 30 °C in MMA, 
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MMA+Leu, or YPD media.  Yeast cells were collected during log-phase and imaged.  
The GFP signal was observed by fluorescence microscopy with a 470-490 nm excitation 
wavelength and 515 nm emission filter fitted to an Olympus microscope.  Both 
fluorescent and differential interference contrast (DIC) images were taken with a 
MicroFireTM camera (Model S99809, Olympus). 
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                                                RESULTS 
 
To advance our understanding of the processes contributing to nitrogen utilization 
in S. cerevisiae, we studied a panel of strains isolated from several widely differing 
growth environments (Table 1).  We included two related laboratory strains, S288c and 
W303, two California vineyard isolates, RM3 and RM8, a vineyard isolate thought to be 
of French origin, Y55 (GREIG et al. 2003), and a clinical isolate, YAT7.  Because 
expression of the dipeptide transporter PTR2 is strongly induced by even micromolar 
amounts of certain amino acids supplemented in the media (ISLAND et al. 1987), we first 
restored all of these strains to full amino acid prototrophy (see Materials and Methods). 
Assaying nitrogen source utilization in diverse strains using Phenotype 
MicroArrays:  We utilized the newly developed PM system to assay the ability of these 
strains to utilize an extensive selection of dipeptides and other compounds as nitrogen 
sources.  Cells were grown in 96 well plates in which each well contained a different 
nitrogen source.  A proprietary tetrazolium dye solution, which is reduced to the purple 
compound formazan, was included in each well.  Plates were photographed every 15 
minutes, generating a growth curve for each well that primarily reflected dye reduction 
(BOCHNER 1989).  The remaining growth signal was attributable to turbidity resulting 
from cell growth.  
As the technology was developed for bacterial cells, we first asked how well the 
PM signal curves reflect yeast cell growth and respiration, and how reproducible these 
phenotypes were in standard yeast laboratory media.  Reduction of the tetrazolium dye 
ostensibly results from cellular respiration (BOCHNER 1989), but when we tested petite 
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strains of S. cerevisiae in the PM assay, they remained capable of robust dye conversion 
(data not shown).  Thus, mitochondrial respiration is not required to produce reductants 
for this dye.  Next, we employed dye-independent measures of growth, such as measuring 
optical density of PM plates lacking the tetrazolium dye and plating serial dilutions of 
cells from PM plates to solid media to measure the number of colony forming units in 
each PM well.  Dye-conversion correlated well with growth (see Materials and Methods), 
except that dipeptides containing the amino acids histidine, lysine, and/or cysteine 
sometimes caused dye reduction in the absence of growth (data not shown).  Interestingly, 
this growth-independent dye reduction occurred only in the presence of cells.  Since it 
reflects an unknown metabolic process, these dipeptides were omitted from our analyses.  
It should be noted however, that this growth-independent dye reduction exhibited strong 
inter-strain variation, suggesting yet another source of metabolic variation for further 
study. 
The PM assay utilizes a viscous medium which supports less vigorous growth 
than typical laboratory media (data not shown).  To determine if growth on diverse 
substrates in PM plates correlates well with standard laboratory media, we assayed 
growth on dipeptides as the sole nitrogen source in both solid and liquid standard media 
(see below), using optical density at 600nm to measure growth in the liquid assays.  
Given the sensitivity of the dipeptide transport machinery to environmental cues, it is 
unsurprising that some differences were observed between these platforms.  In large part, 
however, these differing growth conditions provided similar results, and the 
reproducibility on all tested media was robust.   
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 Shared properties and inter-strain variation in nitrogen source utilization:  
Next, we asked if the natural diversity in our yeast strains produced phenotypic diversity 
in nitrogen source utilization.  The 48 hour PM growth curves for each strain on each 
medium are provided in the supplemental materials.  To simplify comparisons, each 
growth curve was assigned a score reflecting the extent of growth, as shown for 
representative curves in the legend of Figure 2 (see also Materials and Methods).  In 
agreement with an earlier study of the ability of individual amino acids to serve as 
nitrogen sources in S. cerevisiae (LARUE and SPENCER 1967), we found that cysteine, 
histidine, and lysine did not support growth in any of our strains (Figure 2A).  These are 
the same amino acids that, when present in dipeptides, caused some strains to reduce the 
tetrazolium dye in the absence of growth.  Apart from some inter-strain variation in 
growth on glycine and tyrosine, the remaining amino acids supported robust growth in all 
strains tested.   
In contrast to the general uniformity in the utilization of individual amino acids, 
the six strains we analyzed had very different patterns of dipeptide utilization.  To assist 
visualization of the data, dipeptides were separated into two classes, N-end rule 
dipeptides, which upregulate PTR2 by enhancing Ubr1p-mediated degradation of the 
Cup9p repressor (Figure 2B), and non-N-end rule dipeptides (Figure 2C).  The clinical 
isolate YAT7 utilized the broadest spectrum of dipeptides (see Figure 2C in particular) 
and tripeptides (Figure 2D).  Indeed, it grew robustly on many peptides that none of the 
other strains could utilize well, if at all.  (Preliminary analyses of two additional clinical 
isolates, YAT17 and YAT21, suggest that robust di/tri-peptide transport may be a 
common feature of strains adapted to the atypical mammalian host environment; data not  
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Figure 2. Variation in nitrogen source utilization among six strains of S. cerevisiae.   
(A) Amino acids.  (B) N-end rule dipeptides.  (C) Non-N-end rule dipeptides.  (D) 
Tripeptides; amino acids are represented as single letters.  (E) Miscellaneous nitrogen 
sources.  Each square represents the growth of one strain in the PM assay supplied with 
the indicated nitrogen source.  The value reflecting the extent of growth was generated 
from the 48 h signal curve of the Phenotype MicroArray (PM) assay and represented by 
the intensity of coloration, as shown in the legend.  All signal values exceeding 200 
reflected very robust growth, and are therefore represented with the same color.  Blue-
bordered squares denote nitrogen sources that produced varying results in that strain, 
exhibiting substantial variation in signal among replicates (σ2/mean > 10 and at least one 
replicate with signal > 50 or < 200).  Red-bordered squares denote putative substrates of 





shown).  The laboratory strain W303 utilized the fewest dipeptides.  It lacked the broad 
capacity for N-end rule dipeptide utilization characteristic of the other strains (Figure 2B), 
but it did grow robustly on some of these dipeptides.  In contrast, the French vineyard 
isolate Y55 was growth-limited on the non-N-end rule dipeptides in comparison to the 
other strains tested (Figure 2C).  Each strain also exhibited a unique pattern in the 
utilization of other nitrogen sources (Figure 2, D and E). 
Given the close relationship between W303 and S288c (W303 was derived in part 
from crosses with S288c; R. Rothstein, personal communication), it was surprising that 
the PM profiles of S288c more closely resembled those of the California vineyard 
isolates RM3 and RM8.  However, S288c and W303 did share two characteristics: both 
grew robustly on all of the dipeptides in the array that contained C-terminal asparagine 
residues (Figure 2, B and C, boxes with red borders), and both grew well on D-asparagine 
(Figure 2E). 
Overexpression of PTR2 masks inter-strain variation and enhances di/tri-
peptide utilization:  The diversity of dipeptide-utilization traits suggests profound 
differences in the underlying mechanism of di-tri/peptide import among our conspecific 
strains.  One likely source of inter-strain variation in dipeptide utilization is differences in 
PTR2 regulation.  If dipeptide utilization is limited by low levels of Ptr2p, upregulation of 
PTR2 should enhance growth.  To determine how broadly a lack of PTR2 expression 
limits dipeptide utilization, we eliminated the repressor of PTR2, Cup9p, in three strains 
whose wild-type dipeptide-utilization profiles were robust, intermediate, and weak: 
YAT7, RM8, and W303 respectively. 
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In all three strain backgrounds, the CUP9 deletions caused robust growth on most 
of the di- and tripeptides present in the arrays (Figure 3).  Even dipeptides that had not 
supported growth in any of the wild-type strains, such as dipeptides bearing the N-
terminal acidic residues aspartate or glutamate, supported growth upon deletion of CUP9 
(Figure 3B).  Of the 197 dipeptides amenable to PM analysis, only a small fraction – 
most notably Trp-Trp, Trp-Glu, Asp-Asp, and Pro-Pro – supported little growth in the 
cup9Δ strains.  These dipeptides may either be refractory to transport or less amenable to 
use as a nitrogen source following transport.  The robust dipeptide utilization phenotype 
of the cup9Δ mutants indicates that Ptr2p is capable of transporting a very broad array of 
di/tri-peptides, a property that has long been assumed but never addressed with such a 
large spectrum of dipeptides.   
Further, the robust dipeptide-utilization phenotypes of the cup9Δ mutant strains 
indicate that differences in regulatory control of PTR2 are a key feature of the natural 
diversity observed among the strain backgrounds.  Whereas the wild-type strains 
exhibited different dipeptide utilization phenotypes (Figure 2, B and C), relief of PTR2 
repression by deletion of CUP9 eliminated almost all inter-strain variation (Figure 3).  
Thus, the limited capacity for dipeptide utilization in wild-type W303 relative to RM8 
and YAT7 is likely to reflect a difference in PTR2 regulation rather than a difference in 
Ptr2p function. 
Ptr2p is not required for the utilization of some dipeptides:  The only known 




Figure 3 Deletion of CUP9 and PTR2 strongly impacts di/tri-peptide utilization in S. 
cerevisiae strains.  Elimination of the PTR2-repressor Cup9p revealed that Ptr2p can 
facilitate the utilization of nearly all di/tri-peptides tested in the PM assay, yet Ptr2p was 
not required for the utilization of a subset of di/tri-peptides as a nitrogen source. (A) N-
end rule dipeptides. (B) Non-N-end rule dipeptides. (C) Tripeptides; amino acids are 
represented as single letters.  See Figure 2 for a detailed explanation of the yellow boxes 




Figure 3 Continued 
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trains would be unable to utilize any di/tri-peptides in the PM assay.  Surprisingly, this 
was not the case, particularly for non-N-end rule di/tri-peptides (Figure 3, B and C).  All 
three strains tested did not require PTR2 to utilize a subset of these non-N-end rule 
dipeptides.  Indeed, the W303-ptr2Δ mutant grew just as well on the non-N-end rule 
dipeptides as the wild-type strain. 
When examined as a whole, these observations suggested that at least two 
activities contribute to dipeptide utilization: Ptr2p-mediated transport and an as yet 
unidentified activity.  For N-end rule dipeptides, Ptr2p was the main activity contributing 
to their utilization, as evidenced by the almost complete abrogation of growth on these 
nitrogen sources by the ptr2Δ deletions (Figure 3A).  For non-N-end rule di/tri-peptides, 
both Ptr2p and the Ptr2p-independent activity played roles in their utilization (Figure 3B).  
The contribution of Ptr2p to general dipeptide utilization varied from minimal, as 
observed with W303, to substantial, as observed with the clinical isolate YAT7 (Figure 3, 
compare wild-type and ptr2Δ strains).  In contrast, the similar growth properties of the 
ptr2Δ strains suggested that the contribution of the Ptr2p-independent activity was similar 
in all three strain backgrounds. 
Dal5p confers a Ptr2p-independent dipeptide utilization activity:  To identify 
the source of dipeptide utilization in the ptr2Δ strains, we took advantage of the robust 
growth of the W303-ptr2Δ strain when Ala-Leu was the sole source of nitrogen in the 
PM assay.  We speculated that the concentration of Ala-Leu needed to support growth 
would be reduced if the gene allowing its utilization was overexpressed.  Accordingly, 
we screened a high-copy (2µ) genomic library for plasmids that restored growth of 
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W303-ptr2Δ on limiting quantities of Ala-Leu (0.75 mM).  After eliminating candidates 
that contained the PTR2 ORF, the three remaining plasmids were sequenced.  Each 
plasmid carried the allantoate/ureidosuccinate permease gene DAL5 (Swiss-Prot: P15365). 
To analyze the contribution of Dal5p to basal dipeptide utilization, we constructed 
ptr2Δ, dal5Δ, and ptr2Δdal5Δ mutants in a variety of strain backgrounds.  We began by 
testing the growth of serially diluted cells on conventional solid media containing 
different nitrogen sources (Figure 4).  These included the putative Dal5p substrate Ala-
Leu, as well as Tyr-Ala and Ala-Tyr, which had not supported growth of the ptr2Δ 
mutant in any of the strains tested in the PM assay (Figure 3, A and B).  In all strains 
tested, the ptr2Δdal5Δ double-mutant abolished growth on all three assayed dipeptide 
sources.  Thus, utilization of these dipeptides required one of these two systems. 
In the case of the dipeptides Ala-Tyr and Tyr-Ala, utilization was mediated by 
Ptr2p.  Growth on these dipeptides was abolished by deletion of PTR2 alone, whereas 
deletion of DAL5 alone had no apparent effect.  In contrast, the utilization of Ala-Leu 
involved both Ptr2p and Dal5p, but the relative contributions of these two activities 
varied between strains.  Similar results were obtained using both solid (Figure 4) and 
liquid media (2 mM Ala-Leu; Figure S1).  Ala-Leu could be utilized in strains RM8 and 
YAT7 via either Ptr2p or Dal5p, but Ptr2p was necessary and sufficient for wild-type 
growth levels.  Strains W303 and Y55 did not exhibit this functional overlap in Ala-Leu 
utilization.  W303-ptr2Δ grew as well as wild-type W303 on Ala-Leu, but W303-dal5Δ 





Figure 4 The relative contributions of Dal5p and Ptr2p to dipeptide utilization vary 
among strains of S. cerevisiae.  Strains were cultured on YPD plates, as with the PM 
assays, and then suspended in water at a concentration of ~3.5x106 cells/ml and plated as 
1x, 5x, and 25x dilutions (from left to right).  Each plate contained MM media plus the 
nitrogen source indicated at the top of the column (with the exception of the far right 
column, in which YPD plates were used).  Plates were incubated at 30º C for 4 d and then 
photographed.  A Y55-ptr2Δdal5Δ double mutant was not tested, since deletion of PTR2 
alone was sufficient to eliminate dipeptide utilization. 
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Y55-ptr2Δ could not grow, whereas Y55-dal5Δ grew as well as wild-type Y55.  Thus, 
Y55 relied upon Ptr2p for utilization of the assayed dipeptides, whereas W303 relied 
predominantly on Dal5p. 
The scope of the contribution of Dal5p to di/tri-peptide utilization:  Next, we 
used the PM assay to ask how many di/tri-peptides could be utilized as nitrogen sources 
through the activity of the DAL5 gene.  The gene was subcloned into a clean 2μ vector, 
from the original plasmid that was isolated from the genomic screen, and tested in strain 
W303-ptr2Δ.  Unlike the effect of overexpressing PTR2 (in the cup9Δ strain), the multi-
copy DAL5 plasmid only enhanced growth on a small number of di/tri-peptides (Figure 
5).  With the exception of Tyr-Gln, these di/tri-peptides were all non-N-end rule 
dipeptides.  N-terminal alanine, glycine, and serine residues were particularly favorable 
to Dal5p-mediated growth.   
To determine whether Dal5p activity was redundant or supplemental to that of 
Ptr2p, the specific contribution of Dal5p to di/tri-peptide utilization was explored using 
PM assays of the strains Y55-dal5Δ and RM8-dal5Δ (full data presented in Figure S2).  
In the case of Y55, deletion of DAL5 had negligible impact upon dipeptide utilization 
(Figure S2B and Figure 4).  Because the strongest growth defect in wild-type Y55 was in 
the utilization of those non-N-end rule dipeptides that we have found to depend on Dal5p, 
we speculated that Y55 might lack Dal5p activity.  This hypothesis was verified by a PM 
assay of Y55-ptr2Δ.  Unlike our earlier assays of ptr2Δ mutants in YAT7, RM8, and 










Figure 5 Utilization of a subset of dipeptides is enhanced in W303-ptr2Δ upon 
overexpression of DAL5.  Strain W303-ptr2Δ was transformed with either the vector 
pRS426 or the plasmid pRS426-DAL5, a 2µ plasmid containing a genomic fragment 
including DAL5, and phenotyped using the PM assay.  The nitrogen sources shown 
comprise all instances in which the signal values met our reliability criteria (see Figure 2) 
and the presence of pRS426-DAL5 altered the signal value by more than 50 units relative 
to the vector control.  Dipeptides followed by “(2x)” are present in the PM assay plates at 
twice the concentration of the other dipeptides. 
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tripeptides (Figure S2).  Thus, Y55 relies solely upon Ptr2p for the transport of dipeptides. 
In contrast, Dal5p contributed substantially to the utilization of dipeptides in RM8.  All of 
the dipeptides that supported more robust growth in the presence of Dal5p belonged to 
the non-N-end rule category, and the majority contained the small N-terminal residues 
alanine or glycine (data not shown).  Deletion of DAL5 in strains RM8 and W303 did not 
significantly affect the utilization of any non-peptide nitrogen sources, except that growth 
was eliminated on N-acetyl-L-glutamate, an intermediate in arginine biosynthesis (DE 
DEKEN 1962) (Figure S2C).  (The fact that N-acetyl-L-glutamate utilization is an 
indicator of Dal5p activity explains why wild-type Y55 cannot utilize this substrate; 
Figure 2E).  Clearly, DAL5 makes an important contribution to dipeptide utilization in 
yeast, and variations in DAL5 activity contribute to the naturally occurring variation in 
nitrogen utilization in diverse strains. 
Elimination of Ptr2p and Dal5p uncovers additional dipeptide-utilization 
activities:  To determine whether Ptr2p and Dal5p account for all dipeptide utilization in 
the PM assays, we analyzed ptr2Δdal5Δ double mutants in two strains: W303, which 
showed the greatest dependence on Ptr2p-independent mechanisms, and RM8, which 
relied heavily upon both Ptr2p and Dal5p (Figure S2).  In both strains, deletion of these 
two genes abolished all growth on most tested dipeptides and tripeptides in both strains.  
The most notable exception was that W303-ptr2Δdal5Δ, but not RM8-ptr2Δdal5Δ, 
retained the capacity to utilize all dipeptides with C-terminal asparagine residues (Figure 
S2; boxes with red borders).  The obvious candidate for the underlying molecular 
determinant of this activity is the periplasmic asparaginase II (see Discussion).  Since this 
protein is encoded by four copies of the ASP3 gene (Swiss-Prot: P11163), interspersed 
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among rRNA and Ty loci in the genome, the origin of the phenotype was not amenable to 
genetic analysis. 
A second strong exception to the requirement for Ptr2p and Dal5 was the 
utilization of Met-Arg by RM8, which was actually enhanced by the dal5Δ mutation 
(Figure 6) and remained robust in the ptr2Δdal5Δ double mutant (Figure S2).  Similar 
analyses of YAT7, W303, and Y55 mutants (Figure S2B and data not shown) indicated 
that the ability to robustly utilize Met-Arg in the absence of Ptr2p and Dal5p function 
was unique to RM8.  Closer examination of the PM assay plates revealed that this Ptr2p- 
and Dal5p-independent activity might affect the utilization of other dipeptides as well.  
When PM assay plates containing RM8-ptr2Δdal5Δ were incubated at 30 °C for an 
additional one to three days following the PM assay, growth was seen in wells containing 
other dipeptides - specifically, those with C-terminal arginine residues (data not shown).  
This delayed growth phenotype did not require the function of Dal5p or Ptr2p and was 
not observed in plates containing either W303-ptr2Δdal5Δ or Y55-ptr2Δ.  Thus, it 
represented a distinct fourth dipeptide utilization activity. 
Inter-strain variation in sensitivity to the toxic dipeptide Ala-Eth:  The 
benefit of efficient utilization of di/tri-peptides as a nutrient source is likely to be 
counterbalanced by the vulnerability associated with indiscriminate peptide transport.  To 
assay inter-strain variation in vulnerability to toxic peptides, the panel of diverse S. 
cerevisiae strains was exposed to a dipeptide containing L-ethionine (Eth), a toxic 











Figure 6 Deletion of DAL5 in strain RM8 strongly affects the utilization of a subset 
of assayed dipeptides.  All instances in which RM8 and RM8-dal5Δ signal values differ 
by more than 50 units and conform to our reliability criteria (see Figure 2) are presented.  
Dipeptides followed by “(2x)” are present in the PM assay plates at twice the 




Table 2 Halo assay for uptake of the toxic Ala-Eth dipeptide 
 
 
Cells were plated onto MMA media with or without 30 µg/ml leucine, an inducer of PTR2 expression; halo 
diameters in the presence of discs containing the indicated Ala-Eth concentrations are presented as the 
mean ± S.D.; ptr2Δ strains were also tested, and exhibited no halos. 
aHalo boundary was indistinct, often slowly receding as cells closer to the disc began to grow. 
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nitrogen source (COOPER 1996), to eliminate the nutritional requirement for dipeptide 
uptake.  Discs containing different concentrations of Ala-Eth were applied to lawns of 
cells, creating gradients of dipeptide concentration.  Thus, the diameter of the halo of 
growth inhibition surrounding a disc is an indicator of dipeptide import.  In the standard 
halo assay, minimal medium with allantoin is supplemented with 30 μg/ml leucine to 
induce PTR2 expression (MMA+Leu media).  Under these conditions, wild-type strains 
varied substantially in sensitivity to Ala-Eth toxicity (Table 2).  S288c was the most 
sensitive to the dipeptide, while W303 was completely resistant.  In the absence of the 
leucine inducer, only the clinical isolates YAT17 and YAT21 were sensitive to Ala-Eth 
(Table 2). 
Deletion of PTR2 alone was sufficient to confer complete resistance to the toxic 
dipeptide under the conditions tested (RM8- ptr2Δ and YAT7- ptr2Δ were tested; data 
not shown).  While this might suggest that Ptr2p is the primary transporter of Ala-Eth, we 
note that Dal5p may also transport allantoin (CHISHOLM et al. 1987; GRETH et al. 1977), 
raising the possibility that allantoin competed with Ala-Eth for Dal5p-mediated uptake.  
Indeed, Ala-Met, which is structurally similar to Ala-Eth, supports growth in ptr2Δ 
strains (Figure 3B) and dal5Δ strains (Figure S2B), suggesting that Dal5p and Ptr2p both 
contribute to the vulnerability of yeast cells to Ala-Eth.   
Elimination of the PTR2 repressor Cup9p enhanced Ala-Eth sensitivity in all 
strains tested, yet it also revealed additional diversity among the strains (Table 2, cup9Δ).   
The resistance of strain W303 to Ala-Eth was overcome by the cup9Δ mutation to the 
extent that the W303-cup9Δ mutant exhibited higher sensitivity to Ala-Eth than cup9Δ 
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mutants of either RM8 or YAT7.  All of the cup9Δ mutant strains exhibited some 
sensitivity to Ala-Eth in the absence of the leucine inducer.  Curiously, despite the robust 
dipeptide import characteristic of the YAT7 strain, YAT7-cup9Δ produced much smaller 
halos under these conditions than either W303-cup9Δ or RM8-cup9Δ (Table 2; see also 
Figure 7).  Some of the inter-strain variation observed in the halo assay might reflect 
varying sensitivity to ethionine.  However, since both changes in media composition and 
the cup9Δ mutations affected strains differently, this diversity is clearly shaped by the 
complex regulatory controls governing dipeptide import. 
Expression and localization of Ptr2p varies substantially among strains:  
Strain W303 was both highly resistant to the toxic Ala-Eth dipeptide and limited in 
dipeptide utilization capacity.  Therefore, we asked whether PTR2 expression in this 
strain differed from that of the other strains tested.  To directly visualize the expression of 
PTR2, a C-terminal FLAG-2xGFP-6xHis tag was added to the endogenous PTR2 gene of 
strains W303, RM8, and YAT7 by site-specific homologous recombination.  These 
modified strains retained a similar capacity to utilize dipeptides (data not shown).  To 
facilitate comparison of PTR2 expression with the results of the halo assay, expression of 
GFP-tagged PTR2 was assayed in a liquid version of the MMA and MMA+Leu media 
and fluorescence was measured using a uniform exposure level (Figure 7; halo assay 
images included for comparison). 
The presence of Ptr2p at the plasma membrane correlated well with the extent of 
Ala-Eth toxicity observed in the halo assay (except that fluorescence was weaker in RM8 
than might have been expected from its strong Ala-Eth sensitivity in MMA+Leu).  In all  
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Figure 7 Inter-strain variation in PTR2 expression and sensitivity to the toxic 
dipeptide Ala-Eth.  Media composition and the absence of Cup9p affect expression of 
GFP-tagged PTR2 and Ala-Eth toxicity.  Three types of media were tested: MMA, 
MMA+Leu, and YPD.  “MMA” refers to minimal nitrogen media containing 1 mg/ml 
allantoin as the nitrogen source.  “+Leu” refers to the addition of 30 µg/ml leucine, an 
inducer of PTR2 expression.  YPD is a standard rich S. cerevisiae media; the presence of 
methionine precludes its use for the halo assay.  The left and right discs in each halo 
assay panel contained 0.1 µmoles and 0.2 µmoles of Ala-Eth, respectively.  Microscopy 
was conducted using cells grown to log phase in the indicated media.  Three strains were 
imaged: W303, RM8, and YAT7.  In each strain, the endogenous PTR2 gene contained a 
C-terminal tag consisting of a FLAG epitope, two copies of GFP, and a 6xHis tag.  The 













other cases, conditions promoting strong Ala-Eth sensitivity also induced strong PTR2 
expression.  Strikingly, wild-type W303, which was resistant to Ala-Eth, exhibited 
virtually no Ptr2p fluorescence.  The cup9Δ mutation restored strong PTR2 expression 
and also restored Ala-Eth sensitivity. Thus, the resistance of W303 to Ala-Eth in the halo 
assay resulted from an absence of Ptr2p at the plasma membrane.   Moreover, these 
results confirm that W303 contains a functional PTR2 gene subject to atypical regulation.   
Additional aspects of PTR2 regulation: Retrograde recycling of membrane-
bound Ptr2p is thought to represent an additional layer of regulatory control of dipeptide 
import (H. Cai and J. Becker, unpublished observations).  Although GFP-tagged Ptr2p 
was typically localized to the membrane, when strain RM8 was grown in YPD, additional 
fluorescent signal was also observed in the vacuole and what appeared to be large 
vesicles.  The high levels of PTR2 expression in the rich YPD media was itself surprising, 
since PTR2 is thought to be subject to nitrogen catabolite repression in the presence of 
preferred nitrogen sources (ALAGRAMAM et al. 1995).  Although YAT7 also exhibited 
robust PTR2 expression under these conditions, Ptr2p was confined to the plasma 
membrane.  This inter-strain variation was likely influenced by cellular Ptr2p levels, as 
cup9Δ mutants of RM8, YAT7, and W303 all exhibited robust PTR2 expression and 
some intra-cellular Ptr2p localization in YPD media (Figure 7).  However, while wild-
type RM8 and YAT7 both exhibited strong Ptr2p fluorescence in YPD, only RM8 
exhibited abundant intra-cellular compartmentalization of Ptr2p, indicating that 
retrograde transport of Ptr2p is yet another regulatory process that varies between strains 
in S. cerevisiae. 
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The regulation of PTR2 in W303 differed significantly from the other strains 
analyzed in this study.  Considering the possibility that polymorphisms within the PTR2 
promoter region may account for the limited PTR2 expression in W303, we sequenced an 
889 bp region immediately upstream of the PTR2 start codon in the strains W303, S288c, 
RM8, and YAT7 (Table S2).  The promoter region in W303 differed from that of S288c 
at only one base, a C T transition at position -799.  However, this polymorphism was 
shared by the strain RM8, which unlike W303 is sensitive to Ala-Eth and exhibits robust 
PTR2-dependent utilization of N-end rule dipeptides.  Thus, differences in promoter 
sequence are not a likely source for the altered regulation of PTR2 in W303. 
Telomeric regions are common sites of epigenetic regulation, and PTR2 is located 
in proximity (~50 kB) to a telomere.  In our analyses of GFP-tagged PTR2, a small 
subpopulation (1 in 50 to 1 in 1000, depending on conditions) of strongly fluorescent 
W303 cells was consistently observed during growth in either the MMA+Leu media or in 
YPD (Figure 7; inset).  W303 cells exhibiting robust PTR2 expression also arose 
spontaneously at a high frequency (>0.1%) on solid media.  These cells maintain 
competency for PTR2 expression following serial propagation on media that relieve 
selection for active dipeptide transport (J. Manjrekar and S. Lindquist, personal 
communication).  These switching events were far too frequent to reflect mutation, 
suggesting that an epigenetic switch exists that can stably confer competency for PTR2 




We establish that the rich inter-strain diversity and genetic tractability of S. 
cerevisiae can be combined with high-throughput phenotyping to provide new insights 
into basic cellular processes.  Using this approach, we have uncovered previously 
unrecognized functions and regulatory systems governing the utilization of dipeptides as 
a nitrogen source.  In addition, we consider dipeptide utilization in the context of an 
adaptive landscape shaped by opposing selective pressures. 
Using high-throughput phenotyping to study di/tri-peptide utilization:  The 
exploration of natural diversity using high-throughput phenotyping techniques has the 
potential for tremendous synergy with the existing high-throughput technologies that 
have shaped our understanding of the cellular circuitry of S. cerevisiae.  The pursuit of an 
integrated understanding of yeast functional genomics and proteomics (reviewed in 
(BADER et al. 2003)) has been enabled by numerous powerful high-throughput 
approaches.  For example, genetic networks have been elucidated by high-throughput 
screens for synthetic lethality (TONG et al. 2004), protein interaction networks have been 
mapped using mass spectrometry (GAVIN et al. 2002; HO et al. 2002), and transcriptional 
networks have been elucidated by the now ubiquitous technique of transcriptional 
profiling using microarrays and by the mapping of physical interactions between 
transcription factors and promoters (LEE et al. 2002).  The technology for global analysis 
of growth phenotypes remains largely underdeveloped and unexploited - in spite of the 
fact that it is phenotype that determines how cellular systems interface with selective 
pressures.  Thus, the broad synthesis of our understanding of genomic, transcriptional, 
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and phenotypic diversity is contingent upon the development of robust technologies for 
high-throughput phenotyping. 
Here, we have tested one of the first such systems by assaying dipeptide and 
tripeptide utilization on a previously unfeasible scale.  The PM phenotypic assay allows 
simultaneous testing of ~2000 growth conditions, providing a tremendous savings in time 
and labor.  The technology was typically very robust and provided reliable and 
reproducible data that were easily manipulated using the accompanying software.  
However, the PM technology also has several drawbacks that need to be addressed before 
this technology is broadly suitable for use by the yeast research community.  Due to the 
initial design focus on generalized bacterial phenotyping, many of the available PM assay 
plates are not optimized for S. cerevisiae.  Thus, the number of useful growth conditions 
is considerably less than 2000.  This issue is compounded by the high cost of the PM 
assay plates.  Further, different batches of media and PM assay plates provided by the 
manufacturer often affected reproducibility.  Such technical difficulties are not atypical 
for a new technology, and the power of such tools in exploring the phenotypic diversity 
of S. cerevisiae is clear.  Hopefully, the importance of high-throughput phenotyping will 
lead to reduced costs and enhanced suitability of these technologies.   
Uncovering unexpected complexity in di/tri-peptide utilization:  Through 
extensive phenotyping, we found that Ptr2p is but one component of a multifaceted 
system in S. cerevisiae governing the utilization of dipeptides as nitrogen sources.  The 
discovery of these additional components was made possible by the dramatic inter-strain 
variation observed in the contributions of these activities to dipeptide utilization 
(summarized in Table 3).  We have clearly identified one previously unknown  
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Table 3. Activities contributing to the utilization of dipeptides as a nitrogen source 
in each strain background 
Activity YAT7 RM3 RM8 Y55 S288c W303 
Ptr2p yesa yes yes yes yes yesb 
Dal5p yes yes yes - yes yes 
X-Asnc - - - - yes yes 
X-Argd - ND yes - ND - 
 
The contributions of the activities, as indicated by the number of plusses, represent a qualitative summary 
of the data gathered in this study; -, activity is minimal or absent; ND, not determined due to insufficient 
data 
aPtr2p activity was exceptionally robust in this strain 
bPtr2p activity was limited in this strain 
cRefers to the putative Asp3p activity 
dRefers to the capacity to utilize dipeptides containing C-terminal arginine residues (particularly Met-Arg) 





component of this system: the allantoate/ureidosuccinate permease Dal5p, and have 
defined parameters of two others that suggest mechanistic explanations. 
Of these four components, Ptr2p exhibits the broadest dipeptide utilization 
activity.  Relief of PTR2 repression by deletion of CUP9 facilitated robust growth on 
nearly all di/tri-peptides tested.  This was even true of W303, which otherwise grew on 
only a limited subset of the N-end rule dipeptides that supported growth of the other 
wild-type strains.  This restricted utilization of potential Ptr2p substrates provides a 
window into the complex PTR2 regulatory system.  For example, one can ask why W303 
is capable of growing on Trp-Arg, but not Arg-Trp (Figure 3A), even though both are N-
end rule ligands composed of identical residues.  One possibility is that the N-end rule 
pathway in W303 is more responsive to Type I ligands (basic N-terminal residues; e.g. 
Arg) than Type II substrates (bulky hydrophobic N-terminal residues; e.g. Trp).  
Alternatively, substrate preference may arise from dipeptidase specificity (HERRMANN et 
al. 1978) resulting in more robust hydrolysis of Trp-Arg upon import.  While beyond the 
scope of this analysis, additional insights and hypotheses can be derived from the wealth 
of data provided by our high-throughput analysis, and the approach developed here – the 
application of a diverse panel of strains to the PM assay to analyze di/tri-peptide 
utilization – can be employed in future studies to enrich our understanding of PTR2 
regulation and Ptr2p function.   
Dal5p, a second component of the dipeptide utilization system, was previously 
identified as a permease for the pyrimidine biosynthetic precursor ureidosuccinate 
(TUROSCY and COOPER 1987) and the nitrogen source allantoate (CHISHOLM et al. 1987) .  
Expression of DAL5 is subject to complex regulatory control by the nitrogen catabolite 
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repression system (CHISHOLM et al. 1987; RAI et al. 2004; RAI et al. 1987).  It is 
therefore fitting that Dal5p also be involved in the utilization of dipeptides as a nitrogen 
source.  With the exception of Tyr-Gln, all Dal5p di/tri-peptide substrates belonged to the 
non-N-end rule class.  Many of the dipeptides supporting growth in RM8-ptr2Δ (Figure 3) 
did not support growth in RM8-dal5Δ (Figure 6).  Thus, Dal5p-mediated dipeptide 
transport is not redundant to that of Ptr2p, but rather a complementary activity that 
enhances the range of dipeptides that can be utilized. 
A third component, evident in strains W303 and S288c, governs the utilization of 
dipeptides containing C-terminal asparagine residues as nitrogen sources (Figure 2).  
Several lines of evidence support the conclusion that the Asp3p periplasmic asparaginase 
facilitates the utilization of these substrates.  Asp3p activity is closely linked to nitrogen 
utilization.  Nitrogen starvation has been demonstrated to upregulate ASP3 expression 
and promote the secretion of asparaginase II (BON et al. 1997).  Furthermore, the 
enzymatic activity of asparaginase II hydrolyzes either L- or D-asparagine into ammonia 
and aspartate, facilitating the use of D-asparagine as a nitrogen source (DUNLOP et al. 
1978; DUNLOP et al. 1976).  Of the strains tested, only W303 and the related laboratory 
strain S288c were able to utilize D-asparaginase in the PM assay (Figure 2E).  Genomic 
analyses utilizing microarrays have noted a lack of detectable ASP3 in Y55 (LASHKARI et 
al. 1997) and a clinical isolate, YJM789 (WINZELER et al. 1999).  Neither Y55 nor our 
clinical isolate, YAT7, were capable of utilizing the putative Asp3p substrates (Figure 2).  
Most importantly, the asparaginase of the bacterial plant pathogen Erwinia carotovora 
has been shown to deamidate C-terminal, but not N-terminal, asparagine residues of 
small peptides (HOWARD and CARPENTER 1972).  This specificity precisely matches the 
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dipeptide utilization phenotypes observed for W303 and S288c.   Both strains are unable 
to utilize the two dipeptides with N-terminal asparagine residues present in the PM 
nitrogen plates (Figure 2B), but are able to utilize all dipeptides containing C-terminal 
asparagine residues (Figure 2; boxes with red borders).  To our knowledge, our study 
provides the first evidence for such an activity in S. cerevisiae, in which mechanisms of 
extra-cellular peptide processing are rare. 
A fourth component of the dipeptide utilization system, evident in strain RM8 but 
not W303, governs the use of dipeptides containing C-terminal arginine residues, and 
Met-Arg in particular.  Utilization of Met-Arg is clearly enhanced by deletion of DAL5 
(Figure 6) and persists in the ptr2Δdal5Δ double mutant (Figure S2), and thus represents 
another previously unrecognized mechanism of dipeptide utilization.  Given the 
specificity for a nitrogen-rich C-terminal residue, an arginase activity comparable to the 
asparaginase activity of Asp3p would seem a likely candidate. 
Balancing the benefits and potential risks of robust di- and tripeptide import:  
The striking inter-strain diversity in dipeptide utilization revealed in this study represents 
a broad phenotypic landscape.  Variation in the relative strengths of the activities 
contributing to dipeptide import can strongly impact the range of dipeptide substrates 
utilized by the cell.  While di/tri-peptides can serve as a valuable source of nutrients, 
evolutionary pressures opposing indiscriminate import may reinforce mechanisms 
promoting transport specificity.  One such pressure might be the need to avoid import of 
antifungal agents that exploit the di/tri-peptide transport machinery to gain entry into the 
cell (reviewed in (ST GEORGIEV 2000)). 
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Of the di/tri-peptide-utilization activities characterized in this study, the Ptr2p 
transporter provides the means to transport the broadest spectrum of dipeptide substrates 
(Figure 3), yet it is also the source of vulnerability to the toxic Ala-Eth dipeptide (Table 
2).  Thus, strains that exhibit robust PTR2 expression, such as the clinical isolate YAT7, 
efficiently utilize a broad spectrum of dipeptides as a nitrogen source (Figure 2), but are 
also vulnerable to Ala-Eth toxicity (Table 2).  In contrast, the limited PTR2 expression in 
strain W303 provides protection from Ala-Eth at the cost of a more limited capacity to 
utilize di/tri-peptides.  However, in certain growth conditions a fraction of W303 cells 
exhibit robust PTR2 expression, suggesting a possible epigenetic mechanism for 
employing both high- and low-risk di/tri-peptide utilization strategies in an isogenic 
population. 
The optimal strategy for dipeptide utilization will vary between environments.  
For instance, in the presence of toxic peptidomimetics that resemble Dal5p substrates, 
strain Y55 would have a significant fitness advantage over the other strains tested in this 
study, as it exhibits no detectable Dal5p activity (Figure S2).  In environments with a 
strong risk of exposure to a variety of toxic di/tri-peptides, the risks of Ptr2p- and Dal5p-
mediated import may outweigh the potential nutritional benefits.  In such cases, the 
utilization of a limited subset of di/tri-peptides may represent a low-risk mechanism by 
which some nutritional benefit can be extracted from the available di/tri-peptides.  For 
example, extracellular release of ammonia from C-terminal asparagine residues by Asp3p 
would serve as a more limited, but risk-free, means of obtaining nitrogen from dipeptides.  
In contrast, in an environment in which nitrogen sources are scarce and the risk of 
importing toxic species is minimal, robust expression of PTR2 would be a beneficial trait.  
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We note that the clinical isolates YAT7 (Figure 2), YAT17, and YAT21 (data not shown) 
exhibit the most robust dipeptide utilization of the strains studied, perhaps reflecting the 
environmental pressures of the strains’ atypical growth environment in the human host.  
Further investigation into the ecology, population structure and population genetics of S. 
cerevisiae would benefit future attempts to link phenotypic diversity to likely 
environmental pressures.   
High-throughput phenotyping and genetic diversity can provide new insights into 
the genetic determinants governing adaptation to the nutritional and chemical challenges 
of diverse environments.  Our study represents a first case example of how this approach 
can be utilized to elucidate metabolic processes and provide a broader evolutionary 
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 Supplement Table S1  Oligos used in this study 
Oligo Sequence Purpose 
O-007 CAATTCAACGCGTCTGTGAGG Verify SFH deletions 
O-008 GATTCTTGTTTTCAAGAACTTG Verify SFH deletions 
O-138 TATACGCATATGTGGTGTTG Verify URA3 deletion 
O-139 CGACCGAGATTCCCGGGTAA Verify URA3 deletion 
O-203 ATGGTTTGTGAACAGATTGA Verify HSC82 deletion 
O-204 TTGAATGGACGCCGAATTGC Verify HSC82 deletion 
O-206 GTATCGATAAGCTTGATATC 










Amplify URA3 SFH deletion 
cassette 
O-248 TAATACGACTCACTATAGGG 










Amplify lox-flanked HSC82 SFH 
deletion cassette 
O-278 CGCAAGTCCTGTTTCTATGC Verify KanMX excision from HO 









Amplify PTR2 SFH deletion 
cassette 
O-288 GGGCTAACGGCGTCCGCAGA Verify PTR2 deletion 
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Supplement Table S1  Continued 
Oligo Sequence Purpose 









Amplify CUP9 SFH deletion 
cassette 
O-292 GCGTGCTTCCTCACACTGGC Verify CUP9 deletion 
O-293 GAAAGAGAAGATGATAACTA Verify CUP9 deletion 
O-314 CGAATTTGATCTCAATCCAATTTCCGCACC 
SFH integration of FLAG-2xGFP-





SFH integration of FLAG-2xGFP-






PTR2 promoter sequencing (+30 to 
+11) 
O-322 CCGTCCTTTTCACTTCACGT 
PTR2 promoter sequencing (-466 to 
-447) 
O-323 CCGTACAGATAAGAAACCCA 
PTR2 promoter sequencing (-368 to 
-387) 
O-324 GATAAGCTTGGGGTAACGCA 


















Supplement Table S2  Polymorphisms in the region upstream of PTR2, relative to 














































S288c -- -- -- -- -- -- -- -- -- -- 
W303 + -- -- -- -- -- -- -- -- -- 
RM8 + + + + -- + + + -- -- 
YAT7 -- -- -- + + -- -- -- +a +b 
 
A region encompassing the bases spanning from positions -899 to +3 relative to the PTR2 
stop codon was sequenced in the indicated strains. 
a “insT-46” refers to the expansion of a string of 11 “T”’s spanning from -46 to -36 by an 
additional “T”. 
b “del-32CTT” refers to a deletion of the bases “CTT” spanning from -32 to -30 of the 
published S288c sequence. 
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Supplement Figure S1 Dal5p and Ptr2p exhibit strain-dependent contributions to 
the utilization of Ala-Leu as a nitrogen source.  Wild-type, dal5Δ, ptr2Δ and 
ptr2Δdal5Δ versions of the indicated strains were grown at 30°C in liquid MM media 
containing 2 mM Ala-Leu as the sole nitrogen source.  A few timepoints were omitted 
because of technical difficulties with the Bioscreen C growth curve machine. 
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Supplement Figure S2 Additional PM signal profiles reveal the varied contribution 
of Dal5p to di/tri-peptide import in strains RM8, W303, and Y55.  Refer to Figure 2 
for details on data analysis and presentation.  The column label “ptr2Δ (vector)” refers to 
strain W303-ptr2Δ transformed with the high-copy (2µ) vector pRS426.  The column 
label “ptr2Δ (DAL5)” refers to strain W303-ptr2Δ transformed with plasmid pRS426-
DAL5.  Note that the PM assays presented in this figure utilized a more recent 
manufacturing lot of the PM nitrogen plates than those presented in the other figures.  
Different lots can produce subtle differences in signal magnitude.  The wild-type RM8 
and Y55 PM data presented here were derived from the same lot to facilitate direct 
comparison.  
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SUMMARY AND DISCUSSION 
 
Di/tri-peptides are important to organisms as amino acids, nitrogen, and carbon 
sources, and Ptr2p as the major di/tri-peptide transporter is one of the proteins required 
for the utilization of di/tri-peptides. In order to identify genes affecting di/tri-peptide 
utilization, I have performed a systematic, functional examination of dipeptide utilization 
in a haploid, non-essential, single-gene deletion mutant library in Saccharomyces 
cerevisiae.  I have identified 103 candidate genes: 57 genes whose deletion decreased 
dipeptide utilization and 46 genes whose deletion enhanced dipeptide utilization. The 103 
genes were distributed among most of the Gene Ontology functional categories indicating 
a very wide regulatory network involved in the utilization of dipeptides in yeast. In 
addition, to exploit the various strategies of importing and utilizing di/tri-peptides as 
nitrogen sources, we used the Biolog system of “Phenotype MicroArrays™” (PM) 
(BOCHNER 2003; BOCHNER et al. 2001) which represents 284 of the 400 possible 
dipeptide and 11 tripeptide permutations to investigate the difference of growth 
phenotype in these arrays for different strains of S. cerevisiae.  Multiple gene products 
contributing to di/tri-peptide utilization have been revealed ranging from the initial 
processes of importing di/tri-peptides to the metabolic pathways of di/tri-peptide 
degradation. Taken together, the identified genes are involved in different biological 
pathways contributing to both direct and indirect regulation of di/tri-peptide utilization. 
Ptr2p is the key contributor for di/tri-peptide utilization:  
Ptr2p is the only known gene of the PTR family involved in di/tri-peptide uptake 
at the plasma membrane in yeast. After analyzing the preference for any of 284 
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dipeptides and 11 tripeptides as a sole nitrogen source, we demonstrated that Ptr2p is 
essential for many, but all yeast strains, for the utilization of most di/tri-peptides and 
exhibits the broad substrate recognition. For a limited number of peptides and for three 
out of the seven strains tested, another transporter (Dal5p) was able to substitute for 
Ptr2p’s role as peptide transporter. Relief of PTR2 repression by the deletion of CUP9 
facilitated robust growth on nearly all di/tri-peptides tested. In contrast, the deletion of 
PTR2 resulted in the almost complete abrogation of growth on N-end rule dipeptides, 
which contain bulky or basic amino acid in the N-terminus, suggesting Ptr2p contributes 
solely to the utilization of N-end rule dipeptides. For non-N-end rule di/tri-peptides, both 
Ptr2p and Dal5p played roles in peptide utilization.  
 
Several gene products contribute to di/tri-peptide utilization by regulating PTR2 
expression:  
I have identified genes affecting di/tri-peptide utilization by the regulation of 
PTR2 expression or PTR2 mRNA stability, which considerably expands our 
understanding of the regulation of PTR2 expression. First, I have identified gene products 
negatively regulating PTR2 transcription via a modification of histones. For example, 
deletion of Arp5p, Arp8p, Ies6p, or Taf14p, the components of the chromatin remodeling 
INO80 protein complex, or deletion of Eaf3p, a component of the NuA4 histone 
acetyltransferase complex, results in an increase in PTR2 transcription with a subsequent 
increase of dipeptide utilization. The INO80 protein complex preferentially interacts with 
histones H3 and H4 and is involved in the modification of the nucleosome, while Eaf3p is 
involved in maintaining the acetylation of histone H3 and H4 (REID et al. 2004; SANDERS 
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et al. 2002). Second, I have confirmed or identified four gene products with transcription 
factor activity (Cup9p, Dal81p, Stp2p, and Rpn4p) that regulate PTR2 expression. Cup9p 
is the known repressor of PTR2 transcription, and binds to the region between -488 and -
897 upstream of the PTR2 start codon (BYRD et al. 1998). Deletion of this gene product 
leads to an increase of di/tri-peptide utilization. Dal81p, Stp2p, and Rpn4p are positive 
regulators of PTR2 transcription, and deletion of these gene products results in a decrease 
of di/tri-peptide utilization. Dal81p is a transcriptional activator essential for PTR2 
expression induced by the SPS signal pathway (BERNARD and ANDRE 2001). Stp2p is 
proteolytically processed by truncation of the N-teminus and is translocated into the 
nucleus in response to amino acid induction via the SPS system (ANDREASSON and 
LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 2004). Dal81p and Stp2p might act 
synergistically in PTR2 transcription since similar synergistic regulation between Dal81p 
and Stp1p is also proposed in AGP1 regulation in response to amino acid induction 
(ABDEL-SATER et al. 2004). Rpn4p may bind between -610 and -603 due to the existence 
of the Rpn4p binding consensus sequence (5’-GGTGGAAA-3’) present at this site 
(MANNHAUPT et al. 1999). The regulation of PTR2 by Rpn4p was identified in my 
studies. 
 
I have also identified or corroborated that several gene products proposed to 
regulate transcriptional activators are involved in dipeptide utilization. For example, 
Ubr2p, Ptr1p, and Ubc2p modulate the stability of Rpn4p and Cup9p, and deletion of 
these regulators causes an alteration of di/tri-peptide utilization. Ubr2p has been shown to 
be involved in the degradation of Rpn4p; Ptr1p and Ubc2p are involved in Cup9p 
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degradation through the ubiquitination pathway (DU et al. 2002; WANG et al. 2004). 
Since Ubr2p has a high amino acid sequence similarity to Ptr1p, this would presumably 
allow competition with Ptr1p for the stabilization of Cup9p (BARTEL et al. 1990). 
Therefore, Ubr2p likely regulates PTR2 transcription by influencing the stability of both 
Rpn4p and Cup9p. The stability of Cup9p is also dependent on N-end rule dipeptides 
with N-terminal residues containing basic (Type 1: Arg, His, or Lys) and bulky (Type 2: 
Ile, Leu, Phe, Trp, or Tyr) amino acids. Dipeptides serve as ligands to bind to Ptr1p 
substrate binding sites, and binding these peptides cause a release of the Ubr1p 
autoinhibitory domain and allosteric activation of Ubr1p, which leads to the degradation 
of Cup9p. Relief of Cup9p repression of PTR2 results in enhanced PTR2 expression and 
ultimately di/tri-peptide uptake.  This initiates a positive regulatory feedback loop for 
di/tri-peptide utilization (BYRD et al. 1998; DU et al. 2002; TURNER et al. 2000).  
 
Third, I have identified the components of an RNA polymerase mediator 
(Ssn3p/Srb10p, Ssn8p/Srb11p, Ssn2p/Srb9p, and Srb8p) that are involved in PTR2 
transcription, thus regulating dipeptide utilization. This protein complex belongs to a 
cyclin-dependent serine/threonine protein kinase (KORNBERG 2005). The involvement of 
this protein complex is not specific for PTR2 transcription since this protein complex also 
affects the expression of PMA1 encoding a proton transporter. The deletion of SSN3 
results in a change of both PMA1 and PTR2 expression.  
 
Fourth, I have identified genes involved in the stability of PTR2 mRNA which 
affects dipeptide utilization. Both Kem1p and Pat1p belong to an mRNA decay protein 
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complex (BONNEROT et al. 2000; BOUVERET et al. 2000), and the amount of PTR2 
mRNA is considerably higher in the kem1 strain than in wild type. It is likely that PTR2 
mRNA is more stable in kem1 and pat1 strains, which results in more Ptr2p being 
synthesized leading to increased dipeptide utilization. However a deletion of KEM1 could 
affect expression of many different genes, resulting in a non-specific affect on dipeptide 
utilization. Another gene product, Thp1p, is involved in mRNA export from the nucleus 
to the cytoplasm (FISCHER et al. 2002), and deletion of this gene might interrupt PTR2 
mRNA translocation. 
 
Several gene products contribute to di/tri-peptide utilization by regulating Ptr2p 
trafficking 
I have identified genes affecting di/tri-peptide utilization by regulation of the 
Ptr2p trafficking system. Interruption of Ptr2p targeting to the plasma membrane leads to 
an alteration of di/tri-peptide uptake. I have shown that ESCRT-I (endosomal sorting 
complex required for transport), ESCRT-II, and ESCRT-III protein complexes are 
involved in Ptr2p trafficking since deletion of any component of these protein complexes 
caused a defect in Ptr2p-GFP trafficking from the endosome to the vacuole. For example, 
deletion strains srn2, vps36, snf7, eaf7 and vps8 demonstrated a defect in Ptr2p-GFP 
localization and increased dipeptide utilization. Since ubiquitination of membrane 
proteins is essential for sorting by the ESCRT protein system, I infer that Ptr2p 
ubiquitination is required for its turnover. Ubiquitinated Ptr2p has been identified by a 
mass spectrometer analysis supporting this hypothesis (HITCHCOCK et al. 2003). In 
addition to the ESCRT protein complexes, several gene products, such as NPR1, LST4, 
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BUD32, and REG1 showed an accumulation of Ptr2p-GFP in vesicles. They are also 
likely involved in the Ptr2p trafficking system. Strains npr1 and lst4 showed an increase 
of dipeptide utilization while bud32 and reg1 showed a decrease of dipeptide utilization.  
 
Several gene products contribute to di/tri-peptide utilization via Ptr2p-independent 
manner 
I have identified an important gene product involved in di/tri-peptide utilization 
independent of Ptr2p in yeast. Dal5p is a plasma membrane protein, which does not 
belong to PTR system but imports di/tri-peptides from the extracellular environment. 
Dal5p was previously identified as a permease for the pyrimidine biosynthetic precursor 
ureidosuccinate (TUROSCY and COOPER 1987) and the nitrogen source allantoate 
(CHISHOLM et al. 1987) .  Expression of DAL5 is subject to complex regulatory control 
by the nitrogen catabolite repression system (CHISHOLM et al. 1987; RAI et al. 2004; RAI 
et al. 1987).  With the exception of Tyr-Gln, all Dal5p di/tri-peptide substrates belong to 
the non-N-end rule class. For example, many of the dipeptides supporting growth in the 
RM8-ptr2Δ strain did not support growth in RM8-dal5Δ. Since Ptr2p can transport the 
majority of di/tri-peptides, the spectrum of Ptr2p substrates overlaps with that of Dal5p 
but the substrate specificity is strain dependent. In the RM8 strain, Dal5p-mediated 
dipeptide transport is not redundant to that of Ptr2p, but rather a complementary activity 
that enhances the range of dipeptides that can be utilized. 
 
Ptr2p-independent di/tri-peptide utilization is also governed by the activity of 
Asp3p, a periplasmic asparaginase, which facilitates the utilization of dipeptides 
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containing C-terminal asparagine residues as nitrogen sources. For example, W303-ptr2Δ 
dal5Δ strain could utilize X(Ala, Gly, Pro, Val, Ser, Ile, Leu)-Asn dipeptides as the 
nitrogen source. Nitrogen starvation has been demonstrated to up-regulate ASP3 
expression and promote the secretion of asparaginase II (BON et al. 1997).  Furthermore, 
the enzymatic activity of asparaginase II hydrolyzes either L- or D-asparagine into 
ammonia and aspartate, facilitating the use of D-asparagine as a nitrogen source (DUNLOP 
et al. 1978; DUNLOP et al. 1976).   
 
Ptr2p-independent di/tri-peptide utilization also includes the extracellular peptide 
degradation that is related to the utilization of dipeptides containing C-terminal arginine 
residues, particularly Met-Arg. Since the utilization of Met-Arg is enhanced by the 
deletion of DAL5 and persists in the ptr2Δdal5Δ double mutant, it is likely that an 
arginase activity comparable to the asparaginase activity of Asp3p could contribute to 
this dipeptide utilization. 
 
Several cellular metabolic processes are involved in dipeptide utilization 
independent of Ptr2p activity since no significant alteration of expression or localization 
of Ptr2p-GFP was observed. These cellular processes are: 1) the conversion of pyruvate 
into acetyl-CoA which requires pyruvate dehydrogenase complex (Pdx1p, Lpd1, Pdb1p, 
and Lat1p); 2) the conversion of acetyl-CoA to malonyl-CoA, which involved in Hfa1p; 
3) fatty acid synthesis which is involved in fatty acid synthase complex (Oar1p, Mct1p, 
and Etr1p); 4) glycine degradation  in (Gcv2p, Gcv3p, and Lpd1p); and 5) a peptidase 
activity (Prd1p) (BUCHLER et al. 1994; NAGARAJAN and STORMS 1997; SCHNEIDER et al. 
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1997; STOOPS et al. 1997). Since the accumulation of dipeptides is not impaired in these 
mutants as indicated from the non-visible change in Ptr2p-GFP and accumulation of 
[3H]Leu-Leu, the decrease in dipeptide utilization probably results from the inability to 
release amino acids from accumulated dipeptides or from blocking metabolic pathways in 
using the released amino acids for protein biosynthesis. 
 
Other cellular processes might be involved in dipeptide utilization, such as found 
in the ybt1 mutant. Ybt1p belongs to the ABC transporter family exhibiting ATP-
dependent bile acid transport (ORTIZ et al. 1997; PAULSEN et al. 1998). I speculate that 
this protein might be involved in the transport of dipeptides into the vacuole. In the 
deletion mutant the defect in the uptake of dipeptides into the vacuole would lead to an 
increase of dipeptide availability in the cytoplasm. It is also possible that the deletion of a 
gene might result in a de-repression or change in function of other transport systems that 
may mediate dipeptide utilization in the mutant without alteration of PTR2 expression or 
Ptr2p function. 
 
I have identified 15 unknown strains with deletions in genes of unknown function 
that had an alteration of dipeptide utilization, seven strains exhibiting increased and eight 
strains showing decreased dipeptide utilization. Characterization of the phenotype of 
these genes should lead to a further understand their cellular roles. In addition, other 
genes such as UBP14, ubiquitin-specific protease activity, require additional study to 
understand the mechanism of how these genes are involved in dipeptide utilization. 
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To date, molecular components have been reported in the regulation of the human PTR2 
homologs PEPT1 and PEPT2 (DANIEL 2004). In our research, I have identified 52 genes 
encoding proteins with more than 30% identity to human genes, which might be involved 
directly or indirectly in the utilization of dipeptides in yeast. Investigation of these genes 
may promote understanding of the regulation of dipeptide utilization in mammalian 
systems (the complete list of genes is in Table 1).  These genes include those encoding 
transcription factors and mRNA processing proteins (14 genes), proteins involved in 
cellular metabolism (12 genes), protein kinases (4 genes), DNA damage repair proteins (4 
genes), ribosomal proteins (4 genes), actin binding proteins and proteins involved in 
sorting (4 genes), proteins related to ubiquitination (3 genes), peptidases (2 genes), a 
transporter (1 gene), a protein involved in cell cycle regulation (1 gene), a DNA helicase 
(1 gene), a protein related to growth regulation (1 gene)  and a protein of unknown 
function (1 gene). 
 
Suggestions for future experiments 
My research has considerably expanded the understanding of the regulation of 
dipeptide utilization by PTR2 expression, Ptr2p trafficking, and other PTR2 independent 
mechanisms. To further explore the role of these gene products, I propose the following 
experiments.  
1. I have identified that Dal5p is involved in dipeptide utilization by importing dipeptides 
by showing that some of non-N-end rule dipeptide substrates can provide a nitrogen 
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Description of human gene product 
TRANSCRIPTION AND MRNA PROCESSING (14) 
BYE1  Transcriptional elongation 
regulator activity 
DIDO1 Death associated transcription factor 1, contains nuclear localization signals and 
transactivation domains, may have a role in cell death during development, 
overexpression inhibits limb outgrowth 
CUP9  Specific RNA polymerase 
II transcription factor 
activity 
PKNOX1 PBX knotted 1 homeobox 1, a member of the homeodomain family of DNA binding 
proteins that regulate gene expression and control cell differentiation, heterodimerizes 
with PBX proteins to form Urokinase Enhancer Factor 3 (UEF3) DNA binding 
complexes 
DBR1  RNA lariat debranching 
enzyme activity 
DBR1 RNA lariat debranching activity for processing of introns 
EAF3  Histone acetyltransferase 
activity 
Morf4l2 Protein with high similarity to mortality factor 4 (human MORF4), which is a 
predicted transcriptional repressor that binds transcriptional corepressors human 
SIN3A and human TLE1 and negatively regulates cell proliferation 
KEM1  5'-3' exoribonuclease 
activity 
XRN1 5'-3' Exoribonuclease, a putative exoribonuclease that localizes to the cytoplasm, and 
is expressed ubiquitously 
NPL3  mRNA binding SYNCRIP Synaptotagmin binding cytoplasmic RNA interacting protein, component of the ApoB 
mRNA editosome involved in apolipoprotein B (APOB) mRNA editing, may bind 
RNA, may play a role in the regulation of mRNA splicing or transport from the 
nucleus 
PHO2  Transcription factor 
activity 
SHOX2 Short stature homeobox 2, a member of the paired-related family of homeodomain-
containing transcription factors, may have a role in craniofacial, brain, heart, and limb 
development, involved in skeletal defects of Turner syndrome 
RIM101  Specific transcriptional 
repressor activity 
Egr3 Early growth response 3, member of the Egr family of immediate early transcription 
factors; deletion of the corresponding gene results in gait ataxia, increased frequency 
of perinatal mortality, scoliosis, resting tremors, and ptosis 
SFP1  Transcription factor 
activity 
DPF2 D4 zinc and double PHD fingers family 2 (requiem), a member of the d4 domain 
family of zinc finger proteins, may be required for the induction of apoptosis by 
extracellular signals 
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Table 1 Continued 
Yeast gene 
name 





Description of human gene product 
SSN3  Cyclin-dependent protein 
kinase activity 
CDK8 Cyclin dependent kinase 8, forms a complex with cyclin C that phosphorylates cyclin 
H (CCNH) and the C terminus of POLR2A, plays a role in the regulation of 
transcription through Notch signaling and as component of the RNA polymerase II 
holoenzyme 
SSN8  Cyclin-dependent protein 
kinase regulator activity 
CCNK Cyclin K, member of the transcription cyclin family, binds and activates CDK9 
leading to phosphorylation of the RNA polymerase II large subunit, promotes RNA 
polymerase II transcription elongation, overexpression suppresses glioblastoma cell 
proliferation 
STP2  Specific RNA polymerase 
II transcription factor 
activity 
HKR1 GLI-Kruppel family member HKR1, putative transcription factor whose expression in 
lung cancer cell lines is induced in response to cisplatin, may be involved in a signal 
transduction pathway that regulates platinum resistance or lung cancer progression 
RPN4  Transcriptional activator 
activity 
ZNF473 Zinc finger protein 473, an snRNA binding protein in the snRNP U7 complex, 
involved in mRNA processing 
TAF14  General RNA polymerase 
II transcription factor 
activity 
MLLT1 Myeloid-lymphoid or mixed-lineage leukemia translocated to 1, a transcription factor 
with activator and putative repressor activities, binds CBX8; gene translocation causes 
B-cell, myeloid, and acute lymphocytic forms of leukemia 
KINASE (4) 
BUD32  Protein serine/threonine 
kinase activity 
TP53RK a protein serine-threonine kinase that binds to and phosphorylates p53 (TP53) and 
regulates p53-mediated transcriptional control, may be involved in the cell cycle and 
apoptosis 
MCK1 Protein kinases, positive 
regulator of meiosis and 
spore formation 
GSK3B Glycogen synthase kinase 3 beta, serine/threonine kinase that regulates beta-catenin 
(CTNNB1) stability and binds presenilin 1 (PSEN1), associated with Alzheimer 
disease, bipolar disorder, schizophrenia and various neoplasms 
NPR1  Serine/threonine protein 
kinase 
CHEK1 Checkpoint homolog 1 (S. pombe), protein kinase, required for mitotic G2 checkpoint 
in response to radition-induced DNA damage, inhibits mitotic entry after DNA 
damage via mechanism involving CDC25, alternative form is associated with lung 
cancer 
PHO85  Cyclin-dependent protein 
kinase activity 
CDK2 Cyclin-dependent protein kinase 2, interacts with cyclins to regulate kinase activity 
and cell cycle progression, regulates DNA replication; decreased expression or 
inhibition may be therapeutic for many types of cancer 
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Yeast gene 
name 





Description of human gene product 
METABOLISM (12) 
ETR1  Enoyl-[acyl-carrier 
protein] reductase activity 
MECR Nuclear receptor binding factor 1, reduces trans-2-enoyl-CoA to acyl-CoA with chain 
length from C6 to C16 in an NADPH-dependent manner with preference to medium 
chain length substrate, plays a role in mitochondrial respiratory function 
GCV2  Glycine dehydrogenase 
(decarboxylating) activity 
GLDC Glycine decarboxylase (glycine dehydrogenase, P-protein), part of the glycine 
cleavage system that catalyzes the decarboxylation of glycine; mutation of the 
corresponding gene causes nonketotic hyperglycinemia 
GCV3  Glycine dehydrogenase 
(decarboxylating) activity 
GCSH Glycine cleavage system protein H, H-protein component of the glycine cleavage 
system, catalyzes transfer of the methylamine group of glycine from P-protein 
(GLDC) to T-protein (AMT); mutational inactivation results in atypical nonketotic 
hyperglycinemia 
HFA1  Acetyl-CoA carboxylase 
activity 
ACACA Acetyl-Coenzyme A carboxylase alpha, catalyzes the rate-limiting step in long-chain 
fatty acid biogenesis; deficiency leads to defects in fatty acid synthesis 
ELF1  Molecular function 
unknown 
ELOF1 Protein containing a DUF701 putative zinc binding domain, has very strong similarity 




DLAT Dihydrolipoamide S-acetyltransferase E2 component of pyruvate dehydrogenase 
complex, binds coenzyme and pyruvate dehydrogenase kinase 2 (PDK2); mutation 
may cause pyruvate dehydrogenase deficiency; may be associated with primary biliary 
cirrhosis 
LPD1  Dihydrolipoyl 
dehydrogenase activity 
DLD Dihydrolipoamide dehydrogenase, E3 component of pyruvate dehydrogenase complex, 
also a component of alpha-ketoglutarate dehydrogenase and alpha-ketoacid 
dehydrogenase complexes; mutation in the corresponding gene causes lipoamide 
dehydrogenase deficiency 
PDB1  Pyruvate dehydrogenase 
(acetyl-transferring) 
activity 
PDHB E1 beta subunit of pyruvate dehydrogenase complex, oxidatively decarboxylates 
pyruvate to acetyl-CoA 
PDX1  Pyruvate dehydrogenase 
complex protein 
DLAT Dihydrolipoamide S-acetyltransferase E2 component of pyruvate dehydrogenase 
complex, binds coenzyme and pyruvate dehydrogenase kinase 2 (PDK2); mutation 
may cause pyruvate dehydrogenase deficiency; may be associated with primary biliary 
cirrhosis 
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Yeast gene 
name 





Description of human gene product 
SHM2  Glycine 
hydroxymethyltransferase 
activity 
SHMT1 Soluble serine hydroxymethyltransferase, catalyzes the tetrahydrofolate-dependent 
interconversion of glycine and serine, source of folate-activated one-carbon units 
required for purine, thymidine, and methionine synthesis 
TSA1  Thioredoxin peroxidase 
activity 
PRDX2 Peroxiredoxin 2, an antioxidant enzyme, acts in the response to lipid hydroperoxide 
and may play a role in protection of cells from reactive oxygen species, expression is 
altered in neurodegenerative diseases and breast cancer 
YJL046W  Unknown LIPT1 Lipoyltransferase, putative enzyme that transfers the lipoyl group from lipoyl AMP to 
the lysine residue of lipoate-dependent enzymes; tissue expression correlates well with 
expression of lipoate-requiring proteins 
PEPTIDASE (2) 
PRD1    Metalloendopeptidase 
activity 
THOP1 Thimet oligopeptidase 1, a metalloendopeptidase that processes neuropeptides and 
other polypeptides, degrades beta amyloid precursor protein (APP), acts in degrading 
peptides released by proteasomes to limit the extent of MHC class I antigen 
presentation 
YFR044C  Unknown CNDP2 Cytosolic nonspecific dipeptidase 2, member of the M20 metalloprotease family, a 
homodimeric enzyme that requires magnesium ions for full dipeptidase activity and is 
inhibited by bestatin, expressed ubiquitously 
DNA DAMAGE REPAIRMENT (4) 
MLH1  DNA binding; ATPase 
activity 
hMLH1 MutL (E. coli) homolog 1, a DNA mismatch repair protein that may play a role in 
DNA recombination; decreased expression is associated with various cancers; 
increased expression may be therapeutic for colorectal cancer 
MRE11 3'-5' exonuclease activity MRE11A Meiotic recombination (S. cerevisiae) 11 homolog A, an endo- and exonuclease that 
functions in DNA double-strand break repair; mutation of corresponding gene is 
associated with an ataxia-telangiectasia-like disorder, breast cancer, and malignant 
lymphoma 
RAD23  protein that binds to the 
26S proteasome subunits 
and is involved in 
ubiquitin-dependent 
protein degradation 
RAD23B RAD23 homolog B (S. cerevisiae), a damaged DNA binding protein that also binds 
XPC to form a DNA damage recognition protein and functions in global genome 
nucleotide excision repair, may be associated with Machado Joseph disease or 
xeroderma pigmentosum 
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Yeast gene 
name 





Description of human gene product 
TOM72  Minor import receptor of 
the mitochondrial outer 
membrane 
PPP5C Protein phosphatase 5 catalytic subunit, a protein serine-threonine phosphatase that 
promotes cell proliferation, plays a role in DNA damage response and several 
signaling pathways, may promote tumor growth, downregulated in Alzheimer disease 
brain 
RIBOSOMAL PROTEINS (4) 
MRP17  Structural constituent of 
ribosome 
Mrps6 Mitochondrial ribosomal protein S6 
MRPS9  Structural constituent of 
ribosome 
MRPS9 Member of the ribosomal protein S9 or S16 family, has low similarity to C. elegans 
F09G8.3, which is involved in embryogenesis and positive growth regulation 
RPL21A   Structural constituent of 
ribosome 
RPL21 Ribosomal protein L21, component of the large 60S ribosomal subunit; shows altered 
expression in colorectal carcinogenesis 
RPS9B  Structural constituent of 
ribosome 
RPS9 Ribosomal protein S9, a component of the small 40S ribosomal subunit, gene 




ACTIN BINDING AND  PROTEIN SORTING (4) 
ARP5  Actin-related protein Actr5 Member of the actin family, which are major cytoskeletal proteins 
HOF1  Cytoskeletal protein 
binding 
SH3RF1 SH3 multiple domains 2, a ubiquitin ligase that functions in protein sorting at the trans 
Golgi network, plays a role in targeting of HIV 1 to the plasma membrane 
SAC6  Actin filament binding PLS3 Plastin 3 (T isoform), an actin-binding protein involved in actin filament bundling, cell 
invasion by bacteria, and possibly UV protection, expression is altered in cancer and 
Sezary syndrome, autoantibodies are linked to systemic lupus erythematosous 
SNF7  Protein sorting in the pre-
vacuolar endosome 
CHMP4B Chromosome 20 open reading frame 178 (chromatin modifying protein 4b, charged 
multivesicular body protein 4b), a member of the CHMP family of yeast class E 
SNF7-Vps protein homologs, binds Alix (PDCD6IP), may act in protein sorting 
UBIQUITINATION (3) 
SHP1  Ubiquitin binding; 
Enzyme regulator activity 
NSFL1C Protein with very strong similarity to Nsfl1c protein (rat Nsfl1c), which is a 
spermatocyte XY body component that acts in membrane fusion and regrowth of 
Golgi cisternae following mitosis, member of the UBX (ubiquitin-regulatory) domain 
containing family 






Table 1 Continued 
Yeast gene 
name 





Description of human gene product 
UBA3  NEDD8 activating 
enzyme activity 
UBE1C Ubiquitin-activating enzyme E1C, subunit of an E1 (ubiquitin-activating enzyme)-like 
complex, interacts with the amyloid precursor protein binding protein (APPBP1) to 
activate the ubiquitin-like protein NEDD8 and target CUL4A for NEDD8 modification 
UBC2  Ubiquitin conjugating 
enzyme activity 
UBE2B Ubiquitin-conjugating enzyme E2B, predicted to be involved in the conjugation of 
ubiquitin to cellular proteins marking them for proteasomal degradation, involved in 
DNA repair; activity is increased in multiple disease states 
TRANSPORTER (1) 
YBT1  Bile acid transporter 
activity 
ABCC1 ATP-binding cassette subfamily C member 1 (multiple drug resistance protein 1), a 
transporter and multidrug efflux pump that confers resistance to lipophilic drugs and 
chemotherapeutic agents, upregulation correlates with severity of breast cancer 
CELL CYCLE REGULATION  (1)  
NFU1  Involved in maturation of 
mitochondrial iron-sulfur 
proteins 
HIRIP5 HIRA interacting protein 5, interacts with histone cell cycle regulation defective 
homolog A (HIRA) which is involved in the pathogenesis of DiGeorge syndrome and 
the velocardiofacial syndrome 
DNA HELICASE (1) 
HFM1  DNA helicase activity ASCC3 Member of the Sec63 domain containing, helicase conserved C-terminal domain 
containing, and type III restriction enzyme res subunit families, contains two 
DEAD/DEAH box helicase domains, has moderate similarity to human ASCC3L1, 
which binds ATP 
    
GROWTH REGULATION (1) 
ISA1  Mitochondrial protein 
required for normal iron 
metabolism 
HBLD2 Protein with high similarity to C. elegans Y39B6A.3, which is involved in positive 
growth regulation and larval development, member of the HesB-like domain 
containing family 
UNKNOWN (1) 
YPL098C  Unknown C20orf52 Protein of unknown function, has very strong similarity to uncharacterized mouse 
2010100O12Rik 
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source for the growth of a PTR2 deletion mutant, while a double deletion of PTR2 and 
DAL5 lose the capability to utilize all dipeptides. At least three independent microarray 
analyses carried out by other workers showed that the expression of DAL5 is regulated by 
Ssy1p under different growth conditions. First, DAL5 expression decreased three-fold in 
a wild-type strain when Leu was added to the medium. In addition, the expression of 
DAL5 in a SSY1 deletion mutant resulted in an increase of four-fold compared with the 
wild type in medium containing Leu (FORSBERG et al. 2001). Second, the expression of 
DAL5 in a SSY1 deletion mutant increased six-fold compared with the wild-type in rich 
(YPD) medium (KODAMA et al. 2002), and increased two-fold in minimal medium 
(ECKERT-BOULET et al. 2004). Based on these data, I hypothesize that under inducing 
conditions such as the addition of Leu, yeast cells utilize dipeptides in a PTR2-dependent 
manner, while in non-inducing conditions yeast cells utilize certain dipeptides in a PTR2-
independent manner. Further, I postulate that in response to amino acid inducing 
conditions, the SPS system (Ssy1p-Ptr3p-Ssy5p) increases PTR2 expression but represses 
DAL5 expression. In our toxic dipeptide assay (Ala-Eth), preliminary results indicated 
that the PTR2 deletion mutant (BY4742 genetic background) remained sensitive to a high 
Ala-Eth concentration (0.4µmol), suggesting that the sensitivity to high concentration of 
Ala-Eth might result from the activity of Dal5p function due to the fact that Dal5p has a 
low affinity for importing some dipeptides. I suggest the following experiments (a, b, and 
c) to test the above hypotheses: 
a) Confirm Dal5p imports dipeptide in our lab strain. This could be done by creating a 
PTR2/DAL5 double knockout in the BY4742 background; the double knockout 
should not be sensitive to high concentrations of Ala-Eth, if Dal5p imports Ala-Eth. 
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Furthermore, using non-N-end rule substrates, such as Ala-Leu or Ala-His in a 
growth assay would demonstrate whether dipeptides could satisfy the auxotrophic 
requirement of His in a ptr2 strain. Since Dal5p is a low-affinity dipeptide transporter, 
high concentrations of dipeptides should be used for the growth assay. 
b) Explore how Leu, an inducer for the SPS system, changes the expression level of 
DAL5 and PTR2 by using Northern analysis or real time PCR. The wild type strain 
BY4742 will be grown in minimal medium (using proline as the nitrogen source) 
with Leu or without Leu, and total RNA will be extracted. I expect that the expression 
level of DAL5 will be higher in medium without Leu than that with Leu, but the 
expression level of PTR2 will be opposite.  
c) Since the SSY1 deletion mutant is lethal in the BY4742 background, studying the 
Ssy1p signaling effect should be performed in the FY2 genetic background. A series 
of knockout strains, ssy1, ptr3, ssy5, dal5, ptr2, and double knockout mutant strains 
ssy1 dal5, ssy1 ptr2, ptr3 ptr2, and ptr3 dal5 should be created. Growth assays, toxic 
dipeptide assays, and expression of PTR2 and DAL5 under the induction of Leu could 
be performed in these backgrounds. I expect that the expression level of DAL5 in ssy1, 
ptr3, and ssy5 strains will be higher than that of the wild-type in the medium 
containing Leu, but the expression level of PTR2 will have an opposite effect in the 
above conditions. I should also be able to demonstrate the contribution of DAL5 to 
dipeptide utilization by comparing the growth assay and toxic dipeptide assays in 
ssy1/ ptr2 and ptr3/ ptr2 strains with that of ssy1/ dal5 and ptr3 /dal5 strains in 
minimal medium with or without Leu.   
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2. Dal81p, Rpn4p, Ubp14p, and Ubr2p played a role in the regulation of PTR2 expression. 
How these genes fit into the SPS signal transduction pathway should be experimentally 
determined. The following experiments could be performed:  
a)  Epistasis experiments will address where these genes are in the SPS signal 
transduction pathway. Several gene double knockouts need to be created. For 
example, in order to understand the role of Rpn4p in the SPS signal transduction 
pathway, a ptr3/ ubr2 double knockout strain will be created. If the phenotype 
such as the sensitivity to toxic dipeptide in the ptr3/ ubr2 double knockout is the 
same as that in ptr3, it suggests that Ptr3p is upstream of Ubr2p. If the phenotype 
of the double knockout is the same as that in ubr2, it suggests that Ubr2p is 
upstream of Ptr3p. However if the phenotype in the double knockout is additive, it 
suggests that Ptr3p and Ubr2p are in independent regulation pathways.  
b)  Since Ubr2p showed homology to Ubr1p/Ptr1p and impacted the stability of 
Rpn4p, how Ubr2p impacts the positive regulator Rpn4p and repressor Cup9p on 
PTR2 transcription should be tested. The relative amount of Cup9p and Rpn4p 
could be measured in these deletion mutants by Western analysis.  
c)  Dal81p has transcriptional activity, and Ubp14p has ubiquitin-specific protease 
activity. Deletion of either of these two genes showed a decrease of the expression 
level of PTR2. Since both genes are involved in the transcriptional regulation of 
PTR2, it is necessary to exam whether these gene products are related to Cup9p 
repression. The stability of Cup9p in these two deletion mutants could be tested 
by western analysis. This experiment will answer whether Dal81p and Ubp14p 
are involved in PTR2 transcriptional regulation via regulation of Cup9p. 
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3. The gene products impacting Ptr2p trafficking showed a significant effect on di/tri-
peptide utilization. Since ESCRT I, II, III were shown to be involved in Ptr2p trafficking, 
it is very likely that ubiquitination of Ptr2p is required. In addition, Ptr2p ubiquitination 
was shown by mass spectrum analysis. Further experiments should be performed to 
demonstrate the ubiquitination site(s). 
         a) Screening the lysine positions in Ptr2p to show which position(s) are the 
ubiquitination site(s). Point mutations of Ptr2p could be generated to change 
lysine to alanine in Ptr2p-GFP background plasmid (pMS4 or pMS2). The point 
mutations in Lys sites should lead to reduction of Ptr2p turnover and increase the 
amount of Ptr2p in the plasma membrane and lead to an increased uptake of 
dipeptides. 
b) The enzymes involved in the ubiquitination of Ptr2p should be identified and 
tested. The Ptr2p ubiquination process likely follows a similar pattern to that of 
other membrane proteins since involvement of ESCRT protein complex is a 
ubiquitous process for a number of membrane proteins. Npi1p/Rsp5p, 
Npi2/Doa4p, and Bul1p/2 Ptr2p are good candidates for the ubiquitination of 
Ptr2p since these components are also involved in the Gap1p trafficking system. 
        c) Npr1p and Lst4p were shown be involved in the Ptr2p trafficking. Deletion of 
NPR1 and LST4 led to accumulation of Ptr2p containing vesicles. Npr1p is a 
Ser/Thr kinase and played a role in phosphorylation of Bap2p, a branched-chain 
amino acid permease and is involved in the degradation process. Npr1p might 
play a similar role in Ptr2p post-translational regulation. First, the plasmid with 
Flag tagged Ptr2p (pMS2) will be transformed into the wild type and npr1 strain. 
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The degradation of Ptr2p will be examined under NH4+-induced conditions. I 
expect that the degradation of Ptr2p will be reduced in npr1 strain by western 
analysis. Second, in order to find out the phosphorylation sites in Ptr2p, point 
mutations at Ser/Thr sites of Ptr2p will be generated. The contribution of Npr1p to 
the phosphorylation of Ptr2p will be determined by antibodies that react 
specifically with phorphorylated residues.  
d) To further finely define the subcellular localization of Ptr2p in those deletion 
mutants showing changes in Ptr2p-GFP localizaion, the analysis of Ptr2p 
localization by confocal microscopy will be performed. From my research, I 
found deletion mutants of gene product encoding protein sorting such as srn2, 
snf7 and vps36 showed higher accumulation of dipeptide Leu-Leu but no 
significant Ptr2p-GFP expression at the cytoplasmic membrane. One outcome of 
these experiments might lead to an explanation for those mutants that exhibit 
higher Leu-Leu accumulation. In addition, these experiments will also show the 
detail location of Ptr2p-GFP in the endosomal vesicles.  
  
4. A number of metabolic genes, such as the components of pyruvate dehydrogenase 
complex (Pdx1p, Lpd1p, Pdb1p, and Lat1p), are involved in dipeptide utilization. The 
roles of these gene products should be further explored. Deletion of these gene products 
does not influence di/tri-peptide accumulation. In order to examine how these deletion 
mutants impact di/tri-peptide utilization, the degradation process from di/tri-peptide into 
amino acids should be tested. Our preliminary data indicated that the tested dipeptide 
Leu-Leu was degraded into Leu and an unknown metabolite after Leu-Leu is taken up 
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into cells. This unknown compound is more hydrophilic than Leu, and might be an 
intermediate product formed in the process of Leu-Leu degradation or a leu derivation 
product. Identifying this compound will require application of techniques such as HPLC 
and mass spectrometry. 
 
5. Fifteen genes of unknown function were identified to be involved in di/tri-peptide 
utilization. Characterization of these genes will help understand their roles in yeast 
biology.  I propose to start with two gene deletion mutants that showed a strong 
phenotype in the regulation of PTR2 expression and Ptr2p trafficking. High induction of 
PTR2 expression was found in a yor323c mutant, and accumulation of Ptr2p vesicles in a 
ypl073c mutant. In order to characterize the function of YOR323C, first, the expression 
level of PTR2 will be examined by Northern analysis or Real Time PCR. Because a 
deletion in yor323c leads to an increase in dipeptide utilization and a higher Ptr2-GFP 
signal in the cell membrane, I expect to see a higher expression level of PTR2 in yor323c 
strain in comparison to that of the wild-type. Second, bioinformatic analysis should be 
performed for the protein sequence encoded by this gene to see whether there are any 
known protein domains whose function is known. Third, the localization of this gene 
product should also be tested by tagging this gene with GFP.  Further an examination of 
the interaction databases such as the synthetic lethal screens can determine whether there 
are other known gene products interact with Yor323p. Another example for testing is 
YPL073c since this gene is involved in Ptr2p trafficking. Whether this gene product 
interacts with other trafficking related proteins should be tested. The two hybrid 
experiment to detect protein-protein interaction between this gene product and ESCRT 
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proteins or other vesicle sorting proteins will be tested. In addition, the localization of this 
protein should also be tested by tagging with GFP, and Ptr2p turnover should be 
examined by Western analysis in the ypl073 deletion strain.  
 
In summary, the identified genes regulating dipeptide utilization represent a very 
wide regulatory network involved in transport and utilization of dipeptides in yeast.  This 
is the first such study of a membrane transport system in any organism and initiates a 
systems biology approach to understanding membrane transport in cells. Further 
experiments of characterizing these identified genes could provide valuable information 
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